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CHAPTER 1 
THE PUMP STUDY: MOTIVES AND PURPOSES 
Were I to await perfection, 
my book would never be finished 
Tai T'ung (ca. 1300 BC) 
INSULIN DEPENDENT DIABETES MELLITUS 
In the first century AD Aretaeus of Cappadocia described dia-
betes as "a wonderful but not very frequent affection among men 
being a melting down of the flesh and limbs into urine .... , life 
is short, disgusting and painful, thirst unquenchable, death 
inevitable". 
The recognition of this disease with its enormous thirst and 
massive production of honey sweet urine is very old. Nowadays 
diabetes is known as a heterogeneous disorder. Insufficient pro-
duction of biologically active insulin is a common denominator in 
almost all forms of diabetes. Insulin deficiency results in a 
variety of metabolic abnormalities (hyperglycaemia, increased 
lipolysis, increased gluconeogenesis at the cost of amino acids). 
The NIH National Diabetes Data Group discerns 2 types of diabetes 
mellitus: insulin dependent diabetes mellitus (IDDM) and non-
insulin dependent diabetes mellitus (NIDDM) (National Diabetes 
Data Group 1979). IDDM frequently starts in childhood. The inci-
dence in the Netherlands is estimated to be 11.0 subjects per 
100.000 inhabitants per year in the age group below 20 years 
(Vaandrager 1984). Since NIDDM seldom occurs in childhood it will 
be left out of consideration in this study. 
Insulin is produced by beta cells in the pancreatic islets of 
Langerhans. In due time after clinical onset there is hardly any 
beta cell activity evident. An absolute insulin deficiency ensu-
es. As insulin plays a key role in maintaining normal metabolism, 
this implicates a life-long dependency on exogenous insulin admi-
nistration. Since insulin is a peptide which can not be adminis-
tered orally, administration of injections at least once daily is 
necessary. Ten to 15 years after the onset of the disease 
severe complications may develop (micro- and macroangiopathy) 
resulting in a shorter life expectancy and a reduced quality of 
life (Deckert 1978). It is evident that t~is chronic disease and 
its consequences also influence life, the psychological well-
being and development of patients, especially those of child age. 
The cause of this destructive process, which is specifically 
directed against the pancreatic beta cells, remains to be 
elucidated. Current thought is that a hereditary susceptibility 
in combination with an environmental agent can lead to the deve-
lopment of IDDM (Cahill 1981). Immunological disturbances- cel-
lular as well as humoral - have also been found at the onset of 
the disease (Bottazzo 1981, Buschard 1980, Lernmark 1981, Maron 
1983). Their precise role has not yet been clarified. 
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REMISSION PERIOD 
A special feature of the course of the disease in most 
patients is a remission period (or so-called honeymoon phase), 
occurring shortly after the start of insulin substitution. This 
period is characterized by low or even no exogenous insulin re-
quirement, but with good glycaemic control. It then seems 
certainly to patients and parents - as if the fate of the 
diabetic child has changed towards cure. The beta cell function 
appears to recover. Unfortunately, this remission is not perma-
nent. On the contrary, it usually lasts only some weeks or months 
in children. The end of the remission period is characterized by 
an increased need for exogenous insulin to maintain an as normal 
as possible metabolism. Once again the beta cell function 
deteriorates and in time no more beta cell activity can be detec-
ted. In the next chapter the term remission period will be ex-
plained (page 13-14). Criteria will be provided in order to pre-
vent confusion, since this could be easily possible considering 
the literature. 
It is not surprising that the remission period fascinates 
many clinicians and researchers working in the field of diabetes. 
The occurrence of this period suggests that recovery of the beta 
cell function can take place after the clinical onset of IDDM 
resulting in an almost normal metabolism. This phenomenon of tem-
porary recovery creates the impression that progression of the 
disease may be stopped with the right therapeutic intervention. 
Intervention in an early period might change the course of the 
disease. preserve some of the residual beta cell activity and 
prevent or delay the development of major complications. 
The main question is how to accomplish beta cell recovery 
therapeutically in diabetic children. More knowledge of the cause 
of the ongoing destructive process might offer the possibility 
to develop specific intervention therapies. 
There has not yet been an explanation for the cause of a 
remission period. Several studies suggest the involvement of 
patient and disease related factors. Age and symptoms at onset 
(metabolic disregulation) are suggested to be associated with the 
remission phase (Knip 1982, Ludvigsson 1977). Among younger pa-
tients incidence and duration of the remission period seem redu-
ced. A severe ketoacidosis at onset seems also negatively 
associated with occurrence of a remission period. The relation-
ship between immunological disturbances and the remission also 
remains unexplained. Several immunological abnormalities before 
and after clinical onset have been demonstrated, such as islet 
cell antibodies, insulin antibodies as well as changes in T-
lymphocyte subsets. Whether these factors influence the remissi-
on period remains to be clarified. 
Preliminary attempts have been made to prolong the remission 
period through different immune suppression therapies (Elliot 
1981, Ludvigsson 1983). Since the side effects of long-term immu-
ne suppression are substantial and the influence of the immune 
system and its disturbances are not yet clear, this kind of 
treatment seems as yet unjustified (Rossini 1980). Caution 
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should be exercised, especially with children. 
Retrospective studies suggest a beneficial effect on the 
remission period of a rapid normalization of the metabolic dis-
turbances at onset (Knip 1982, Ludvigsson 1979). A tight metabo-
lic control from onset onwards seems to improve the beta cell 
function in the first period of the disease. One study describes 
a significantly increased incidence and duration of the remission 
in adult diabetics, treated shortly after onset for several days 
by an artificial beta cell. They achieved an excellent metabolic 
control (Mirouze 1978). An intensified injection therapy -con-
sisting of three or more injections a day, combined with self-
control (home blood glucose measurements\ has shown to exert a 
posLtLve influence on the beta cell function, even in patients 
with a longer duration of IDDM (Madsbad 1981). This has resulted 
in one of the main questions of this thesis: does near normogly-
caemia, obtained in newly diagnosed diabetic children, result in 
a preservation of the residual beta cell function? Obtaining a 
good metabolic control in young children raises - however - other 
problems. Injections cause stress in most children, especially in 
toddlers. Augmenting the injection frequency to more than twice 
daily might increase the already heavy burden on diabetic chil-
dren. The stress induced by increased injection frequency, in 
combination with expected deterioration of the injection sites, 
may actually work against an improvement in metabolic control. 
As a result of the recent development in technology in the 
field of insulin delivery devices, reliable continuous subcuta-
neous insulin infusion pumps (CSII) have become available in a 
size usable in children. With these pumps near normoglycaemia and 
restoration of the metabolic state can be obtained in IDDM (Sher-
win 1980, Tamborlane 1979). The combination of available devices 
to pursue near normoglycaemia in diabetic children and the possi-
ble benefit of this improved metabolic control on the remission 
period has led to the setting-up of this pump study. 
P~PSTUDY 
The purpose is to investigate whether CSII improves the meta-
bolic control and influences the residual beta cell function 
in diabetic children when started immediately after the onset of 
IDDM. Although the excellent metabolic control in adult diabetics 
of recent onset results in a considerable prolongation of the 
remission phase, an equal effect using CSII for children is 
uncertain. Incidence and duration of the remission phase seem to 
be inversely correlated to the age. 
To evaluate the effects of CSII on metabolic control and 
the residual beta cell function in a small group of newly diagno-
sed diabetic children, a prospective randomized design has been 
chosen. Thirty children, consecutively referred to the Sophia 
Childrens' Hospital, have been treated from diagnosis onwards 
with either CSII or a conventional injection therapy (CT) 
consisting of one or two injections a day. Since remission in 
children usually starts in the first month after the onset and 
ends within a year, the results in this thesis are given of all 
5 
children after one 
in order to obtain 
tion is noted 
effect. 
year. A 
- if an 
further 
follow-up of two years has been chosen 
effect of CSII on the beta cell func-
information on the duration of the 
The execution of a prospective randomized study with pumps in 
children requires a specialized setting as base. The organization 
of the Diabetes Clinic and its policy for the treatment of IDDM 
are described in chapter three. 
CSII has never been used for newly diagnosed diabetic chil-
dren. Hence, it is imperative to evaluate carefully the psycho-
logical impact of its use. The feasibility of CSII in a group of 
unselected newly diagnosed diabetic children is the first ques-
tion that has been investigated by this study. Problems or mani-
pulation with the pump at home, the frequency of phone calls to 
the hospital and home visits. by the nurse practitioner, reacti-
ons from and acceptation (problems) by the diabetic child and its 
family all have to be taken into account. To evaluate the psycho-
logical effect of diabetes and the treatments thereof on the 
child and its family, children and parents involved in this study 
(CSII and CT!) have been submitted to a psychological test at the 
end. 
The second question is whether CSII will lead to a better me-
tabolic-control. Metabolic control is evaluated by a regular de-
termination of stable glycosylated hemoglobin. The insulin dose, 
home measured blood glucose levels, some intermediary metabolites 
and lipid metabolites are also included as parameters for metabo-
lic control. 
The influence of CSII on the incidence and duration of the 
remission period is the third question which is examined in this 
study. Assessment of the endogenous insulin secretion is one of 
the main parameters of the study. To determine the endogenous in-
sulin secretion, C-peptide levels have been measured in plasma 
and urine. The logical consequence of the third question is the 
determination of factors by which the results can be explained. 
Several parameters have been determined for this purpose. As it 
has been suggested that metabolic control exerts a beneficial ef-
fect on the residual beta cell function, the relationship between 
stable glycosylated hemoglobin and the beta cell function will be 
evaluated. The contribution of the immune system to the 
remission period also remains to be elucidated. Several humoral 
factors, insulin antibodies and islet cell antibodies, have been 
measured. To evaluate the importance of genetic factors, discove-
red so far, and the possible influence of environmental agents, 
tissue typing has been performed and virusserology has been de-
termined. The fourth chapter describes the exact design of the 
study, the statistical methods used along with these parameters. 
The characteristics of the participating children and the re-
sults after one year of follow-up are given in chapter five. 
The results are discussed in chapter six and since research 
never gives only answers, but always provides new questions, some 
suggestions are given for future research. 
In summary, this prospective randomized investigation has been 
undertaken to study the effect of CSII on the metabolic control 
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and the remission period of newly diagnosed insulin dependent 
diabetic children. Since CSII has not been used before in a not 
selected group of children, the feasibility and psychological im-
pact of the treatment are also evaluated. 
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CHAPTER2 
THE REMISSION PERIOD IN INSULIN REQUIRING DIABETIC 
CHILDREN 
INTRODUCTION 
In th·e natural course of diabetes mellitus the acute onset is 
often followed by a clinical remission. The remission period or 
so-called honeymoon period is characterized by relatively low or 
no exogenous insulin requirements and good metabolic control. It 
suggests a functional recovery of beta cells. Many investigators 
are fascinated by this phenomenon, since it raises hope that a 
reversal, or at least intervention in the ongoing destructive 
process may be possible. Retrospective studies suggest that this 
period - its occurrence and duration - can be influenced by a 
tight metabolic control. In this thesis the remission period is 
studied and an attempt is made to evaluate its relationship with 
the metabolic control in diabetic children. 
Before concentrating on the remission period, a short outline 
is given of current knowledge of IDDM, its etiology and natural 
course and of the psychological impact of this chronic disease on 
children. After defining the criteria for remission several as-
pects - morphological, metabolical and immunological - are dis-
cussed. Subsequently the possible benefit of the remission period 
and the attempts, undertaken so far to influence its course, are 
described. The chapter ends with a summary. 
INSULIN DEPENDENT DIABETES MELLITUS 
The course 
One may divide the course of IDDM into three periods (figure 
2. 1). The first one (I) is the period with genetic susceptibili-
ty without beta cell mass destruction. The second period (II) 
starts after the triggering of the immune system by an environ-
mental factor or by a spontaneous anti-self reactivity, resulting 
in destruction of beta cells. In this period islet cell antibo-
dies (ICA) can appear, recognizing the islet cell (Lernmark 
1981). The endogenous insulin production may be fluctuating but 
is still sufficient and above a certain critical level in order 
to maintain normoglycaemia. 
The presence of an abnormal first phase insulin response to an 
intravenous glucose load has been demonstrated in this period 
(Srikanta 1983). The duration of the second period is unknown. 
ICA have been detected up to thirty months before the development 
of the overt disease (Gorsuch 1981). In some subjects however, 
these ICA disappear without any sequelae, suggesting that ICA de-
tection does not always presage IDDM (Helmke 1980). At a given 
moment, the critical level of beta cell mass to guarantee normo-
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glycaemia has been passed and clinically overt IDDM develops as 
the third period (III). 
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Figure 2. 1. The time course of IDDM. 
From dr G.J. Bruining, with kind permission 
The appearance of the disease is highly variable. In some 
patients increasing polyuria and polydipsia may be present for 
several months before there is such a marked degree of weight 
loss and debilitation, that they are brougt to a physician's at-
tention. In others the onset may be explosive with only a few 
days of subjective symptoms before ketoacidosis occurs. From this 
moment onwards insulin injections in combination with a diet are 
necessary for the rest of the patients' life. 
One of the unique features of the natural history of IDDM is 
the remission period, central theme of this thesis. The majority 
of children will go through such a period. The duration of this 
period varies, but hardly ever lasts longer than one year. It 
will be outlined in the following paragraph. 
For 10 to 15 years after the diagnosis of IDDM, chronic com-
plications are uncommon. After that period, microangiopathy and 
macroangiopathy often develop resulting in severe complications 
such as retinopathy, nephropathy and neuropathy (Deckert 1978). 
Life expectancy is shortened and deterioration begins. The cause 
of these complications has not yet been elucidated. Indirect ar-
guments from biochemical, enzymatic and functional studies show 
that optimal insulin and/or blood glucose control reverse some 
early diabetic changes that are probably related to the late 
events (Brownlee 1981). Several data suggest that the mechanisms 
responsible for diabetic microangiopathy are initiated as . a 
result of insulin deficiency. The development of the 
microvascular complications of diabetes may be inhibited and/or 
delayed by careful control of blood glucose levels (Engerman 
1977, Tchobroutsky 1980). However, the possible importance of ge-
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netic susceptibility for microangiopathy as well as the influence 
of immunological disturbances on the development of the vascular 
complications can not yet be excluded (Andersen 1976, Mancini 
1969, Schernthaner 1979). 
With all the unanswered questions and with the prognosis in 
mind, it is not surprising that extensive research is done in the 
field of.diabetes, its complications and the prevention of both. 
Prevention in the first period and intervention in the second 
phase would both prevent the overt disease. Identification of the 
subjects at risk as well as more knowledge on what is going on is 
necessary before an effective prevention can be realized. When 
the disease has become clinically manifest - the third phase of 
IDDM - insulin therapy via injections and diet are prescribed to 
achieve an as normal as possible metabolism. This means the start 
of a life-long dependency on insulin. 
The cause 
Genetic susceptibility combined with an environmentally 
initiated - perhaps viral - perturbation of the immune system is 
suggested to result in the autoimmune destruction of the host's 
own beta cells (Cahill 1981, Craighead 1978). 
Almost two decades ago the inheritance of IDDM was said to be 
a geneticist's nightmare. Rotter recently stated that the night-
mare may gradually be subsiding but a headache still remains. A 
striking association has been found between the histocompatibili-
ty alleles (RLA-Dr 3 and Dr 4) and IDDM (Nerup 1978, Platz 
1981). Thus inheritance may be related to one or more genes on 
chromosome 6 in association with the HLA complex. This associati-
on suggests an immunopathological process, occurring either as an 
isolated phenomenon or, more likely, as one initiated by a sensi-
tizing insult to the beta cell. Hence, certain HLA factors may 
also be associated with the course of the disease. This emphasi-
zes the importance of tissue typing of the patients participa-
ting in this study. 
As initiating factors viruses and chemical factors have been 
mentioned. The hypothesis, that a viral infection may precede the 
onset of IDDM is supported by a case report, describing the deve-
lopment of a fatal insulin requiring diabetes in a previously 
healthy boy of 10 years of age after an influenza-like illness. 
Culture of pancreatic homogenates led to the isolation of Cox-
sackie B4. Inoculation of this virus into mice produced hypergly-
caemia (Yoon 1979). Mumps, rubella and cytomegalyvirus have also 
been mentioned in association with the origin of some cases of 
IDDM (Ratzmann 1984). Chemical factors in the environment may 
also be diabetogenic (Helgason 1981, Karam 1980). Although initi-
al factors are seldom found in newly diagnosed diabetics, the 
determination of virusserology has been included in this investi-
gation. 
The autoimmune reaction, either spontaneous or as a consequen-
ce of external factors, is demonstrated by the presence of the 
auto-antibodies, cell-mediated cytotoxicity or both. The possible 
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involvement 
and in the 
16-17). 
of the immunologic disturbances at the onset of IDDM 
first period thereafter is discussed elsewhere (page 
The psychological impact of IDDM in childhood 
The onset, the course and the treatment of IDDM are particu-
larly stressful for children. Which other disease requires daily 
self administration (or by parents) of medication with hypodermic 
syringes, with the threat of disaster if this practice is not ob-
served? A chronic disease such as diabetes entails different 
challenges, tasks and responses at various moments in time, since 
it affects almost continuously the every-day life, not only of 
the child but also of its family. The diabetic children are fre-
quently faced with their diet restriction (especially at seconda-
ry schools with their wide consumption of sweets and candy). It 
may not be surprising that this disease influences the psycho-
logical development of diabetic children. Psychological problems 
can, in turn, affect the metabolic control and thus the course of 
the disease (Anderson 1980, Hauser 1979, Simonds 1981). Thus far, 
conflicting results have been published, concerning the influence 
of IDDM on the psychological development (Hauser 1979, Sullivan 
1978, Swift 1967). Sullivan suggests, that diabetes - in adoles-
cent girls - emerges only as a focus for the expression of normal 
adolescent conflicts. Swift, on the contrary, finds significant-
ly more psychopathology in diabetic children. 
Intensification of the therapy and the diabetic control (with 
CSII or multiple injection therapy) results in a significant re-
duction of depression and anxiety and in a more positive "self-
concept" in diabetic patients (Seigler 1982). With CSII mealtimes 
can be varied. For extra food the insulin dose can be easily ad-
justed. This may promote the participation of the child in acti-
vities of its peer group. It may also relieve some strain of the 
family. Considering the expected beneficial effect of CSII on the 
metabolic control, possibly reduced physical complaints may also 
promote the activities of the child. On the other hand the 
constant confrontation with the disease, carrying a visible devi-
ce, can induce feelings of shame and a sense of inferiority. This 
may lead to withdrawal of the children from their peer group. 
Whether CSII in children has a positive effect is studied in this 
project. 
For patients, especially children with IDDM, the role of the 
family is very important. Drash and Becker discuss several rea-
sons why the family is so critically involved: (I) family mem-
bers are constantly required to make clinical judgements that af-
fect management decisions and (2) the diabetic regimen overlaps 
with, and usually restricts, many well established family routi-
nes (Drash 1978). 
It is evident, that many factors, such as age, sex, interfa-
miliar interactions and others, are relevant for the psychologi-
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cal impact of IDDM. An attempt is made to gather some information 
on the influence of CT and CSII therapy on the psychological 
well-being of diabetic children. Preliminary and not yet complete 
results are given in this thesis. 
REMISSION PERIOD 
Definition and parameters 
In the 1940's Lieutenant Commander Brush described a period of 
functional recovery of the "islet apparatus" starting six to ten 
days after the onset of the disease and the start of the insulin 
treatment (Brush 1944). Starting in newly diagnosed diabetic 
children a treatment consisting of a strict diet and large 
amounts of insulin resulted after several days in a functional 
recovery of the islets and a considerable reduction in exogenous 
insulin (2 to 8 units). During subsequent weeks to months these 
children were essentially free of glucosuria. They seemed to 
achieve a steady state of endogenous insulin production. 
Thus, shortly after the onset of IDDM a decrease in the exoge-
nous insulin need can be observed, suggesting the recovery of 
beta cell function (Park 1974). It often creates a false hope of 
cure in children and their pirents. for it raises the expectation 
that in due time no more insulin administration will be necessa-
ry. Unfortunately, nothing is less true. This remission period, 
usually starting in the first month after the start of the treat-
ment, lasts several months at maximum and eventually ends with an 
increase in exogenous insulin need (Drash 1980). A considerable 
variation in frequency (25 to 100%) as well as in duration (I 
month to 13 years) has been described (Ludvigsson 1980, Madsbad 
1983). An exact definition of the remission period may contribute 
to a more consistent result. 
First of all a clear difference must be made between total 
clinical remission and a partial clinical remission. A total 
clinical remission indicating normoglycaemia without any exoge-
nous insulin administration is a very rare phenomenon in child-
hood diabetes (Pirart 1971). Only a few cases have been described 
(Weber 1972). The term partial clinical remission is usually used 
with respect to the period shortly after the clinical onset. This 
partial remission fits to the description given earlier: a clini-
cal improvement coinciding with a reduction in exogenous insulin 
requirement. In this thesis the term remission period refers to a 
partial clinical remission. 
Several criteria have been formulated for the remission period 
(Akerblom 1980). Some authors define it as a period, lasting for 
at least one month, in which insulin requirement is less than 0,5 
U/kg per day and glucosuria is absent or minimal. Others do not 
include the insulin dose in the definitions as this depends to 
some extent on the policy of the responsible physician (Lud-
vigsson 1978). If this policy could clearly be explained however, 
the insulin dose would be a valuable parameter in the assessment 
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of the residual beta cell function. Glucosuria is often used to 
assess the overall metabolic state. It depends inter alia on the 
renal threshold of the child. Most authors do not mention when or 
how often glucosuria is determined: for example after an over-
night fast? To get a correct impression of the metabolic control 
glucosuria ought to be measured in every urine voiding. Present 
possibilities of assessing the overall glycaemic control by way 
of stable glycosylated hemoglobin (sHbAl) may offer a more relia-
ble parameter for the glycaemic control. 
One of the most important features of the remission period is 
the apparent improvement in beta cell function. Hence a parameter 
to estimate the beta cell function has been included. C-peptide 
is secreted in the same quantity as insulin into the portal cir-
culation but is, contrary to insulin, not extracted to any signi-
ficant degree by the liver (KGhl 1978). The development of an 
assay for the determination of C-peptide has provided a valuable 
tool for direct studies of the endogenous insulin secretion in 
insulin dependent diabetic subjects (Block 1973). 
Thus, following 3 criteria are taken into account in this the-
sis when considering the remission period: the insulin dose, the 
overall glycaemic control and the endogenous insulin secretion. A 
remission period is characterized by an insulin dose below 0,5 
U/kg/24 hours, a sHbAI and a C-peptide production within the 
normal range. 
Morphological changes 
Morphologically the pancreas of insulin dependent 
subjects is characterized by a reduction in number and 
the islets of Langerhans, as has been described by Gepts 
1981). 
diabetic 
size of 
(Gepts 
As long as beta cells can be determined, inflammatory changes 
such as insulitis can be observed in children up to about six 
months after the onset. In this period regeneration can also be 
found. Two types of islets seem to be formed after the onset of 
IDDM. The small new islets, proliferating out of the epithelial 
cells of the distal parts of the excretory ducts are composed of 
hyperactive beta cells with a high RNA and low insulin content. 
These islets are irregularly distributed throughout the 
pancreas. Especially after a longer duration more and more 
atypical islets, composed of sinusuoid cords of cylindrical cells 
and identified as PP cells, can be found. In time the regenerati-
ve capacity of the pancreatic tissue, which has probably already 
been strained before the clinical onset of the disease, 
deteriorates. This leads more and more to the development of the 
atypical PP cells. 
Hence, in the first period after diagnosis regeneration and 
hyperactivity of the beta cells can be noted. Both disappear in 
time and sooner in younger patients. Since pancreas biopsies are 
still hazardous, it is not possible to distinguish what the con-
tribution of these factors is to the remission period. The deve-
lopment of the C-peptide assay has provided a tool to assess the 
residual beta cell function. Although one can not distinguish hy-
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peractivity and regeneration with this method, it offers valuable 
information on the functioning of the beta cells. It is evident 
that the determination of the C-peptide production is one of the 
main parameters of this study. 
Whether this regeneration, the hyperactivity and the eventual 
degeneration reflect the natural course of diabetes is unknown. 
One may speculate that these phenomena occur as well before as 
after the overt onset of IDDM. Exceeding a critical level of 
rema~n~ng beta cell mass (necessary to maintain normoglycaemia) 
would result in that case in the clinical manifestation of diabe-
tes. If so, the remission period may reveal further information 
on the pathogenesis of IDDM. 
Metabolic abnormalities 
The decreasing insulin levels lead after passing a critical 
level to hyperglycaemia, an increased lipolysis and ketogenesis 
(Cherrington 1982). Several products of these processes- such as 
non-esterified fatty acids (NEFA) - are known to reduc.e the ef-
fect of insulin on the peripheral tissues. 
At the same time an increase in glucagon, catecholamines and 
cortisol levels can be observed. These hormones are also known as 
insulin antagonists. Their increased concentration will provoke 
in the absence of sufficient insulin levels a further increase 
of lipolysis and ketogenesis (Johnston 1982). Thus a circulus vi-
tiosus is created, which will be interrupted by the start of 
insulin therapy. The reversal of this process and the decreased 
concentration of insulin antagonists may contribute to improved 
metabolic control. This increase in insulin sensitivity effect 
after the start of the treatment may be associated with the oc-
currence of a remission period. Since not all patients go through 
a remission period the phenomenon of remission does not seem ful-
ly explained by an increase in insulin sensitivity alone. Retro-
spective studies suggest that the seriousness of the metabolic 
disregulation at onset and the metabolic control after the onset 
show indeed an association with the occurrence and duration of 
the remission period (Knip 1982, Ludvigsson 1977a). Ludvigsson 
used serious ketoacidosis with drowsiness (not further 
specified), presence of ketonuria and blood glucose levels as 
parameters for the seriousness of metabolic disregulation at on-
set of diabetes. Knip includes as parameters for metabolic disre-
gulation blood glucose levels, plasma ketostix ®, urine 
ketostix ®, blood pH (capillary) and blood carbon dioxide 
(capillary). In this thesis serious ketoacidosis, reflected in a 
blood pH below 7.2, the presence of ketonuria and blood glucose 
levels are used as parameters for metabolic disregulation at the 
clinical onset of IDDM. Overall glycaemic control after the onset 
of IDDM is reflected in glycosylated hemoglobin levels. Several 
intermediary metabolites have also been included in this study to 
evaluate the metabolic control of diabetic children. 
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Immunological disturbances 
IDDM demonstrates a high incidence of antibodies directed 
against the pancreatic islet cells (Bottazzo 1981, Lernmark 
1981). At diagnosis antibodies reacting with intracellular compo-
nents of islet cells are often present (in 60-70% of the 
subjects). These islet cell cytoplasmic antibodies (ICCA) can be 
complement fixing, probably dependent on the titer of the ICCA 
(Bruining 1984). In a large prospective study ICCA have been de-
monstrated before the onset of IDDM, suggesting a possible role 
for them as marker for the ongoing beta cell destruction (Gorsuch 
1981). Literature gives mixed results concerning the relationship 
between ICCA and residual beta cell function (Crossley 1981, 
Madsbad 1980, Mustonen 1984). However, the pathogenetic importan-
ce of ICCA seems less likely, since they solely react with intra-
cellular components, which are inaccessible in living cells. 
Islet cell surface antibodies (ICSA), on the other hand, bind 
to component(s) facing the exterior of the cells (Van de Winkel 
1982). Their capability to mediate a complement-dependent cyto-
toxic reaction may eventually lead to membrane lesion and cell 
death, thus suggesting a possible involvement in the pathogenesis 
of IDDM. In vitro studies suggest that ICSA alters the insulin 
secretion of beta cells (Kanatsuna 1982). Whereas Kanatsuna des-
cribes an inhibitory effect of these ICSA on the beta cell 
function, Nielsen finds that sera of newly diagnosed diabetic pa-
tients stimulate the insulin production of mouse islets (Nielsen 
1981). Thus, ICCA and ICSA may play an important role in IDDM, 
either as marker for beta cell destruction or as factors involved 
in the destructive process. 
Not only against the hormone producing cells but also against 
the hormone itself antibodies can be detected. Injected insulin 
is immunogenic and the administration of even human insulin may 
induce an antibody production. Conflicting data have been 
published on the relationship of these antibodies with the meta-
bolic control or with the remission period of patients (Asplin 
1978, Ludvigsson 1976, Ludvigsson 1977b). A recent study descri-
bes the presence of autoantibodies against insulin before the 
start of insulin injections (Palmer 1983). This indicates that 
these antibodies may also be involved in the pathogenesis of 
IDDM. 
Maron and co-workers demonstrate the presence of antibodies 
in sera of newly diagnosed diabetic children exerting an insulin-
like effect on fat cells (Maron 1983). 
The complexity of the immunological disturbances is evident. 
It can certainly not be excluded that other - not yet identified 
- antibodies play a role in the pathogenesis of IDDM. The antibo-
dies may influence the beta cell function or cause their destruc-
tion. They may be produced only after the start of the 
destructive process as epiphenomenon or as marker of beta cell 
destruction. Antibodies may influence the effect of insulin, 
positively or negatively, at the level of the receptor. 
Not yet mentioned is the cellular immunity. At diagnosis of 
IDDM a reduced suppressor T-cell concentration is found in the 
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presence of an increased quantity of killer T-cells (Buschard 
1980, Pozzilli 1979). In this thesis several antibodies have been 
determined in order to obtain further information on the humoral 
disturbances present in IDDM and possibly influencing its course. 
Possible benefit of the remission period 
Possible benefit of any residual beta cell function for the 
long term has been shown by a Danish group (Deckert 1980). They 
have found significantly less eye complications in patients with 
longer than 15 years IDDM who had some residual beta cell func-
tion compared with those having no beta cell function left. It is 
tempting to suggest that some residual beta cell function might 
contribute to a delay or even to prevention of the late diabetic 
complications. The results of Deckert have not been confirmed by 
others (Bodansky 1981). 
Another merit of the residual beta cell function has been 
shown by insulin withdrawal studies (Madsbad 1979). Deprivation 
of insulin results in later occurrence of hyperglycaemia and 
ketonbodies in patients who had some residual beta cell function 
compared with patients without any residual beta cell function. 
This suggests a decreased risk for a fast metabolic disregula-
tion, so often resulting in hospital admittance because of severe 
ketoacidosis. During the first ten hours of insulin withdrawal 
patients without any beta cell function decompensate faster 
despite similar peripheral free insulin concentrations. In 
healthy subjects about 50 to 70% of the secreted insulin is 
extracted immediately by the liver, without having circulated in 
the peripheral tissue. Exogenously administered insulin first 
"travels" through the periphery towards the heart to arrive 
finally in the liver. To get a similar effect on the liver more 
insulin is needed. The relatively large amount of insulin admi-
nistered peripherally might reduce the sensitivity of the peri-
pheral tissue, whereas centrally (in the liver) still an insuf-
ficient effect of insulin can be observed. This emphasizes the 
importance of some residual beta cell function. 
It is evident that further metabolic importance of even a 
minimal degree of preserved beta cell function might be based on 
the finding that the beta cells are capable of modulating insulin 
secretion in response to variations in blood glucose concentra-
tion (Mads bad 1982). Although the first .phase response of the 
beta cells may have disappeared, the tops of the swings in blood 
glucose concentrations may be reduced by the endogenous insulin 
production, contributing to an improved metabolic control (Mads-
bad 1983). 
Finally the remission period may reflect the natural course of 
IDDM, thus offering the opportunity to obtain more information 
on the pathogenesis of the disease. It also raises the expecta-
tion that with an adequate therapy further progression of the 
disease may be stopped. A prolongation of the remission period 
(if possible unlimited) will improve the life expectancy and the 
quality of life of the diabetic patients (Madsbad 1982). 
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Attempts to influence the remission period 
Especially for insulin dependent children the impact of the 
diabetogenic process is usually greater during the first 12 
months after diagnosis (Crossley 1981). Potential therapeutic ef-
forts to limit islet cell damage need to be applied early. It is 
possible that these efforts may not need to be continued much 
beyond 12 months after diagnosis. 
What has been done so far to preserve residual beta cells and 
to prolong the remission period? 
Two main approaches can be distinguished in attempts to in-
fluence the occurrence of a remission period and the preservation 
of the residual beta cells by therapeutic means. 
One approach originates from the hypothesis that insulin-
requiring diabetes may be an autoimmune disease, smoldering for 
many years before becoming clinically apparent. Immunosuppression 
or, even better and more specific, immunomodulation may prevent 
further damage of beta cells. Glucocorticoids, human leukocyte 
interferon, levamisole, plasmapheresis, cyclosporin A, and an-
tilymfocyte globulin all have been tried (Elliot 1981, Ludvig-
sson 1983, Rand 1981). There have been no reports of total cure 
(completely normal oral glucose tolerance and return of the first 
phase insulin release after intravenous glucose), although eugly-
caemia of variable duration with a normal sHbAl is possible. An 
obvious consideration is that dosages, timing and duration may 
not have been ideal. Before considering other more extensive, 
prolonged and aggressive immunotherapies, it might be useful to 
emphasize looking not only at possible benefits but also at risks 
of immunotherapy, especially in children. Of course, not all 
immunotherapy is the same in terms of tox1c1ty and potential 
efficacy. The risks are not trivial and are related to the inten-
sity and duration of therapy. The possible benefit is the cure of 
diabetes. At present this has still not been achieved by immune-
regulatory therapy after the clinical onset of the disease. 
The other approach towards preservation of the residual beta 
cell function derives from retrospective studies, which suggest 
a possible benefit of a good metabolic control immediately after 
the clinical onset (Gillet 1980, Knip 1982, Ludvigsson J977a). 
Those patients, having received a mOre vigorous treatment in 
the first days after clinically overt onset, have both a higher 
incidence of remission and a better metabolic control. 
One prospective study describes a significantly higher 
incidence of remissions in recent onset diabetics treating them 
for a short period with an artificial pancreas thus achieving an 
excellent metabolic control (Mirouze 1978). 
The achievement of normoglycaemia has been a very difficult 
task for a long period, especially in children. Frequent 
injections are known to result in a good metabolic control. How-
ever, an increase in injection frequency in children does not al-
ways result in better control. An increase of stress factors as 
well as deterioration of injection sites (indicating a less pre-
dictable resorption and effect of insulin) may be the result. 
Self monitoring, the possibility to measure and adjust blood 
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glucose levels at home, forms a great improvement in the therapy 
of children. But more is necessary to obtain near normoglycaemia, 
for there is a limit to control of blood glucose levels via fin-
ger pricks and adjustment by extra insulin injection. 
Recent technological development offers new possibilities 
(Pickup 1980, Soeldner 1981). The insulin delivery devices pro-
duced nowadays have a size applicable in children. With these 
devices a restoration of the metabolism can be obtained (Pietri 
1982, Sherwin 1980, Tamborlane 1979). Continuous administra-
tion of insulin with the boluses for each meal is a better imita-
tion of the physiological situation than ~nJections once or 
twice daily (page 27). These devices may be useful in achieving a 
tight metabolic control in the newly diagnosed diabetic child 
without limiting the child in his movements. Until now CSII has 
never been used in a randomized group of newly diagnosed diabe-
tic children. 
The pump study, as described in this thesis, has been underta-
ken to evaluate the benefit of a strict metabolic control - ob-
tained by CSII - on the remission period in newly diagnosed 
diabetic children. 
SU~RY 
1. In the natural course of IDDM three periods can be discerned: 
I. only genetic susceptibility 
II. beta cell destruction without any clinical symptoms 
III. clinically overt diabetes with its sinister prognosis. 
A genetic susceptibility combined with an environmental agent 
may cause an immunological perturbation that leads to the 
autoimmune destruction of the beta cell mass. This will result 
in insulin requiring diabetes mellitus. 
2. The remission period, frequently occurring shortly after cli-
nical onset of IDDM, is characterized by a relatively low or 
no insulin need with good metabolic control. In this study the 
combination of following 3 criteria is used for a remission 
period: an insulin dose below 0,5 U/kg per day, a sHbAl and C-
peptide production within the normal range. 
3. The psychological impact of IDDM in children depends upon many 
factors. The influence of 2 different therapies (CSII and CT) 
on the psychological well-being of diabetic children is stu-
died and preliminary results are given in this thesis. 
4. Morphologically the remission period is characterized by rege-
neration and hyperactivity of the beta cell mass. Metabolic 
abnormalities present at the onset of IDDM are reversed by 
insulin therapy. This may lead to an improved insulin sensiti-
vity. Finally a variety of immunological abnormalities, cellu-
lar as well as humoral, against the organ as well as against 
its product can be observed. In this thesis an attempt is made 
to evaluate the relationship between these factors and the re-
mission period in diabetic children. 
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5. A possible benefit of the remission period is the effect it 
may exert on the metabolic regulation. The association found 
between the decreased incidence of major complications and an 
endogenous insulin reserve is of great importance. This period 
may also offer opportunity for intervention in the ongoing 
destructive process after the clinical onset of the disease. 
6. Attempts at intervention with immunosuppressive agents have 
not been too hopeful. A tight metabolic control may have a be-
neficial effect on the residual beta cell function. With the 
recently developed continuous insulin delivery systems achie-
vement of tight control proves possible providing thus the op-
portunity to test the suggested benefit of a eight metabolic 
control on the occurrence and duration of the remission peri-
od. 
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CHAPI'ER3 
THE TREATMENT OF INSULIN DEPENDENT DIABETIC 
CHILDREN: ORGANIZATION AND POLICY 
INTRODUCTION 
The aim of treatment of insulin dependent diabetic children is 
to achieve (near) normoglycaemia without hypo- or hyperglycaemic 
symptoms and with normal development of the child, physically and 
psychologically. 
Until recently this aim has been pursued in the Sophia Chil-
drens' Hospital, SKZ (part of the University Hospital Rotterdam); 
with the conventional injection therapy, focussing on self-con-
trol and home care. Recent technological development has introdu-
ced new possibilities: the continuous subcutaneous insulin deli-
very devices. This has led to the study described in this 
thesis. Without the present setting, the Diabetes Clinic in the 
SKZ, this study would not have been possible. In the first 
paragraph of this chapter some general remarks are made on the 
organization of the Diabetes Clinic, on the home care and the 
self-control, pertaining to CT patients. With pump therapy only 
little experience has been obtained before the start of this stu-
dy. Regarding the home care and self-control of the pump patients 
the same applies. In the second paragraph the theoretical back-
ground of pump therapy is briefly explained. The chapter ends 
with a summary. 
CONVENTIONAL TREATMENT OF DIABETIC CHILDREN 
At the Diabetes Clinic of the Sophia Childrens' Hospital a 
diabetes team, consisting of two pediatricians (one pediatric 
endocrinologist, one general pediatrician), a nurse practitioner, 
a dietician and a research fellow during this study, is 
responsible for the care of about 150 diabetic children. Once a 
month a pediatric psychiatrist is consulted by this team to dis-
cuss problematic children. The pediatric endocrinologist - head 
of the team - and the research fellow work full time in the field 
of diabetes. The general pediatrician works (officially) for 20% 
on diabetes. The nurse practitioner devotes 70% of her time to 
the diabetic children. 
Patient (and parent) education and self monitoring - at home -
are the pillars on which the treatment of the children and their 
parents is based (Baum 1981, Bruining 1984, De Visser 1977). Hos-
pitalization is reduced as much as possible. Whether hospitaliza-
tion can be avoided at the onset of the disease depends on seve-
ral factors: physical condition of the child (dehydration, 
ketoacidosis with a pH< 7.2), social background (telephone at 
home, knowledge of Dutch) and availability of the nurse practi-
tioner. 
Usually an intensive training is started at home during the 
first weeks (1-3) after the onset of the disease. The nurse 
practitioner is responsible for the training at home. The trai-
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ning consists of practical skills as well as an explanation of 
the theoretical background. Several practical skills must be ac-
quired in the first period after the onset of IDDM. The correct 
injection technique (administering insulin in the deep subcutane-
ous tissue) and methods to control the blood glucose level, keto-
nuria and glucosuria, are taught. 
Usually the child will start with one insulin injection per 
day. On the basis of metabolic control (sHbAl and home measured 
blood glucoses) this frequency may be increased to two injections 
a day. This change usually occurs after 6 to 12 months, commonly 
during an infectious disease. The thigh, the buttocks and the ab-
domen are the sites used for injections. In the beginning, often 
only the thigh is used, whereas in the following two years the 
other LnJection sites are included. Thigh and buttocks are 
considered to be similar with respect to the resorption of insu-
lin. The abdomen as injection site, however, is suggested to re-
sult in a faster resorption of the administered insulin and is 
therefore not interchangeable with thigh and buttocks without 
precaution. 
Blood glucose measurements are performed with 20/800 hemoglu-
cotest strips (Boehringer, Mannheim, FRG). Glucosuria and ketonu-
ria are measured with Ketodiabur test strips, or Ketur and · Dia-
bur test strips·(Boehringer, Mannheim, FRG). In the first week 
after the onset of IDDM blood glucose measurements are performed 
once or twice daily (before the administration of insulin). When 
the child (and/or the parents) know how to perform the measure-
ments they are requested to measure the blood glucose levels at 
different hours during the day, usually before and after the 
meals, at 00.00 hours and at 03.00 hours. Thus information is ob-
tained on the glycaemic control at different moments. 
After the initial period (after 3 weeks after the onset of 
IDDM) the patient and/or parents are advised to measure the blood 
glucose value about 3 to 5 times a week at different hours of the 
day and night. Achievement of blood glucose levels between 4.4 
and 10.0 mmol/1 is pursued. In special situations (some of them 
are listed in table 3.1) the frequency has to be increased in 
order to adjust the insulin dose adequately. 
Table 3.! Special situations, requiring~ blood glucose 
measurements 
Intercurrent illnesses 
Parties 
Dinners 
Sporting activities 
Travelling 
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The determination of glucosuria as a parameter for glycaemic 
control in most cases has been replaced by blood glucose measure-
ment. In very young children it is used in order to reduce the 
frequency of blood pricks. Ketonuria is measured when hypergly-
caemia is found. It will give some information on the duration of 
hyperglycaemia (hyperglycaemia with ketonuria suggests a longer 
duration) and its presence indicates that more insulin is needed 
to reduce the blood glucose level towards normal. 
The theoretical part of the training consists of information 
on the disease itself, the cause, the immediate therapeutic and 
dietary implications and the acute complications (hypo- and hy-
perglycaemia). The way insulin acts and the relationship between 
insulin, physical activities and diet are discussed. The diffe-
rent types of insulin are mentioned. Naturally time is taken to 
answer the parents and/or child's questions. Some time after the 
onset chronic complications, heredity and future possibilities 
are discussed. 
During visits to the outpatient clinic the diet is discussed 
with the dietician. Taking into account as much as possible the 
nutritional habits of the family, a wholesome diabetic diet is 
composed. This consists of 15 a 20% protein, 30 a 35% fat (up 
to 15% of the fat unsaturated) and 50 a 55% carbohydrates. 
Since 1984 "fast" carbohydrates (such as glucose and fructose) 
can be included in the diet, provided that (a) they are taken in 
combination with a main course and (b) the quantity does not ex-
ceed 5% of the total caloric intake of that meal. 
The aim of the training is to teach parents and children to 
control blood glucose values, ketonuria and/or glucosuria, to 
interpret these values in the context of a given situation and to 
consequently adjust diet or insulin dose adequately. 
Certainly in the first year(s), the parents are advised to con-
sult one of the members of the diabetes team in case the measured 
blood glucose levels exceed the limits or when ketonuria is 
detected. 
A 24 hours telephone service provides the possibility to reach 
one of the team members at any time. Early adjustments of insulin 
doses or diet can thus be made in order to prevent longer or more 
serious metabolic disregulations. To avoid a long-continued hypo-
glycaemia every patient is provided with a glucagon infusion set 
(NOVO, Bagsvaerd, Denmark). This set consists of a syringe with 
i.m. needle, 1 mg glucagon and solvent. The parents are taught 
how (deep intramuscularly) arid (hypoglycaemia with unconsci-
ousness) glucagon must be used. 
During the first month after onset the patient visits the out-
patient clinic 2 to 4 times. Thereafter the frequency is reduced 
to a visit once every 6 weeks or 3 months, dependent on the de-
gree of metabolic control. During these visits several members of 
the diabetes team see the patient: the doctor each visit and 
usually the nurse practitioner and the dietician. During each vi-
sit weight and length are measured to obtain information on the 
development. After each visit the patient's problems, general 
condition and the laboratory results (sHbAI) are discussed by the 
diabetes team. If necessary, proposals are made to change the 
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insulin dose and/or diet. The nurse practLtLoner informs the pa-
tient (or its parents) by telephone of the laboratory results and 
the proposals made. Sometimes, circumstances or specific problems 
necessitate an extra home visit by the nurse practitioner. Pro-
blems can be of any nature, purely practical~ psychological, 
questions regarding school, etc .. Before a holiday abroad a short 
refresher course is sometimes given. If required, instruction is 
given by the nurse practitioner to schoolteachers, trainers etc. 
About one-half to one year after the onset of the disease the 
parents are invited to participate in a refresher course lasting 
5 evenings (20.00- 22.00 h.). This course consists of a recapi-
tulation of the theoretical aspects of diabetes, the treatment 
and adjustments of insulin dose or diet in special situations. 
Parents' questions as well as recent developments in the field of 
diabetes are discussed. These evenings offer not only the oppor-
tunity to repeat the first training but they create the possibi-
lity to talk about and discuss common experiences with other 
parents. Usually about 70% of the parents attend these evenings. 
In general patients leave the pediatric hospital to attend the 
outpatient clinic for adults (Dijkzigt Hospital, part of the 
University Hospital Rotterdam) at the age of 18 years. 
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION PUMP 
TREATMENT 
The use of continuous subcutaneous insulin infusion devices 
is expected to result in a more physiological administration of 
insulin, hence a better metabolic control. 
Although CSII still delivers insulin in the wrong place - in 
the peripheral subcutaneous tissue - the administration of a ba-
sal rate, combined with boluses before each meal, results in a 
better imitation of the physiological situation. In simple terms, 
the beta cell delivers insulin into the blood stream at two ra-
tes: a continuous slow basal rate, which controls glucose output 
from the liver and restrains lipolysis and proteolysis, and meal-
time bursts which dispose of the digested nutrients. Diurnal 
profiles of free insulin in CSII patients, CT patients and the 
range for healthy volunteers are shown in figure 3.1 (Home 1982). 
These profiles have been made in adults. They indicate that the 
free insulin levels in CSII patients approximate the normal ran-
ge. The curves of the CT group differ considerably however, es-
pecially between the meals. 
The indications for CSII treatment in children are examined 
by this study. Only one diabetic child in the SKZ already begun 
with CSII before this study because of a brittle diabetes, 
characterized by frequent and serious ketoacidoses requiring hos-
pitalization (Natham 1982). 
Because of ignorance about problems related to this treatment 
in children, the costs of pump treatment (Appendix II), the risks 
of it (Teutsch 1984) and no guarantee for an optimal metabolic 
control (Bruining 1983) indications for starting such a treatment 
have to be carefully formulated. 
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STELLINGEN 
Continue subcutane insuline infusie pomp therapie 
bij nieuwe niet geselecteerde diabetes patienten 
op de kinderleeftijd is geed uitvoerbaar, mits de 
opvang door het behandelend team aan bepaalde eisen 
voldoet. 
(Dit proefschrift) 
2 Kinderen, die vanaf het moment dat bij hen insuline 
afhankelijke diabetes mellitus is vastgesteld, be-
handeld worden met continue subcutane insuline in-
fusie pomp therapie, vertonen in het eerste jaar 
een betere metabole regulatie (wat betreft het ge-
glycosyleerde hemoglobine) dan kinderen, die con-
ventioneel behandeld worden. 
(Dit proefschrift) 
3 Indien bij kinderen van vijf jaar of jonger insuline 
afhankelijke diabetes mellitus wordt geconstateerd, 
verdient het aanbeveling deze pati§nten vanaf het 
begin met pomp therapie te behandelen. 
(Dit proefschrift) 
4 De correlatie tussen de endogene insuline productie 
van insuline afhankelijke diabetes patienten bij de 
diagnose en na een jaar geeft weer, dat gestreefd moet 
worden naar een zo vroeg mogelijke ontdekking en be-
handeling van deze aandoening. 
(Dit proefschrift) 
5 De aanwezigheid van insuline antistoffen vOOr het 
starten van insuline substitutie bij insuline af-
hankelijke diabetes pati§nten is geassocie§rd met 
een snellere afname en een geringere produktie van 
endogene insuline. Dit suggereert, dat deze anti-
stoffen een 'marker' zijn voor beta eel destructie. 
(Dit proefschrift) 
6 Gelet op de gevoeligheid van de thermo-esthesiometer 
en de geringe belasting van deze meetmethode voor 
de patient, lijkt deze techniek een veelbelovende 
parameter voor de vroegtijdige ontdekking van stoornis-
sen in de perifere zenuwen van kinderen met insuline 
afhankelijke diabetes mellitus. 
(Bertelsmann F, J of Neurol, Neurosurg and Psychiatry 
1985, blz 686 - 690) 
7 De ethische eis, dat aan niet-therapeutische ingrepen 
bij kinderen slechts minimale risico's verbonden mogen 
zijn, is niet voldoende genuanceerd. Het is de vraag of 
deze restrictie onverminderd geldt in het geval van niet-
therapeutische ingrepen bij gezonde zusjes of broertjes 
van zieke kinderen, indien eerstgenoemden zelf bereid 
zijn meer dan minimale risico's te aanvaarden. 
(Contra : De Beaufort I D, Ethiek en medische experimenten 
met mensen 1985, Van Gorcum, Assen) 
8 De gedachte, dat het in termen van racisme interpreteren 
van kinderboeken als BABAR en LITTLE BLACK SAMBO de 
jongere generatie voor dit kwaad kan behoeden, is even-
als vele andere ontsproten aan een wens. 
(Contra : Dixon B, Catching Them Young; Sex, Race and 
Class in Childrens 1 Fiction 1977, Pluto Press, Landen) 
9 Vrouwen, die om financiele redenen draagmoeder willen 
worden, dienen zich af te vragen of het kind niet het 
kind van de rekening zal zijn. 
10 De aanbeveling* om de interpretatie van het Verdrag be-
treffende de Status van Vluchtelingen (Geneve 1951) zo-
danig te verruimen, dat diegenen, wier mensenrechten op 
grond van sekse worden geschonden, kunnen worden begrepen 
onder 1 bepaalde sociale groep' (zeals genoemd in artikel I 
van de Conventie van Geneve betreffende de Status van 
Vluchtelingen 1951), dient zeker ook door vrouwelijke 
artsen te worden ondersteund. 
*(Seminar 1 Vrouwelijke Vluchtelingen 1 1985, Soesterberg) 
11 Het argument van H Nord (Vice-President van het Europese 
Parlement) tegen het beperken van het aantal werktalen 
in de instellingen van de Europese Gemeenschap luidt: 
Van de vertegenwoordigers van de lidstaten met een klein 
taalgebied mag niet de beheersing van een vreernde taal 
verlangd worden, alvorens zij kandidaat voor een functie 
of zetel kunnen zijn. Dit argument dient als rernrnend en 
onzinnig voor de Europese integratie beschouwd te worden. 
(Contra : Nord H, Europa van Morgen, 15 januari 1986) 
12 De woorden van Franc;:ois Robichon de la GuE!riniere " Niet 
een rnartelende onderwerping, maar buigzaamheid en ont-
spannenheid zijn de eerste vereisten voor (dan vrijwillig 
aangeboden) 'JG:hoorzaamheid ~lan het paard" verdienen meer 
aandacht van de huidige ruiter. 
(Een koninkrijk voor een paard, Isenhart H H, BUhrer E M, 
Van Gaade, Den Haag) 
13 Gelet op de publicaties en congresverslagen, waarin succes-
volle isolatie technieken van humane eilandjes van Langer-
hans worden beschreven, is het verbazingwekkend, dat niet 
op grote schaal onderzoek gedaan wordt met in kweek ge-
brachte humane eilandjes. 
14 Het verdient aanbeveling om de wetenschappelijke voordrachten 
tijdens wetenschappelijke congressen naar de pauzes te ver-
plaatsen, omdat men mag aannemen, dat de informatie uit-
wisseling in de wandelgangen door de daaraan verbonden 
ambiance en het inforrnele karakter effectievtr is. 
Carine de Beaufort, 
1986 
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Figure 3. I Plasma free insulin profiles in C-peptide negative 
diabetics (n"" 10) on twice daily insulin injections ( •-•) and 
during continuous subcutaneous insulin infusion (A-&). The sha-
ded area indicates the normal range for a group of healthy con-
trols. Data from dr P. Home et al. 
with kind permission 
SUMMARY 
I. The aim of the treatment of insulin dependent diabetic chil-
dren is to achieve (near) normoglycaemia, without hypo- or hy-
perclycaemic sypmtoms, and with a normal development, physi-
cally as well as psychologically. 
2. Patient (and parent) education and 
porting pillars for the treatment of 
tic children. 
self monitoring are sup-
insulin dependent diabe-
3. Hospitalization is reduced as much as possible. Theoretical 
and practical instruction is given at home by the nurse prac-
titioner. 
4. A frequency of 3 to 5 blood glucose measurements per week is 
recommended for all patients, whether treated conventionally 
or with CSII. 
5. CSII is expected to result in a more physiological administra-
tion of insulin. The indications for CSII use in children can 
only be formulated when more experience has been acquired. 
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CHAPTER4 
THE PUMP STUDY: COMPARATIVE RANDOMIZED STUDY OF 
CSII AND CT: DESIGN AND PARAMETERS 
INTRODUCTION 
The aim of the pump study is to evaluate the influence of 
CSII, started in not selected newly diagnosed diabetic children, 
on the remission phase in these children, compared with CT. 
This has resulted in the following questions: 
- Is CSII feasible in not selected newly diagnosed diabetic 
children? What is the psychological impact of the therapy? 
-What is the influence of CSII on the metabolic control? 
- Does CSII prolong the remission phase in diabetic children? 
- Which factors contribute to the remission phase? Which factors 
do not exert a (direct) influence on it? 
The general design of the study, the parameters and the methods 
of determination are described in detail in the following para-
graphs. The chapter will end stating in more detail the questi-
ons that are discussed in this thesis. 
PUMP STUDY: DESIGN AND PROTOCOL 
To evaluate the effect of CSII treatment on the remission 
phase 30 children - consecutively referred to the Sophia 
Childrens' Hospital - are treated with either CSII or CT? consis-
ting of I to 2 injections per day. In both groups semisynthetic 
human insulins (NOVO~) are used. Which child will receive which 
therapy is randomized, based on order of entry using a table of 
random permutations. The study has a final follow-up of 2 years. 
In this thesis an evaluation of the results after I year follow-
up is given. This point of time has been chosen because several 
studies as well as experience in our clinic indicate that the 
mean duration of the remission period is less than one year 
(Knip 1982, Ludvigsson 1977). A final follow-up of two years has 
been chosen in order to obtain information concerning the durati-
on of the possible effect. 
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Protocol 
At the onset of IDDM several determinations have to be perfor-
med in order to confirm the diagnosis, to evaluate any direct 
trigger for the acute disregulation, and to assess whether hospi-
talization is necessary. These parameters are shown in table 4.1, 
group la and b. They are arranged in four groups: 
(1) the initial parameters - usually determined at the onset of 
the disease - include inter alia HLA typing and virusserolo-
gy, 
(2) the parameters for metabolic control, consisting of stable 
glycosylated hemoglobin, home measured blood glucose levels, 
intermediary metabolites, cholesterol and HDL cholesterol, 
(3) the C-peptide concentration as parameter for the endogenous 
insulin production, determined in 24 hours urine as well as 
in plasma, 
(4) the immunological parameters, possibly involved in the aetio-
logy and the course of IDDM, to wit ICCA, ICCA-CF, ICSA, 
IgGia and IgGib (page 132: list of abbreviations). 
It has been suggested as previously mentioned, that the 
severity of metabolic disregulation influences residual beta cell 
activity (Ludvigsson 1977). In the result section only data rele-
vant to the investigation are given, to wit blood glucose concen-
tration, blood pH and ketonuria. The duration of symptoms before 
clinical onset and the duration of the hospitalization (if any) 
are also noted. Blood glucose concentration is determined by a 
glucose oxidase method (GOD-PAP, Boehringer, Mannheim, FRG). 
Blood pH is measured by a blood gas analyzer (ISL 1302, 
IJsselstein, Holland). Ketonuria is determined by test strips 
(Ketur strips® or Keto-diabur strips ® Boehringer, Mannheim, 
FRG). 
HLA typing (A, B, C and Dr) has been performed by the standard 
microcytotox~c~ty assay using peripheral blood lymphocytes. The 
typing has been performed by the Department of Immunohaematology 
and Blood Bank, University Hospital Leiden, Leiden (Head of 
Dept.: Prof. dr J.J. van Rood) (Van Rood 1979, Van Leeuwen 1980). 
All patients have been typed. 
Virusserology has been performed to obtain, if possible, in-
formation concerning the direct trigger of the acute metabolic 
disregulation. The determinations for the detection of influenza 
A and B, adenovirus, RS virus, mycoplasma, parainfluenza 1, 2 and 
3, psittacosis, mumpsvirus, german measles, measles and chicken 
pox virus, cytomegalyvirus, Ebstein Barrvirus, Q-fever virus, 
hepatitis B virus and herpes virus have been performed by the De-
partment of Virology, Erasmus University and University Hospital 
Rotterdam (Head of Dept.: Prof. dr N. Masurel). Virusserology is 
considered positive if at least a 4 fold antibody rise in comple-
ment fixation is found or a specific IgM in a single sample is 
determined. 
After confirmation of the diagnosis IDDM, the project and its 
purpose are presented to the child and its parents. The advanta-
ges and disadvantages of the 2 therapies are described as clear-
ly as possible as well as the extra burden, arising from the par-
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Table 4.I Protocol for laboratory tests 
Time (weeks after the 0 4 8 12 16 20 24 28 32 36 40 44 48 52 
clinical onset) 
Parameters 
I.a. Blood: glucose, Na+, 0 
K+, Astrup, Hb, Ht, 
Leucocytes differen-
tiation, bloodgroup, 
Urine: pH, glucose, 
ketones, albumin, 
sediment 
HLA typing 0 
b. Virusserology 0 0 0 
2. sHbAl 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Lactate 0 
Pyruvate 0 
3-0H-butyrate 0 
Triglycerides 0 
NEFA 0 
Amino Acids 0 
Cholesterol 0 0 0 0 0 0 0 
HDL-Cholesterol 0 0 0 0 0 0 0 
3. Glucagon Stimulation 0 0 
Test 
Urinary C-peptide 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
4. Islet Cell Cyto-
plasmic Antibodies 0 
(ICCA) 0 
Islet Cell Cytoplas-
mic Antibodies Comple-
ment Fixing (ICCA-CF) 0 0 
Islet Cell Surface 
Antibodies (ICSA) 0 0 
Insulin Antibodies: 
(l) IgGia 0 0 0 0 0 
(2) IgGib 0 
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ticipation in the study. If a posLtLve decision is taken regar-
ding participation in the study, therapy is started. In due 
time the parents receive a letter which outlines the study. 
Parents and children (12 years of age and older) are requested to 
sign in order to indicate their knowledge about and approval of 
participation in the study (Appendix I). 
Pump treatment is started in the hospital. The children are 
hospitalized for about 10 days. During these first days the fre-
quency of blood glucose control varies between 6 and 9 times in 
24 hours (before and after each meal, at 0.00 hours and at 03.00 
hours). After discharge from the hospital, this frequency is re-
duced to 3 to 5 times per week, except in special situations 
(page 26). The children, starting with the conventional treatment 
can usually leave the hospital after the administration of their 
(first) insulin injection. In general a combination of long (zinc 
or isophane) and short-acting insulin is injected. For more de-
tails on the conventional therapy the reader is referred to the 
third chapter (page 25- 28). 
During the first month, both groups of patients visit the hos-
pital once a week. They are seen by the same doctor (the research 
fellow). The second month this frequency is reduced to once 
every other week. 
From the third month onwards the patient visits the hospital once 
per month. At the hospital the patient is seen each time by the 
doctor and usually by the nurse practitioner and the dietician. 
After the initial period home visits are only made when necessa-
ry. 
The parameters to evaluate the feasibility and psychological 
impact of CSII in children, include the frequency of home visits, 
the acceptation of CSII, problems with the pump, and psychologi-
cal tests. The psychological tests are performed after two years 
of follow-up, resulting in a limited number of patients tested as 
yet and described in this thesis. The socioeconomic class has 
been assessed according to the occupation of the fathers (table 
4.II). 
At the end of the pump study, those patients who are treated 
by CSII are asked whether they want to continue the treatment. If 
their reaction is positive, a request for financial support for 
the continuation of the treatment is sent to their insurance com-
pany. 
After the follow-up of two years the patients, conventionally 
or pump treated, enroll in the routine Diabetes Clinic program. 
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Table 4.!! Classification of occupational levels 
Socioeconomic classes Occupation of the fathers 
LOll 1. Unskilled employees 
2. Skilled manual employees 
3. Clericals, technicians, minor professi-
onals 
MIDDLE 4. Owners of small businesses 
UPPER 
5. Supervisory, lesser professionals 
6. Executives, major professionals 
Owners of large businesses. 
ETHICAL CONSIDERATIONS 
Before a study is begun in the Sophia Childrens' Hospital the 
study protocol has to be submitted to and approved of by the Me-
dical Ethical Committee of the Medical Faculty, Erasmus Universi-
ty and University Hospital Rotterdam. No study can be started 
without its approval. It is evident that, especially with minor 
patients, a certain number of ethical requirements has to be met 
before undertaking an investigation. 
It must be impossible to acquire the same information by per-
forming the study on adults. Since it is known that the course 
of IDDM in adults may be milder, certainly during the first 
years, this study on the remission phase has to be done with 
minors. 
Parents and children, taking into account their age and abili-
ty to understand, must be well informed on the positive and 
the negative aspects of participation. 
This study starts at a most awkward moment for both patients as 
well as parents. Ethically it would be preferable to provide a 
written summary of the study, its purpose, the advantages and the 
disadvantages, before treatment is started. Due to the nature of 
this study, however, a summary can only be presented some time 
after the decision to participate in the study (Appendix I). A 
letter with signature as an indication of knowledge of and under-
standing about and consent to participation in the study are 
returned to the researcher. 
Both at the start of the study and in the letter it is empha-
sized that participation may be stopped at any time during the 
study without explanation. It is stated explicitly that a refusal 
to (further) participation will not influence the relationship 
between patient and physician. In that situation, however, pump 
treatment will only be continued in case it is evidently better 
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for this particular patient and when the financial support for 
this treatment is taken over by either the insurance company or 
the parents themselves. Otherwise, the patient will start with 
conventional injection therapy. 
The end of the study may pose another problem. The costs of 
CSII are considerable (Appendix II). It is not certain that all 
insurance companies will provide financial support. The study 
budget is not sufficient to provide financial support after the 
two years of the study. This implies that refusal by the insuran-
ce company will result in either a change of treatment or in 
considerable financial burdens. Considering the possible benefit 
with regard to the acute and late complications of IDDM, however, 
the costs of pump treatment may cost the insurance companies less 
in the long run. 
FEASIBILITY AND PSYCHOLOGICAL TESTS 
Feasibility 
Since CSII has never been used in not selected newly diagno-
sed diabetic children, an investigation into the feasibility and 
the psychological impact of the therapy is an important facet of 
this study. 
With feasibility not only the practicability of the started 
treatment is meant, but also the potentially improved quality of 
life. Although it is especially difficult to evaluate the latter, 
following aspects have been studied: 
- Acceptation of the therapy by parents and child 
- Practical problems of CSII 
- Frequency of phone calls for advice 
Frequency of home visits by the nurse practitioner 
The child and the parents are explicitly asked to give the 
diabetes team their opinion on the therapy. Problems are openly 
discussed in order to evaluate carefully whether continuation of 
the treatment is justified. Practical problems with the pump 
treatment can result in a metabolic disregulation. This may be 
caused by pump failure or by inadequate handling of the pump by 
the patient or his parents. If these problems are caused through 
inadequate handling of the pump on purpose, CSII treatment has to 
be terminated. 
The frequency of telephone calls to the diabetes team can be 
used as an indication of the complexity of the treatment. It 
provides information on the frequency with which consultation is 
needed with respect to adjustments in insulin dose and/or diets, 
in special situations or during intercurrent infections. 
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Sometimes parents will contact the nurse practitioner when peda-
gogical or psychological problems with their child arise. 
With respect to the telephone calls, the patients (and/or pa-
rents) are divided in 3 categories: 
contacting the nurse practitioner I time per month or less 
- contacting the nurse practitioner 2 - 5 times per month 
- contacting the nurse practitioner more than 5 times per month 
Home visits by the nurse pract~t~oner, after the initial 
instruction period can be divided in four groups: 
- to instruct new skills (other injection sites) 
- refresher courses before holidays, a check of already acquired 
skills 
- instruction to schoolteachers, trainers etc. 
- home visits to discuss psychological or pedagogical problems 
These home visits, their purpose and frequency, provide important 
information about the burden and the feasibility of CSII treat-
ment in newly diagnosed children. After 1 year the 2 groups (CT 
and CSII children) are compared with respect to these parameters 
in order to gain an impression of the feasibility of CSII treat-
ment. 
Psychological tests 
To compare the psychological impact of the two therapies, the 
children are tested psychologically at the end of the study, 2 
years after the clinical onset of the disease. The children are 
tested by dr Slijper and Mrs Kicken (Dept. of Child Psychiatry, 
Erasmus University and Di_ikzigt Hospital/So.phia Childrens' Hos-
pital, Rotterdam. 
In collaboration with dr Slijper several general tests - sta-
ted below - have been selected to evaluate certain aspects of the 
child's personality and its relation with its family (and vice 
versa). The test scores of the 2 groups are compared with each 
other. (If reference scores are available the scores of each 
group are also compared with these scores). Two questionnaires 
(5, 6) have been designed specifically for this study. 
1. Wechsler Intelligence Scale for Children (WISC) 
2. Junior-Dutch Personality Test 
3. Family Relation Test 
4. Family Environment Scale 
5. Diabetes Questionnaire 
6. Assessment of Acceptation Scale. 
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Of the WISC only the vocabulary subtest and the block design 
subtest have been performed to obtain some information on the in-
telligence. For youngsters (< 4 years) a modified test (WIPPSI) 
has been used, providing comparable scores. 
The Dutch Personality Test for Juniors provides information on 
several aspects of the personality of the children (Bucking 
1975). The items are summarized in Appendix III. The test is only 
suitable for children of 9 years and older. 
The Family Relation Test quantifies the negative and pos~t~ve 
feelings of the child towards his family (parents and siblings). 
It also reflects the feeling of the family towards the child, as 
experienced by the child! Children of 4 years of age and older 
can participate in the test. 
The Family Environment Scale gives a reflection on "family li-
fe" as observed by the different members of the family. The items 
are given in Appendix IV. The parents of the children have been 
requested to answer the questionnaire belonging to this test, ei-
ther in the hospital or at home. 
The Diabetes Questionnaire has been designed specifically for 
this study. The 58 questions (Appendix VI) provide information on 
9 items, shown in Appendix V. 
This test is directed specifically at the two treatments, 
their influence on every-day life with possible consequences for 
the behaviour of the child and his coping responses. 
The Assessment of Acceptation Scale consists of 5 questions 
(Appendix VII), concerning acceptation, metabolic regulation, 
physical and psychological well-being and the compliance of pa-
rents and child to effectuate a given advice. The parents and 3 
members of the diabetes team are independently requested to ans-
wer these questions. The scores given are from very good towards 
poor from 1 to 5. Equality of assessments or incongruity will 
give important information. It is evident that a negative (high) 
score of this test by all persons suggests more problems than 
only a negative score of one reviewer. 
If psychopathology is observed during the tests further 
contact will be sought in that particular case in concert with 
the diabetes team. 
38 
METABOLIC CONTROL 
The goal of the treatment of IDDM is achieving near normogly-
caemia, no symptoms of hypo- or hyperglycaemia and a normal de-
velopment (in this context: physical development). To evaluate in 
how far CSII treatment contributes to achieving this goal compa-
red to the conventional injection therapy, the following parame-
ters have been chosen: 
- stable HbAl (sHbAI) 
- home measured blood glucose values and hypoglycaemia 
- intermediary metabolites, to wit lactate, pyruvate, 3-0H-buty-
rate, triglyceride and non-esterified fatty acids (NEFA), bran-
ched amino acids 
- cholesterol and HDL-cholesterol 
- normal physical development 
Stable HbAl, most intermediary metabolites, cholesterol and HDL 
cholesterol have been determined by the Department of Clinical 
Chemistry, Erasmus University and University Hospital Rotterdam 
(Head of Dept.: Prof. dr B. Leynse). The amino acids have been 
measured by the Metabolic Laboratory of the Sophia Childrens' 
Hospital, Rotterdam (head of Lab.: Ir W. Blom). 
Although the insulin dose is strictly speaking no parameter 
for the metabolic control, it is mentioned in this paragraph 
because of its close relationship to the metabolic control. 
sHbAI 
Stable glycosylated hemoglobin is the principal parameter for 
the glycaemic control. The introduction by Koenig and others of 
sHbA1c as a parameter for the integrated glycaemia over the 
previous 3 to 4 weeks, has lead to the use of it as a clinical 
tool for diabetes control (Koenig 1975, Monnier 1982, Goldstein 
1984). The velocity of the reaction depends on the blood glucose 
concentration and the span of exposure of hemoglobin to this con-
centration. Total sHbAI is formed through condensation of a mole-
cule of glucose with the amino terminal valine of the betachain 
of hemoglobin and represents the major component of total sHbAI, 
measured throughout this study. This reversible reaction (shown 
in figure 4. I) is followed by the irreversible "Amadori" 
rearrangement to form a stable ketoamine. The formation of HbAlc 
is a non-enzymatic reaction. 
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Changes in sHbAlc in the patients are assessed by the measurement 
of sHbAl once every month. 
An electrophoretic method for the determination of sHbAI has 
been used. This method is unaffected by variations in temperature 
or minor variations in pH of ionic strength of the buffer (Me-
nard 1980). To measure the sHbAl percentage of total Hb, 0.5 ml 
of whole blood is incubated overnight at 37 C in excess saline 
0.15 mol/ I. Erythrocytes are collected by centrifugation, lysed 
and applied onto an agarose gel (Corning, New York, USA). The 
sHbAJ fraction is separated by electrophoresis. After drying, 
the percentage is measured by direct scanning at 420 nm. Every 
value is the mean of a duplicate measurement. The inter assay 
variation coefficient (SD: X. 100%) in the lower range (sHbAI : 
6.8%) is 8% and in the higher range (sHbAJ : 13.2%) is 3.9%. The 
reference interval (mean ± 2 SD; 42 non-diabetic children, visi-
ting the outpatient clinic for minor problems, range of age: 
J - 20 years) for sHbAI with this method is 5.4 - 9.0%. 
Home measured blood glucose levels 
As previously mentioned, a frequency of 3 to 5 measurements 
per week is recommended for blood glucose measurements at home. 
All patients and/or parents receive a "diabetes diary" to note 
all blood glucose values, special situations and diabetic 
symptoms etc .• The blood glucose measurements are used primarily 
for an adequate and fast adjustment of insulin and/or diet. Since 
these controls are performed at different hours of the day and 
for different reasons, it will be difficult to compare these home 
measured blood glucose levels. It is relevant to calculate the 
mean frequency of determinations per 28 days in the two groups. 
Besides information obtained from diaries, insurance companies 
have been approached by letter (Appendix VIII) to provide infor-
mation, if possible, on the quantity of blood test strips refun-
ded by them. 
It is imperative to know the incidence of low blood glucose 
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levels (( 2.2 mmol/1), since 
result in a higher frequency 
dy group 1985, Arias 1985). 
groups: 
it has been suggested that CSII may 
of hypoglycaemic periods (KROC stu-
Hypoglycaemia is classified in 2 
I. hypoglycaemia with unconsciousness, requiring glucagon or 
glucose i. v.; 
2. blood glucose levels of 2.2. mmol/1 or lower and/or subjecti-
ve hypoglycaemic symptoms, to wit dizziness, altered cons-
ciousness, aggressive behaviour~ trembling and sweating. 
From the diaries the mean frequency (per month per group) of the-
se forms of hypoglycaemia is determined. Whether or not hypogly-
caemia has occurred the month previous to the hospital visit is 
noted each month in the records of the patients. These records 
have also been used to obtain information on the occurrence of 
hypoglycaemic periods. 
Intermediary metabolites 
Blood lactate and pyruvate, intermediary metabolites of the 
carbohydrate metabolism, are increased after a longer period of 
insufficient insulin effect (Cherrington 1982) thus providing in-
formation concerning chronic metabolic disregulation. They have 
been measured after an overnight fast 6 and 12 months after the 
onset of IDDM. After immediate deproteinization of the venous 
blood samples lactate and pyruvate concentrations have been de-
termined by spectrophotometry (Bergmeyer 1974 1,2) using the CO-
BAS BIO (Roffman-LaRoche, Basel, Switzerland). Results are given 
as the mean of 2 measurements. The reference interval for lactate 
is < 3.0 mmol/1 for newborns and 1.0- 2.0 mmol/1 for children 
and for pyruvate (for children of all ages) it is 40- 70 ~mol/ I. 
Triglyceride, NEFA and 3-0H-butyrate concentrations supply 
information concerning the lipid metabolism. Increased lipolysis 
as a result of insufficient insulin levels, leads to an increase 
in NEFA and 3-0H-butyrate levels. Triglyceride concentration will 
also increase during a period of insulin deficiency. Because of 
the high sensitivitiy of fat cells for insulin, even a small re-
sidual insulin production can reverse these effects (Madsbad 
1979). Triglyceride, 3-0H-butyrate and NEFA concentrations are 
measured by spectrophotometry (Bergmeyer 1974 3,4), using the 
COBAS BIO (Roffman-LaRoche, Basel, Switzerland). Results are gi-
ven as the mean of 2 measurements. Reference intervals for tri-
glyceride, 3-0H-butyrate and NEFA are for children respectively < 
2.29 mmol/1, 0.06- 0.2 mmol/1 and 0.5- 1.2 mmol/1. 
It is suggested that insulin promotes the uptake of the bran-
ched amino acids (leucine, isoleucine and valine) by muscle as 
well as exerts an inhibitory effect on the release of peripheral 
amino acids (Stryer 1981). Branched amino acids have been deter-
mined 6 and 12 months after the onset of IDDM. The amino acids 
analysis has been performed with an LKB 4151 Alpha Plus R Amino 
Acid Analyzer (LKB, Cambridge, England). The results are the mean 
of 2 measurements. Reference intervals for leucine, isoleucine 
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and valine are for infants and children respectively 0.045 
0. 155. 0.026 - 0.094 and 0.057 - 0.262 mmol/1 (Soupart 1962). 
HDL cholesterol and Cholesterol 
Higher cholesterol and HDL cholesterol levels have been demon-
strated in diabetic children compared to healthy controls 
(Ewald 1984). As discussed by Nikkila, this might be associated 
with an increased concentration of circulating insulin (Nikkila 
1981). Taking into account one of the major complications of IDDM 
- atherosclerosis - it seems justified to study whether the 
treatments differ with respect to these factors. 
Cholesterol and HDL cholesterol have been determined every 2 
months. Total serum and HDL cholesterol have been measured by the 
enzymatic CHOD-PAP method (Boehringer, Mannheim, FRG). Results 
are given as the mean of 2 measurements. Reference intervals for 
cholesterol and HDL cholesterol are respectively for children 
3.57- 6.25 mmol/1 and 0.62- 2.09 mmol/1. 
Physical development 
The growth of the child is followed by measuring height and 
weight during each visit to the outpatient clinic. This is noted 
on the growth charts (weight for height) for Dutch children (Van 
Wieringen 1972) and results in a percentile along which the child 
is growing. Data of the growth before the onset of the disease 
(at least 6 months before) are obtained through the parents from 
the "Baby and Toddler Clinics". It is assumed that the child 
will usually continue to grow after the start of an adequate 
insulin administration along the same percentile level as before 
the onset of IDDM (again at least 6 months before). When gross 
differences from this percentile are found, they may point to a 
chronic metabolic disregulation (deflection towards a lower per-
centile) or an "over"treatment (increase towards a higher per-
centile). Both necessitate extra attention of the diabetes team 
to elucidate the possible cause. 
The exogenous insulin administration 
The insulin dose is noted at each visit to the Diabetes Clinic 
in the patients' records. It is expressed in units per kg body-
weight per 24 hours. The moment at which the dose exceeds 0.5 
U/kg bodyweight/24 hours is considered to be the end of the re-
mission period with respect to the insulin dose. 
ENDOGENOUS INSULIN RESERVE 
The estimation of the endogenous insulin production is one of 
the principal parameters of this study. The C-peptide secretion, 
stimulated by 1 mg (i.v.) glucagon, is a widely accepted method 
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to study the endogenous insulin reserve in insulin dependent 
diabetic patients (Faber 1977, Hendriksen 1977, Madsbad 1981). 
This test which frequently induces nausea and vomiting is rather 
traumatic for children. Hence, it can not be used to follow the 
endogenous insulin secretion at frequent intervals. 
Provided that the integrated plasma C-peptide levels and the 
C-peptide concentration in 24 hours urine correlates well, 24 
hours urinary C-peptide excretion may serve as a measure for the 
actlVlty of the beta cells during a 24 hours' day (Meistas 
1981). Before using this parameter we have studied the relation-
ship between the 24 hours urinary C-peptide excretion and the 
plasma C-peptide levels during the glucagon stimulation test and 
after an overnight fast. 
First the method is described according to which plasma and 
urinary C-peptide levels are determined. The C-peptide determina-
tions have been performed by the Department of Clinical Chemis-
try, Erasmus University and University Hospital Rotterdam. This 
is followed by a comparison of the 2 methods. Finally reference 
intervals for the 24 hours urinary C-peptide levels in healthy 
children are estimated, obviously necessary to interpret the data 
obtained from diabetic children. 
Methods 
After collecting blood samples in heparinized Vacutainer tu-
bes, the samples are placed on ice. Shortly thereafter tge sam-
ples are centrifuged. Plasma samples are stored below -20 C un-
til assay within a fortnight. 
Urine is collected at home during 24 hours. Every voiding is 
frozen immediately in the freezing part of the home refrigerator 
(-9° Cor less). The urine samples for the C-peptide measurement 
are processed under the same conditions as the plasma samples. 
Plasma C-peptide and urinary C-peptide levels are determined 
in the same assay according to the method described by Reding, u-
sing the antibody Ml230 (NOVO, Bagsvaerd, Denmark) (Reding 1975). 
All samples are pretreated with PEG-6000 (Merck, Darmstadt, FRG) 
to a final concentration of 12.5% to remove possible antibody 
bound (pro)insulin. Then they are centrifuged. An adaptation of 
the original procedure is the completion of the separation of 
bound and free C-peptide performed by precipitation with PEG-6000 
(final concentration 15%) instead of ethanol. A study of 30 plas-
ma samples containing significant amounts of C-peptide showed no 
difference in PEG pretreatment directly after sampling or after 
storage of untreated samples below -20P C (for maximally 14 days) 
and pretreatment just prior to C-peptide determination. Human 
albumin (Behringwerke, Marburg, FRG) in phosphate buffer 0.04 
mol/1, pH 7.4, was added to all urine samples until 6% (w/v), 
in order to avoid matrix induced differences between serum and 
urine samples. From each sample dilutions 1:3, I: 11 and 1:33 
were made. Upon dilution the nrine samples thus treated showed 
good parallelism. As the standard curve encompassed 0.01 to 0.25 
nmol/1 C-peptide urine samples, diluted up to a concentration of 
approximately 0.15 nmol/1, are taken to calculate the C-peptide 
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concentration in the original urine sample. In this way the most 
accurate part of the standard curve is sought. 
The lower limit of sensitivity in our assay (expressed as c.p.m. 
for zero standard and 3 SD) is 0.02 nmol/1 for plasma samples 
and 0.06 nmol/1 for (at least threefold diluted) urine samples. 
For plasma samples the intra assay coefficient of variation 
(cv) is 7% in the lower range (0. 19 nmol/1), 4% in the middle 
range (0.38 nmol/1) and 5% in the upper range (0.56 nmol/1) res-
pectively (n=9). For urine samples the intra assay cv is 14% 
(0. 13 nmol/1), 3% (2.6 nmol/1) and 4% (12 nmol/1) respectively 
(n=10). The inter assay cv's for plasma samples are 26% (0.09 
nmol/1, n=20), 6% (0.42 nmol/1, n=20) and 7% (0.68 nmol/1, n=l3). 
The inter assay cv's for urinary samples are 17% (0. 16 nmol/1, 
n=38), 9% (2.7 nmol/1, n=42) and II% (13.8 nmol/1, n=39). 
Comparison of plasma and urinary C-peptide levels 
In order to evaluate the relationship between plasma C-peptide 
levels after an overnight fast, during the glucagon stimulation 
test and the 24 hours urinary C-peptide excretion the 30 partici-
pating children have been tested and have collected 24 hours uri-
ne, as previously described. It is assumed that the children 
maintain their usual insulin regime, diet and level of activity 
during each collection period. 
The glucagon stimulation test has been performed in the hospi-
tal. The morning of the test the children have arrived fasting 
at the hospital at 8.00 a.m .. On admission an indwelling intrave-
nous catheter (22G) has been inserted through which blood sam-
pling has taken place. Its patency has been maintained by 
flushing with saline 0.15 mol/1 with 50 units of heparin/ml sali-
ne after each blood sample. At 15 and 0 minutes before and 6, 15, 
30 and 45 minutes after a slow intravenous injection of I mg 
glucagon~ (NOVO, Bagsvaerd, Denmark) blood samples have been ta-
ken to measure the C-peptide and glucose concentrations. Blood 
samples are kept on ice until further processing is carried out, 
as previously described. Within one week of the glucagon stimu-
lation test (but with at least a 24 hours difference) the 30 
children have collected at home 24 hours urine, freezing each 
voiding immediately. 
Plasma C-peptide values obtained during the glucagon test are 
expressed as the area under the curve, taking the X-axis as lower 
limit. 
The plasma C-peptide concentrations during the glucagon sti-
mulation, expressed as area under the curve (AUG) and the fas-
ting plasma C-peptide levels show a significant correlation with 
the C-peptide excretion in 24 hours urine (nmol/24h) with r=0.83 
(p < 0.001) and r=0.83 (p < 0.001), respectively figure 4.2a and 
4.2b. 
This correlation indicates that the stimulation of beta cell 
act~v~ty in insulin dependent diabetic children by glucagon 
administration and under 'normal life' activities and meals re-
sults in comparable C-peptide values. The relationship between 24 
hours urinary and fasting plasma C-peptide concentrations sug-
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gest that the beta cells are also stimulated during the early 
morning. This may be ascribed to the increased insulin 'need' or 
decreased insulin sensitivity during the early morning (Campbell 
1985). 
Apparently, different hyperglycaemic stimuli, resulting in the 
24 hours urinary and fasting blood C-peptide levels, provoke a 
comparable and probably maximal activity of the residual beta 
cells. 
Glucagon administration also results in a stimulation of the 
residual beta cells. Both ways of stimulation therefore appear to 
result in a maximum activity of the beta cells, although effectu-
ated by different mechanisms. 
Thus the measurement of 24 hours urinary C-peptide levels 
seems to be a reliable and non-traumatic method to estimate beta 
cell activity. In the pump study the children have collected 24 
hours urine once a month (before or just after their visit to the 
hospital). Because the mechanisms of stimulation probably differ, 
the glucagon stimulation test has not been entirely stopped. It 
has been conducted after 6 and 12 months. 
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Figure 4.2a and 2b The relationship between the 24 hours urina-
ry C-peptide production (nmol/24h) and 
stimulated plasma C-peptide values, expres-
sed as area under the curve (AUC) (2a) 
- fasting plasma C-peptide values, expressed 
as nmol/1 (2b) 
in 30 insulin dependent diabetic children 
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Estimation of reference intervals 
For the interpretation of the 24 hours urinary C-peptide ex-
cretion with regard to the different ages of the diabetic 
patients, reference intervals have to be estimated. Control data 
have been obtained from 30 healthy siblings (S<;j?, 22 cJ'). The-
se children have a normal sHbAl percentage, no islet cell anti-
bodies nor any other relevant disease. To observe the physiolo-
gical variation in urinary C-peptide excretion, 19 of these 
siblings have collected 24 hours urine once every 5 to 7 weeks 
during I year. Eleven children have collected 24 hours urine 3 
times. Informed consent has been obtained from the parents of all 
part~c~pating children, according to the Helsinki Declaration. 
The statistical analysis of the control group data comprises 
analyses of variance, segregating variability between children 
(c), between sampling days (d) and the residual variability 
(within) children and the intra assay variability (r). Analyses 
of variance are performed using a special computer program (GLIM) 
to take account of the fact that the urine samples of the 30 
children could not always be assayed within the same batch and 
therefore could be considered randomly distributed between assay-
batches (Baker 1978). Since the data have been obtained from RIA 
calibration curves using a logscale, the data as recorded 
(nmol/24h) are transformed to logarithms before executing the 
analysis. The results of the analysis of variance of all sibling 
data are given in table 4.VI. 
Table 4.VI Analysis of variance of siblin~ data 
Source of Degrees Mean Expected vari- Individual com-
variation of square ance components ponents of vari-
freedom ance 
between 2 
.,2 "2 • children 29 0.401 "r + 7 c c 0.052 
between 2 30 a2 2 days 41 0.058 
"r + d (jd = 0.001 
residual 139 0.038 "2 2 r "r" 0.038 
Clearly residual variability (mainly physiological - within 
children - variability) and variability between children contri-
bute most to overall variability. The variation between assay 
days is negligible. In order to investigate whether part of the 
variability can be explained by variation -in age, a scatter plot 
has been drawn (figure 4.3). To take this relationship between 
age and urine C-peptide excretion into account, the method of 
segmented regression is applied to derive regression equations: 
mean log (Urinary C-peptide excretion) = 0.19 + 0.089 age (upto 
10 years); mean log (Urinary C-peptide excretion) = 1.084 (~ 10 
years ) (Draper 1981). 
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Figure 4.3. Scatter plot of logarithms of C-peptide excretion 
data (nmol/24h) against age (years) for 30 healthy 
siblings; each point represents the mean of 3-10 
monthly determinations. Regression lines fitted ac-
cording to segmental method are shown. 
,.z "2 .... z The estimated components of variance ( Gc, G'd and <fr and 
the estimated regression equations are used to derive estimates 
of reference intervals for the urinary C-peptide excretions. The-
se reference intervals are estimated as 
predicted mean + factor times standard deviation. 
The factor depends on the desired amount of coverage of the 
population and on the degree of confidence that this amount Cor 
more) will be covered (Geigy 1968). Given the number of indivi-
duals on which the present regression equations are based this 
factor is K = 2.2, so that on average 95% of the population stu-
died is covered. The standard deviation is derived from the esti-
mated components of variance, taking into.account the number of 
independent replicate determinations (n) per individual, accor-
ding to the formula: 
2 
(standard deviation) + 
n n 
The estimated reference intervals are given in table 4.VII 
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Table 4.VII 95% Reference interval for C-peptide excretion 
;aiues, applying ~various conditions 
--------------------------------------------------------------------------
Age 
(yrs) 
Predicted mean 
logscale rrmol/24h 
Number of replicates per individual (n) 
1 2 3 5 10 
--------------------------------------------------------------------------
2 0.368 2.3 0. 7- 7.8 0.9- 6. 1 l. 0- 5.5 l. 1- 5.0 l. 2- 4.6 
4 0.346 3.5 1.0-11.8 1.4- 9. 1 1.5- 8.2 1.6- 7.5 1.8- 7.0 
6 0.724 5.3 1.6-17.8 2.0-13.7 2.3-12.4 2.5-11.3 2.7-10.5 
8 0.902 8.0 2.4-26.8 3. 1-20.7 3.4-18.7 3. 7-17. 1 4.0-15.8 
~10 1.034 12. 1 3.6-40.7 4.7-34.5 5.2-28.4 5.7-25.9 6.1-24.0 
standard deviation 
Clogscale)* 
0.239 0. 188 0. 168 0. 150 0. 135 
2 
* (SD) 
0.043 
n 
+ 0.014 
For easy interpolation they are also shown in graphical form 
(figure 4.4.). These results indicate that the actual reference 
limits will narrow by a factor of about 2 when means of excretion 
values from 5 independent samplings are considered instead of a 
single determination. There is a considerable variation in UCP 
per child. This is not unexpected since these reference values, 
obtained in healthy siblings, will probably not represent a maxi-
mally stimulated endogenous insulin production, as is more likely 
to be the case in diabetic children. The linear increase in uri-
nary C-peptide excretions from 2 to 10 years emphasizes the 
importance of taking age into account when evaluating the urinary 
C-peptide excretion in children. 
In the pump study the urinary C-peptide excretion will be ex-
pressed as a percentage of the predicted mean value (UCP), accor-
ding to the age of the child (calculated for each month). 
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IMMUNOLOGICAL PARAMETERS 
The following antibodies have been included in order to obser-
ve their possible influence on the residual beta activity after 
clinical onset of IDDM: 
islet cell cytoplasmic antibodies (ICCA) 
- islet cell cytoplasmic antibodies, which are complement fixing 
(ICCA-CF) 
- islet cell surface antibodies (ICSA) 
- anti insulin antibodies IgGia 
anti insulin antibodies IgGib 
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Islet cell cytoplasmic antibodies are detected with indirect 
immunofluorescence assays on sections of a fresh frozen human 
blood group 0 pancreas as described in detail by Marner and co-
workers (Marner 1983). They have been measured by the Department 
of Clinical Immunology, (dr Molenaar, Stichting Samenwerkende 
Delftse Ziekenhuizen, Delft). The results are given in a semi-
quantitative scale, varying from negative (0) towards highly 
positive (4+). Blood samples are assayed at onset and after 6 and 
12 months. 
For the detection of islet cell surface antibodies (ICSA) in 
the sera of the diabetic children viable rat islet cells are 
used. Indirect immunofluorescence is used to demonstrate the 
binding of human antibodies to rat islet cell membranes. A more 
detailed description of the assay is given by Van de Winkel (Van 
de Winkel 1982). The patients' samples have been kindly tested at 
onset and after 6 and 12 months by the Department of Clinical Re-
search, (Head of Dept.: Prof. D. Pipeleers, VUB, Brussels, Belgi-
um). The results thus obtained are also given in a semiquantita-
tive scale, varying from negative (0) up to highly positive (4+). 
To study the antibody production in the participating children 
before the start of insulin therapy and 3, 6, 9 and 12 months la-
ter, insulin antibody levels have been kindly determined by NOVO 
Research Laboratory (Bagsvaerd, Denmark) according to the method 
of Christiansen (Christiansen 1973). These form the classic 
insulin antibodies (IgGia). 
The presence of anti insulin antibodies before the start of 
insulin therapy (IgGib) has also been checked by a more sensitive 
method. Blood samples of our patients taken before the start of 
the therapy have been kindly tested by the Hagedorn Research La-
boratory (dr C. Binder, Gentofte, Denmark). The detection of the 
antibodies has been performed by means of a sensitive, modified 
PEG-assay (Lauritzen 1982). Non-specific binding is subtracted. 
This implies that positive figures indicate a significant and 
specific binding. 
STATISTICAL ANALYSIS 
The results are given as mean + 1 standard error of the mean 
(SEM)) 
sHbAl, UCP and insulin dose 
The statistical analysis has been performed in close collabo-
ration with Professor Van Strik (Department of Biostatistics, 
Erasmus University Rotterdam, Rotterdam). 
Three parameters, sHbA1, UCP and -the insulin dose have been 
studied inter alia. To facilitate the evaluation of these data 
with respect to each other as well as with respect to the two 
groups, several characteristics have been calculated for each of 
these parameters. 
The sHbAI values have been plotted against time. Following 
aspects are studied: increasing or decreasing trend in time, the 
variability of sHbA1, as an indication for the stability of 
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metabolic control, 
ter which the sHbAI 
the course of sHbA1 and the breakpoint at-
increases significantly compared with previ-
ous determinations. 
To approximaLe Lhe decreasing or increasing trend, without an 
assumed normal distribution and minimizing the influence of 
extreme values, a median straight line is drawn through the 
plotted points. This means that before and after the median value 
on the X-axis respectively the same numbers of values are situa-
ted above and below the line (Brown 1951, Mood 1950). The slope 
of this line (henceforth called Mood line) provides an estimate 
of the trend that describes the course of sHbA1 values in time. 
Since the first two values of sHbAl (at onset and after 1 month) 
are affected by the previous period (before the onset) these 
points are not included. 
Not only the trend but also the level of sHbAl is relevant. 
The value on the Mood line after one year (influenced by all pre-
vious points), has been chosen to characterize, in addition to 
the slope, the course of sHbAl. 
The degree of variation around the Mood line is characterized 
by the number of crossings of subsequent points above and below 
the Mood line in relation to the total number of points (varia-
bility index). 
Three successive sHbA1 values above 9.0% are considered to 
characterize the end of the remission period regarding the meta-
bolic control. The first of these 3 successive points in time at 
which the sHbA1 exceeds 9.0%, is considered to be the breakpoint 
and therefore the end of the remission period with respect to the 
metabolic control. Finally the sHbAl value at onset is used as 
parameter for the metabolic disregulation. Hence, the sHbAl 
course is characterized by the following factors: 
- the initial sHbAl level - as parameter for the metabolic disre-
gulation 
- the slope of the Mood line 
- the sHbAI value on the Mood line after one year of IDDM 
the variability index 
- Lhe first moment of three at which a sHbAl above 9.0% is measu-
red. 
For the course of UCP the same methodology as described above 
is used. As discussed previously, the urinary C-peptide values 
are given as percentage of the predicted mean for a certain age 
(age is expressed in years+ months). These pe~centages are plot-
ted againsL time. Criteria for the evaluation of the UCP course 
is the presence or absence of a significant increase of UCP after 
the starL of the treatment, its maximal value, the speed of the 
decrease, the (predicted) moment at which no UCP can be detected 
anymore and the variability in UCP. First the Mood line is drawn 
through the plotted dots, as described above, taking account of 
all determinations. Sometimes it is not possible to draw this 
line through all points, because of a considerable increase of 
UCP after the onset, henceforth called "a peak". This peak is 
characterized by a maximal value and the point in time at which 
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it terminates. In these cases the line will be drawn from this 
turning point onwards. 
The assessment of the presence of a peak has been performed by 
two observers. One of the observers has received the plotted 
data, without knowledge of the patients and their treatments. If 
UCP is still detectable after I year, extrapolation of the line 
towards UCP = 0 provides information on the predicted point in 
time at which no UCP will be present anymore. 
The variability index for UCP is, similarly as for sHbAl cha-
racterized by the number of crossings in relation to the number 
of determinations. Thus, the UCP course is characterized by the 
following factors: 
- the 
- the 
(in 
-
the 
- the 
ted 
the 
initial UCP 
maximal UCP 
the presence 
slope of the 
(predicted) 
anymore 
variability 
of a peak) the end time of the peak 
Mood line 
point in time at which no UCP can be calcula-
index. 
The insulin dose usually increases gradually. The moment at 
which the dose exceeds 0.50 U/kg bodyweight/24 h marks the end of 
the remission period with respect to the insulin dose. Hence, 
this parameter will be characterized by the following aspects: 
the increase of the dose during the first year 
the frequency and the size of the increasing steps 
the point in time at which the dose exceeds 0.50 U/kg body-
weight/24 h. 
Psychological tests 
To evaluate whether in the psychological test "Assessment of 
Acceptation" the opinions of the 5 reviewers are in agreement, 
the test of Friedman has been applied (DeJonge 1983 1). If the 
hypothesis "the various observations of the different reviewers 
are not in agreement" is rejected, the .scores of the different 
reviewers for each child can be added. This has the advantage 
that the scale of this assessment test increases from 1-5 to 5-
25. 
This increased diversity of the results may allow a better compa-
rative evaluation of the two groups. 
Comparison of~~ groups: CSII ~ CT 
The two-sided test of Wilcoxon (or U-test of Mann & Whitney) 
is applied to compare the two groups of patients with respect to 
quantitative data at significance level of a= 0~05 (De Jonge 
1983 2). The Chi-square test (for a 2 x 2 Table) is used to eva-
luate the differences between the two groups with respect to 
binary observations (DeJonge 1983 3). Finally, the test of Yates 
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and Cochran has been applied to analyse the semiquantitative da-
ta (DeJonge 1983 4). 
Relationship between the different parameters 
To determine whether an association exists between the time 
courses of UCP and sHbA1 the Pearson contingency coefficient is 
determined (Sachs 1978). 
For the evaluation of the relationship between the 
parameters the Spearman coefficient of correlation (r 
Calculated (De Jonge 1983, 3). s 
different 
or r ) is 
An P value < 0.05 is considered to indicate statistical signifi-
cance. To evaluate differences between 2 coefficients the Spear-
man coefficient (r ) must be transformed into a Pearson coeffi-
cient Crp), since ~o test has been developed yet to analyse the 
difference between 2 Spearman coefficients. The Pearson coeffi-
cients are transformed in a Z value according to the following 
formula: (Z""" 1.1513 (log (1 + rp)- log ( 1- rp )). The statis-
tic Z is standard normally distributed. 
The transformation of r 8 to rp may be performed according to 
the formula: rp = 2 sinus 1/6 1t. rs , with 2 assumptions. These 
assumptions, a binormal distribution and sufficiently large 
random samples ( >30) are (probably) not fulfilled. This implies 
that if no significant difference is found it is highly unlikely 
that the difference may become significant in other tests, speci-
fically developed for Spearman coefficients. 
SUMMARY 
The study design and protocol and the parameters chosen for the 
pump study are expected to supply answers to the following ques-
tions: 
I. Is CSII feasible in previously randomized newly diagnosed dia-
betic children? What is its psychological impact? 
Are CSII-treated children and/or their parents requiring mo-
re attention from the diabetes team, and in particular from 
the nurse practitioner? 
Are the treatment and its consequences accepted by the child 
and its family? 
- Are the problems caused by the therapy acceptable? 
- Is it reducing possible effects of IDDM on the personality 
and the social contacts of the child? 
2. Does CSII improve the metabolic control of insulin requiring 
diabetic children? 
Do the CSII treated children achieve a better metabolic con-
trol or even near normoglycaemia? 
- Does the metabolic control remain better (or near normal) 
during a longer timespan. 
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Does CSII treatment result in a more stable metabolic regu-
lation, reducing the frequency of necessary blood glucose 
measurements at home? 
Do CSII treated children need smaller insulin doses? Is 
their dose adjusted more frequently with smaller amounts? 
3. Does CSII prolong the remission period and is it possible to 
elucidate which factors contribute to the effect of CSII on 
the remission phase. Can some factors be excluded to exert a 
(direct) influence on it? 
- Is CSII resulting in a larger UCP during a longer period of 
time? 
- Is the slope of the UCP path less steep in CSII treated 
children? 
- Can a distinct association be demonstrated between the cour-
ses of sHbAI and UCP? 
Is the occurrence and duration of the remission period rela-
ted to characteristics of the patients (HLA type, metabolic 
disregulation, age)? Can a relationship be shown between 
these characteristics and the individual parameters of the 
remission? 
- Or can an association be demonstrated between the presence 
of immunological disturbances (ICCA, ICCA-CF, ICSA, IgGia 
or IgGib) and the remission period? 
Does CT or CSII treatment induce a different production of 
insulin antibodies (IgGia), using human insulin in both 
groups? 
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CHAPI'ER5 
RESULTS OF THE PUMP STUDY 
INTRODUCTION 
From November 1981 until June 1984 34 newly diagnosed diabetic 
children have been referred to the Sophia Childrens 1 Hospital. 
Thirty participate in this prospective study and have started at 
random with either CSII or CT. 
The first paragraph of this chapter deals with the characte-
ristics of the children participating in the study. Subsequently 
results of one year of follow-up are given. As mentioned previ-
ously, the results of the psychological tests are incomplete as 
the children are tested only after two years. As a result a total 
of 15 children has been tested psychologically so far (6 chil-
dren with CSII and 9 with CT treatment). The chapter ends with a 
summary. 
CHARACTERISTICS OF THE PARTICIPATING CHILDREN 
The characteristics of the 30 children who entered with infor-
med consent this study, are given in table 5.1. Each child will 
be identified by a number in the subsequent text (I-15 for the 
CSII group and 16-30 for the CT group). 
Table 5.1 Characteristics of the participating children 
CSII patients CT patients 
patienta age at 
onset 
(yrs) 
I !0.9 
2 16.8 
3 12.3 
4 13.9 
5 10.3 
6 13.2 
7 3.0 
8 7.2 
9 5.8 
10 7.6 
II 11.5 
12 12.5 
13 6.0 
14 1.9 
IS 9.6 
M 
M 
M 
F 
F 
F 
M 
F 
M 
F 
F 
F 
M 
M 
M 
HLA Dr 
4 6 
4 3 
2 3 
4 3 
5 3 
7 3 
4 8 
4 3 
4 I 
I 3 
4 3 
4 6 
3 3 
3 3 
4 3 
socio-
economic 
class 
2 
6 
6 
6 
4 
2 
6 
5 
5 
5 
2 
6 
6 
6 
3 
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patients age at 
onset 
(yrs) 
16 3. I 
17 4.8 
18 12.3 
19 8.8 
20 11.8 
21 I 1. 1 
22 6. 9 
23 5.1 
24 4.5 
25 4.3 
26 4.2 
27 11.6 
28 4.8 
29 10.2 
30 1.8 
M 
F 
F 
M 
F 
M 
M 
M 
F 
F 
F 
F 
M 
F 
M 
HLA Dr 
4 3 
4 3 
3 3 
4 2 
I 8 
4 4 
4 I 
6 3 
9 3 
4 3 
4 3 
4 4 
6 3 
4 4 
4 2 
socio-
economic 
class 
5 
6 
3 
3 
6 
2 
3 
6 
5 
3 
6 
6 
2 
4 
6 
Of the 34 originally referred children 4 "dropped out". One 
Moroccan child has not been treated as planned with CSII because 
she had already started manipulating the pump in the hospital. 
This together with the language problem has necessitated the de-
cision to terminate CSII treatment. Two children, 5 and 2 years 
old respectively, have started with CT instead of the planned 
pump treatment because of their age at onset. Smaller pumps have 
just become available early in 1984. Starting CSII (the 
Autosyringe AS6C) with these children would have evoked images 
not of children with pumps but of pumps with children. Finally, 
one child started with CSII instead of the CT because of her fa-
mily history. Her 2 year-older diabetic sister had just started 
with CSII, because of a brittle diabetes. Her well-being and me-
tabolic control had improved considerably. Not only the risk of 
meeting the same problems with this second child, but especially 
in consideration of all the family had been through provoked 
the decision to start immediately with CSII. The data of these 
patients are not included in this thesis. 
None of the participating children has any other relevant 
disease. 
The mean age of the two groups differs significantly (CSII 
group: 9.5 ± 1. I years; CT group: 7.0 ± 0.9 years), possibly as 
a consequence of the drop outs in the beginning of the study. 
The two groups do not differ with respect to sex. Eight boys 
and 7 girls have started with CSII, whereas 7 boys and 8 girls 
have started with the CT. 
As expected most children have either HLP.- Dr 3, HLA-·Dr 4 or 
HLA-Dr 3,4, except for only one child (20) who has HLA-Dr 1,8. 
The two groups do not differ with respect to their socioeco-
nomic background. Thus the only significant difference between 
the two groups of children is the age at onset. 
Clinical onset of IDDM 
At the onset no difference between the two groups has been 
found with respect to the degree of metabolic disregulation, en-
dogenous insulin production, or duration of previous symptoms 
(polyuria, polydipsia, evident weight loss, listlessness). They 
are shown in table 5.II. Three children (14, IS, 30) have been 
hospitalized because of dehydration and/or metabolic disregula-
tion requiring rapid intravenous administration of fluid and 
insulin. One conventionally treated child (16) has been hospita-
lized because of the absence of the nurse practitioner. As pre-
viously mentioned, in principle CSII treatment is started at 
the hospital. One exception has been made for a girl (8), who had 
a brother with IDDM. Since the family of this patient had suffi-
cient knowledge of the disease itself, starting CSII at home (as 
only new element) seemed justified. (One of the drop outs - with 
a positive family history for IDDM - also started at home with 
CSII for the same reason). 
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FEASIBILITY AND PSYCHOLOGICAL IMPACT OF CSll 
Pump treatment is usually started during a hospitalization. 
Hospitalization is certainly necessary for the newly diagnosed 
children, participating in this study. So far two types of pumps 
are used: the Autosyringe AS6C and the Eli Lilly/CPI Betatron 
9204. The pumps are shown in figure S.Ja and 5. lb. For more de-
tailed information on the functioning of those pumps the reader 
is referred to the two instruction booklets. 
During hospitalization the practical skills needed for an ade-
quate use of the pump are learned by patients and/or parents. The 
filling of the syringe and the catheter without air bubbles, the 
insertion of the needle in subcutaneous tissue, the adjustment of 
a basal rate and administration of bolus doses are skills that 
have to be performed correctly before the patient is allowed to 
leave the hospital. Once every day a new battery (recharged) is 
to be put into the pump. 
Ia lb 
Figure 5. Ia and lb. The 2 pumps: 
la: Autosyringe AS6C 
lb: Eli Lilly/CPI Betatron 9204 
From the instruction booklets, designed by 
Berenice Noordam 
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In most cases the syringe is refilled once a day. The needle and 
catheter are changed every 2 to 7 days and in case of skin in-
filtration, obstruction or activ~t~es which can only be perfor-
med without pump (swimming). The place where the pump is carried 
during daily life, differs per patient. Some children wear it on 
their side (on a belt) just like the very popular walkman or in 
their pockets. Others carry it under their arm, in a small bag 
attached to shirt or bra. Only a few children wear the pump on 
their back or belly. Most mothers (and fathers) have proven quite 
inventive by making small pockets of cotton or corset tape on 
shirt or bra. These pockets can be closed with "sticking tape". 
In this way each child can choose its own preferred place. 
One may wonder how much time the pump costs the children. One 
child told us, that he spent at most 10 minutes per day on it and 
compared it to brushing his teeth. Usually it will vary from 10-
20 minutes (including a total change of the infusion system) to 5 
minutes (only the change of the battery and the syringe). 
Measuring blood glucose levels, ketonuria and glucosuria is 
also taught in the hospital. 
The insulin dose is given as a basal rate (continuously during 
24 hours) and as bolus before each meal. Short acting insulin is 
always used in the pump. In general, the basal rate consists of 
40% to 60% of the total dose. In younger children this ratio 
changes towards 25% basal and 75% bolus doses. The boluses are 
usually equal for each meal, although differences in activities 
or in caloric intake during a meal may result in different requi-
rements. Preferably bolus doses are given half an hour before 
each meal. In practice, however, this will only be done at break-
fast. The bolus is given before showering and getting dressed. 
The basal rate is determined on the basis of fasting and early 
morning blood glucose levels (03.00 h). The latter are measured 
about once every month. Bolus doses depend on the blood glucose 
values before and after the meals. 
Patients and/or parents are advised to control the blood glu-
cose level 3 to 5 times a week. The same advice is given to the 
CT group. Blood glucose values between 4.4 and 10.0 mmol/I are 
pursued. 
Newly diagnosed children and their parents receive the same 
information concerning the theoretical background of diabetes 
(see chapter 3). Generally the nurse practitioner will give this 
instruction, but sometimes the department nurses take over. 
Adjustments in special situations. (see table 3.I) can be 
accomplished by changes in the basal rate as well as in bolus do-
ses. An advantage- especially for children- is the easy way in 
which extra insulin can be administered. However, if hypergly-
caemia seemingly without explanation is found, the entire system 
(syringe, catheter with needle) must be replaced. Several sports 
(swimming, rugby) require extra action since they can not be done 
at all or less well with a pump. The pump must be disconnected 
and reconnected afterwards. 
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During the first period after diagnosis the timespan without 
pump - and as a result without insulin - can last surprisingly 
long (sometimes upto 6 hours) without causing metabolic disregu-
lations. However, after several months (for some children several 
years !!) it becomes evident- through r~s~ng blood glucose 
levels - that extra insulin must be administered before or after 
the period of disconnection. The duration of this period without 
insulin has to be reduced in time to a maximum of one hour. 
Acceptation of CSII 
Opinions of parents and patients have been asked regularly by 
the doctor during the visits to the hospital and by the nurse 
pract~t~oner. Especially during warm weather patients have hesi-
tated and seriously considered changing the pump therapy into in-
jections. Still, none of them really wanted to start with CT. Af-
ter 28 months of CSII one child (4) has decided to stop the CSII 
treatment. So far the other children all want to continue. Thus 
far, the insurance companies of 5 of the children, who have 
finished the study, have agreed to take over the costs of pump 
therapy after the two years of the study. 
Problems 
A new therapy never before used in a certain population will 
be accompanied by new problems. 
The problems encountered with CSII treatment in more than 360 
patient months (considering only the participating CSII children) 
are listed in table 5.III. 
The problems are divided in 3 groups: directly caused by fai-
lure of the pump (I), errors or negligence of the patient (or pa-
rents) (IIa), and topical reactions at the insertion place (IIb). 
The frequency with which these problems have been reported 
during the first year is scored I (< 5 times), 2 ( ~5 times, < 15 
times) or 3 (~ 15 times). 
After a fall in the water by one of the children (the drop 
out, treated with CSII) her Autosyringe AS6C started to adminis-
ter continuously increased insulin doses, obviously requiring an 
immediate removal of the pump. The fact that the pumps are not 
waterproof has been confirmed by other accidents. Accidently put-
ting the pump in the washing machine or in the toilet has resul-
ted in irreparable damage as well. To what extent these actions 
point to problems in handling the pump or problems with the ac-
ceptation of the disease remains questionable. Except for these 
problems the pumps have proven to be "child-proof". 
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TABLE S.III Problems with CSII 
Pump-related Frequency* Patient-related Frequency* 
I. Defective syringe 
holder 
Defective batteries 
IIA Forgotten to give 
2 meal doses 3 
3 ** Forgotten to change/re-
fill the syringe 2 
Defective charger Forgotten to change/ 
charge the battery 2 
Detachment of the needle 
from the catheter 
Defective syringe top 
Leakage of the syringe 
Alarm without a clear 
explanation 
Inadequate adding system 
2 
2 
Too late change of the 
catheter and needle 
Air bubbles in the ca-
theter 
Clogged catheter (blood 
clot) 
Detached catheter (from 
the skin) 
IIB Irritation of the skin 
at the insertion place 
2 
2 
2 
2 
(scratch effects) 2 
* I: < 
2: 
3: 
5 
< 15 
~ 15 
times 
times~ ~ 5 times 
times 
Infiltration around the 
insertion place 2 
Haematoma at the inser-
tion place 3 
** only during the first 6 months, because of a poor batch of 
batteries. 
A serious problem has been caused by the detachment of the 
needle (inserted in the subcutaneous tissue of the abdomen) from 
the catheter. This necessitated surgical intervention, with lo-
cal anaesthesia, to remove the needle. The adding system (of Eli 
Lilly/CPI Betatron 9204) has caused commotion twice by indicating 
entirely different doses from what was expected. The correct and 
planned dose of insulin was administered anyway and no metabolic 
disregulation occurred. It was possibly caused in one case by a 
defective back-up battery. In both cases the pumps have been 
returned to the producers in order to be checked over and repai-
red. 
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Defective syringe tops resulting in leakage between the syrin-
ge and the catheter and leaking infusion sets have evoked blood 
glucose increases, especially if the catheter is changed in the 
evening (and the deficit is not noticed until the next morning). 
Defective syringe holders of the Autosyringe AS6C are seen 
rather often. This defect can be caused easily be inserting the 
syringe into the holder too brusquely (haste??). 
The first batch of batteries, belonging to the Eli Lilly/CPI 
betatron 9204, had to be replaced because some of them did not 
function correctly for at least 24 hours. 
The patient-related problems speak for themselves. Meal doses 
are certainly easily forgotten in the first period after the 
diagnosis, especially by teenagers at school before lunch. This 
error is usually corrected during or shortly after the meal. 
Clogged catheters, usually caused by a blood clot, are fre-
quently seen in youngsters after a romp with friends, brothers 
and sisters, and in older children after sports. Removal of the 
catheter is not always necessary. In case a meal dose has to be 
given the clot may be removed through this shortly after its dis-
covery. 
Air bubbles form a problem also known by syringe users. It is 
very important, however, that the syringe as well as the catheter 
are free of air bubbles, since air replaces insulin. 
During the first period of pump use, the ~nJeCtion technique 
has been changed for several patients. To prevent leverage of the 
part of the needle still in the catheter (usually about SO%) the 
needle is bent just beyond the catheter. Thus for each patient an 
ideal angle can be obtained to administer the insulin deeply into 
the subcutaneous tissue. This has resulted in a reduction of the 
hematoma at the insertion site. 
Infiltration around the insertion place has been considerably 
reduced by the use of Cremer Chlorhexidin FNA R. The application 
of a little bit of this cream on the skin before inserting the 
needle or after removal of the needle is very effective. If too 
much is applied before the needle is inserted, problems arise 
with the adhesive plaster, which will no longer stick. 
Irritation of the skin caused by scratching has been reduced 
but not stopped by the application of Calmitol cream (5% calmitol 
in Cetomacrogolcream). 
In general problems encountered with the use of pumps for chil-
dren have been minor so far. They certainly do not form an ob-
stacle for the continuation of this treatment in all age groups. 
Required attention: phone calls and home visits 
The last two parameters considered in evaluating the feasibi-
lity of CSII in newly diagnosed children are the frequency of 
phone calls and home visits. Their frequency has been assessed by 
checking the nurse practitioner's agenda and the patients' re-
cords. 
Three arbitrary categories of telephone calls of patients/pa-
rents to the nurse practitioner can be distinguished: 
l. seldom contact (~ I call per month) 
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2. regular contact (> 1 and $ 5 calls per month) 
3. frequent contact (> 5 calls per month) 
Frequent telephonic contacts have been made by the parents of 
2 CT children. The parents of 8 CT and of 4 CSII children have 
regularly telephoned the nurse practitioner. The parents of 5 CT 
children and of 10 CSII children telephoned seldom. This suggests 
a distinct difference between the two groups with respect to the 
frequency of telephonic contacts. 
About 245 visits to the homes of the patients have been made 
by the nurse practitioner. In 97 cases the purpose was initial 
education, metabolic regulation and practical lessons for the 
newly diagnosed CT children. These daily visits for instructio-
nal purposes have been made with a mean duration of 7.5 days. 
A refreshers' course (practical or theoretical) has been given 37 
times to the CSII group and 59 times to the CT group. An inte-
resting fact is the small annotation in the diary of the nurse 
next to the written appointment with the first CSII patient: 
"Must have a look how everything is going". She told afterwards 
that the purpose of her visit was for her own instruction to see 
how a child with CSII was doing at home! 
Instruction to schoolteachers, general physicians etc. 
been given 13 times for CSII children and 14 times for the 
group. 
has 
CT 
Home visits for psychological and/or pedagogical problems have 
been made 9 times for CSII children and 11 times for CT children. 
One CT child has not been visited by the nurse practitioner. Very 
good collaboration with district nurses has resulted in their in-
volvement. During the first 3 months this child was visited dai-
ly by the district nurse (90 times!). Thereafter this frequency 
was reduced and now a check is made regularly (twice each month). 
The frequency of home visits does not differ significantly. 
There is a lighc tendency for less visits co CSII patients. Of 
interest is, as yet unmentioned, the category of home visits 
not made for the benefit of the patients but by request of doc-
tors with visiting colleagues. Several times parents and patients 
have been very kind in receiving these visiting foreign doctors 
at home, which is not always an easy matter considering inter 
alia the frequently occurring language barrier. 
Psychological tests 
So far, 15 of the 16 children who have finished the 2 years of 
follow-up have been tested psychologically. Of 1 CT child the 
parents have refused participation in psychological tests. Nine 
CT and 6 CSII children have been tested. The age (at the test mo-
ment) of the two groups differs significantly (CT group: 9.3 ~ 
1.2 years of age; CSII group: 14.9 ~ 1.0 years of age). 
The results of the tests are summarized in table 5.IV. 
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The two groups do not differ significantly with respect to the 
intelligence test or the Junior Dutch Personality Test. Compared 
with the scores for the Junior Dutch Personality Test of normal 
children, the CT group has normal scores for 3 items: perseveran-
ce, dominance and inadequacy. Their scores are low normal for the 
social inadequacy and recalcitrance. The score for dominance of 
the boys is low-normal and for the girls normal. The CSII group 
has normal scores for inadequacy, perseverance and social inade-
quacy. For recalcitrance the score is high. The two boys score in 
the normal range for dominance, whereas the girls score high on 
this scale. 
In the Family Relation Test the possibility to express 
feelings towards a sibling has been excluded for children without 
siblings. The CSII children show significantly more negative fee-
lings towards their mothers than the CT children. The feeling of 
overprotection by any person (siblings, parents or nobody) is not 
experienced more often in either one of the two groups. 
The scores of the fathers and the mothers in the Family 
Environment Scale are all within the normal range. The mothers of 
the 2 groups score significantly different with respect to the 
control exerted by the family members towards each other. The 
mothers of the CSII group score significantly lower than the 
mothers of the CT group. The fathers' answers differ with respect 
to the item on family organization. The fathers of CSII children 
score significantly higher. The incongruence scores between 
fathers and mothers in both groups do not show a significant dif-
ference and are within the normal range. 
The Diabetes Questionnaire results only in significantly 
different scores for the two groups with respect to the item con-
cerning physical complaints. The CSII group indicates that it is 
less bothered by physical complaints. 
Application of the test of Friedman reveals information on the 
comparability of the 5 observers in the Assessment of Acceptation 
Scale. Because 1 father has not participated at all and because 
by accident 1 question (on I child) has not been answered by 
one member of the diabetes team, the scores of 12 to 14 children 
are used in the test of Friedman (a< 0.05). The 5 observers are 
comparable with respect to questions 2 and 4, but score diffe-
rently for questions I, 3 and 5. Sinc·e not all the children can 
be included in the combined score, the individual scores (for 
each observer) have been given in table S.IV. 
The scores on the first question by fathers, mothers and one 
team member indicate a significant difference between the accep-
tation of IDDM and coping with it by the CSII group versus the 
CT group. The CSII treated children are assumed to accept their 
diabetes better. Two of the team members maintain that accepta-
tion by the two groups is similar. The combined score for the 
metabolic control does not reveal a significant difference con-
trary to the individual scores. However, one must take account of 
the fact that only 12 children are included (instead of IS). The 
physical condition of the CSII group is regarded as significant-
ly better than that of the CT children by all observers except 
one (one of the diabetes team members). The compliance towards 
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Table S.IV Psychological~: 
0-
®-
tests~ answered by the children 
tests, answered by parents of the 
diabetes team 
participating children and 
WISC-R 
WIPPSI 
Junior- Dutch 
Personality 
Test 
Family 
Relation 
T.::st 
Diubetes 
Questionnaire 
@ Tests 
Family 
Environ-
ment Sc.:J.le 
CSII~ 
Fat.h<>rs Mothers 
(F) (M) 
Assesam.-.nt 
of 
Acceptation 
Scale 
Numb.::r of 
Patients 
Number of 
Participants 
.£! £:_rou:e_ Diabetes 
Fathers Mothers ~
(F) (M) (DT) 
8 
Wilcoxon 
Mann & Whitney 
) 0.05 
) 0.05 
< 0.05 for I it.::m: 
feelings towurda 
mothers 
< 0.05 for I item: 
physical complaints 
Wilcoxon 
Mann & Whitney 
< 0.05 for 
- organiZ<ltion : F 
control : M 
< 0.05 for 
- acceptation 
F, M, l DT 
- metabolic control 
F,M,3DT 
physical condition: 
F,M,2DT 
- compliance 
F, I DT 
-psychical he<~lth 5 
F, 2 DT 
* In case of significant differences. the relevant item is 
s.-.parately mentioned. 
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advice from the diabetes team is considered to be equal for both 
groups, analysing the combined scores. Individual scores, how-
ever, (of the fathers and one of the team members) show a signi-
ficant difference between the two groups, indicating that advice 
from the diabetes team is executed more easily by the CSII group. 
The psychical health of the two groups is judged differently by 
the various observers. Two members of the diabetes team consider 
the psychical health of the CSII group to be significantly bet-
ter. However, the fathers score in such a way that the opposite 
result is obtained. The mothers and one of the team members as-
sess the psychical health alike in both groups. 
METABOLIC CONTROL 
sHbAl 
To give a rough impression of the course of sHbAI the mean 
sHbAI values of the 2 groups are shown in figure 5.2. 
More important, however, are the individual data, listed in ta-
ble S.V. 
The sHbAI percentages at onset do not differ significantly be-
tween the two groups. 
The slope of the Mood lines varies in the CSII group between 
-0.1 to -0.3 (mean: +0.06). The Mood lines of the CT group show 
a slope of -0.2 to +0. l (mean: +0.02). The 2 groups do not dif-
fer significantly with respect to this slope. In most children 
the sHbAl levels remain rather constant during the first year 
(excluding the first 2 months). 
The sHbAI on the Mood line differs significantly between the 
2 groups after I year, indicating a better overall metabolic 
control in the CSII group. 
The variability indices do not differ significantly between 
the two groups (CSII group (range): 0.27 - 0.62; CT group 
(range): 0.27- 0.72). 
The moment at which the sHbAI level exceeds 9.0% is signifi-
cantly earlier in the CT group compared with the CSII group (CT 
group: 3.7 ~ 0.8 months, range: 2-ll months; CSII group: I J.l 
~ 2.5 months, range: 2-26 months) *· 
Four children, treated with CSII, have a sHbAl still in the nor-
mal range 1 year after onset, whereas all the CT children have 
higher sHbAl percentages. 
* For these results all data thus far obtained, are used. For 
those children still having UCP above 30%, a normal sHbAI and 
an insulin dose below 0.5 U/kg/24h, a maximal score (2 years) 
is used for the calculations. The mean values given are lower 
than they are in reality. Two CSII and 2 CT children have a 
UCP above 30% after 2 years of diabetes. One CSII treated 
child has an insulin dose below the limit of 0.5 U/kg/24h. Fi-
nally 4 CSII children still have a sHbAI in the normal range 
after 2 years of follow-up. 
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Figure 5.2. Comparison between the sHbAl (%) in diabetic chil-
dren treated with CSII (0-0) and CT (D-0). The sha-
ded area represents the range for healthy children 
(n = 42, age: 1 - 20 years). 
TABLE 5. V 
CSII patients 
p.:>ticnts initial 
sHbAl 
(;:) 
I 16.8 
2 12.3 
3 ]4.4 
4 18.3 
5 II. 7 
6 13.2 
7 16. 1 
8 9. 0 
9 10.0 
10 16.6 
11 17.6 
12 11.4 
13 14.4 
" 
14.7 
15 13.9 
Characteristics of sHbAl 
sHbAl 
(t~ l yr 
on Mood 
line ) 
(!) 
6.9 
II. 7 
7. 5 
12.9 
8.7 
6. 6 
11.4 
12. 0 
9. 0 
8. I 
9. 0 
8. 7 
9. 9 
8. 7 
10.8 
end of * 
remission 
(months) 
.. 
-
7 
•• 
-
2 
13 
.. 
-
6 
2 
6 
2 
5 
.. 
-
8 
2 
9 
CT patients 
J)oJtients 
" 17 
" 19 
20 
21 
22 
23 
" 
25 
26 
27 
28 
29 
30 
the end of remission with respect co sl:IbAl (sl:IbAl > 9.0;:) 
** (he sEbAl is still :, 9.oz 
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initial 
slibA I 
10.4 
II. I 
19.7 
IS. 0 
13.3 
11.4 
" 
6 
9 0 
12 5 
13. \ 
12. 1 
16.0 
9. 0 
15.4 
13.8 
sHbAI 
(t~l yr 
on Mood 
line ) 
(;:) 
9. 6 
12.9 
12.6 
9. 6 
12.3 
14.7 
10.8 
10.8 
9. 9 
9. 0 
II. I 
9. 9 
11.4 
12.6 
12.6 
end of * 
remission 
(months) 
2 
2 
5 
11 
2 
2 
2 
9 
2 
2 
2 
8 
3 
2 
2 
Home measured blood glucose levels 
The diaries demonstrate an enormous variety in frequency and 
time of and reasons for the determination of home measured blood 
glucose values. Diaries have not been obtained from 3 children. 
This does not imply that measurements have not been performed. 
The booklets may have been gotten lost either in the hospital or 
at home. Sometimes small papers are used in the absence of a dia-
ry, which are doomed to disappear. From all but 3 children (all 
CT children) a mean frequency of blood glucose measurements has 
been calculated to get an impression of this frequency in the two 
groups. In the pump group a mean of 21 determinations (range: 9-
42) per 28 days is found. In the CT group this number is 20 
(range: 10-27) per 28 days. Although this result is only based on 
a part of the groups, it suggests that blood glucose monitoring 
is performed with a similar frequency in both groups. 
From the insurance companies the following information has 
been obtained concerning test strips. Six insurance companies 
have not replied. Nine companies could not reveal which materi-
als had been declared and/or refunded. Fifteen companies, insu-
ring 8 CSII and 7 CT children, could indicate how many blood test 
strips had been refunded. A mean of 6.4 pots of Hemoglucotest 
strips has been refunded to the CSII group, whereas a mean of 9.6 
has been refunded to the CT group during the first year. The dif-
ference is significant. One has to be careful with conclusions 
since only information on a part of the groups has been obtained. 
One may assume that the data missing are aselectively distribu-
ted over the 2 groups. Thus, calculation of the noted home measu-
red blood glucose values suggests a similar frequency for both 
groups, whereas a larger amount of pots is declared by the CT 
group. 
Hypoglycaemia requ~r~ng glucagon administration intramuscu-
larly has occurred once in both groups. In the pump group a child 
(3) got a hypoglycaemia in the first month after onset. The meal 
dosis before breakfast had been administered, just as in the hos-
pital, one half hour before breakfast. Without the stress of the 
hospital and with the increased endogenous insulin production, 
this timespan proved to be too long and a hypoglycaemia 
occurred. The hypoglycaemia of the CT child is less easily ex-
plained. It concerns a young child (16) with poor ~nJection 
sites, probably resulting in less regular insulin uptake. This in 
combination with the unpredictability of childrens' activities 
may have evoked this hypoglycaemia. 
As far as the less severe hypoglycaemic periods are concerned, 
incomplete information has been obtained from diaries. The pa-
tients' records also provide information on whether or not hypo-
glycaemic periods have occurred, but do not report the frequency 
of the hypoglycaemic periods per month. 
The diaries have been used to calculate the mean frequency of 
hypoglycaemic periods per 28 days. Again information from 3 CT 
children is missing. A mean frequency of 0.8 hypoglycaemic peri-
ods per 28 days (per child) was found in the 15 children treated 
with CSII (range: 0 - 2.2) and 2.3 periods per 28 days (per 
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child) in the 12 CT children (range 0 - 14.0). This difference is 
not significant. The patients' records reveal that during the 
hospital visits 3.9 times per month (range: 2-8) hypoglycaemic 
periods have been reported by the CSII group vs 5.2 times per 
month (range: I-8) by the CT group. This difference is also not 
significant. 
Hospitalization 
During the first year one CT child (21) has been hospitalized 
as well as one (14) of the CSII treated children. For the latter 
the reason for hospitalization was an isotone dehydration because 
of severe gastroenteritis (without at that moment a ketoacido-
sis). The CT patient was hospitalized because of very poor meta-
bolic regulation. 
Intermediary metabolites 
Of the intermediary metabolites only the branched chain amino 
acids have been determined in all patients. The mean values 
(given as mean ~ I SEM) for the CSII and the CT group are respec-
tively after 6 months for leucine 0.19 ± 0.02 and 0.17 + 0.02 
mmol/1; for isoleucine 0.10 ± 0.01 mmol/1 and 0.09 ± 0.01 mmol/1 
and finally for valine 0.32 ± 0.03 mmol/1 and 0.31 ± 0.03 mmol/1. 
After one year mean values are found respectively for leucine 
0.20 ± 0.02 mmol/1 and 0.19 ± 0.01 mmol/1, for isoleucine in 
both groups 0.10 ± 0.01 mmol/1 and for valine 0.32 ± 0.02 mmol/1. 
It is evident that these concentrations do not show a significant 
difference. They are, however, slightly increased when compared 
to reference intervals. 
Pyruvate, lactate, 3-0H-butyrate, triglycerides and free fatty 
acids ought to be determined each time the patients come to the 
Diabetes Clinic for the glucagon stimulation test after an over-
night fast. In the initial period of the study, however, several 
practical problems concerning the method of blood sampling have 
made determinations difficult. This has resulted in a reduced 
number of tested patients. The data are given in table S.VI. The 
results of the tested patients do not differ significantly with 
respect to each other. 
HDL-cholesterol and cholesterol 
The cholesterol levels of the two groups do not differ signi-
ficantly after 6 months nor after I year (CSII group: after 6 
months: 4.6 ~ 0.3 mmol/1; after I year: 4.9 ± 0.4 mmol/1; CT 
group: after 6 months: 5. l ± 0.2 mmol/1; after 1 year: 4.6 ± 0.2 
mmol/1). The difference in each group in time is not significant 
either. The individual values for both groups are in the normal 
range except for one patient (7). He has a mild hypercholes-
terolaemia with a mean level (in the first 6 months) of 7.6 
mmol/1 and in the second part of the year of 8.7 mmol/1. Further 
investigation revealed a positive family history (of the father's 
side) for early cardiovascular problems. This also points towards 
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hypercholesterolaemia. Extra dietary advice has been given in or-
der to reduce the cholesterol intake as much as possible. 
The mean HDL cholesterol values are for both groups in the 
normal range (CSII group after 6 months: 1.28 ± 0.04 mmol/1; af-
ter 1 year: 1.39 + 0.07 mmol/1; CT group: after 6 months: 1.58 ± 
0.09 mmol/1; afte~ 1 year: 1.49 ~ 0.06 mmol/1). 
After 6 months the CSII group has a significantly lower HDL 
cholesterol level compared with the CT group. However, after one 
year this difference has disappeared. One patient (2) has a mean 
HDL cholesterol level just below the lower limit (0.61 mmol/1). 
Since, except for 1 value, the concentrations are within the 
reference interval no further action has been undertaken. 
Physical develo?ment 
All children are growing above the lOth percentile (weight for 
height). Five of the CSII and 3 of the CT children are growing 
above the 90th percentile, weight for height, but they also fol-
lowed this percentile before the overt onset of the disease. 
The exogenous insulin administration 
The insulin doses administered after 6 months and 1 year do not 
differ significantly between the 2 groups (respectively 0.50 vs 
0.48 U/kg bodyweight/24h and 0.71 vs 0.66 U/kg bodyweight/24h for 
the CSII and the CT group). The increase in the CSII group after 
the initiation of the treatment is 0.35 U/kg bodyweight/24h (from 
0.36 in the first month towards 0.71 U/kg bodyweight/24h after 1 
year). In the CT group a larger dose is given in the first month 
(0.44 U/kg bodyweight/24h) resulting in the relatively low in-
crease of 0.22 U/kg bodyweight/24h during the first year. The in-
sulin dose has been changed in total 63 times in the CSII group 
resulting in a mean of 0. 15 U/kg bodyweight/24h at one time and 
74 times in the CT group with a mean of 0. 12 U/kg bodyweight/24 h 
at one time. 
The moment at which the insulin dose exceeds the 0.5 U/kg bo-
dyweight/24h varies in both groups from I to 26 months with a 
mean in the CSII treated group of 9. I ~ 2. 1 months and in the CT 
group of 9.5 + 1.7 months, thus not indicating a significant dif-
ference between the two groups. 
In short, the metabolic control differs significantly between 
the 2 groups with respect to the sHbAl. Intermediary metabolites 
and hypoglycaemic periods do not differ significantly. Home mea-
sured blood glucose testing has been performed probably about as 
often in both groups. Incomplete information prevents although 
definite conclusions. The insulin dose does not differ 
significantly between the two groups after 6 months and year. 
The moment at which the insulin dose exceeds the 0.5 U/kg body-
weight/24 h does not differ significantly between the 2 groups. 
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ENDOGENOUS INSULIN RESERVE 
Urinary C-peptide excretion 
The course of UCP, expressed as mean value for each group, is 
shown in figure 5.2. 
More important is the evaluation of the individual data. The 
course of UCP shows in most cases a spiking pattern. The variabi-
lity indices vary considerably in both groups (CSII group 
(range): 0- 0.77; CT group (range): 0- 0.66). No significant 
difference between the two groups is noted regarding the variati-
on. 
Since endogenous insulin production is one of the three crite-
ria for the remission period, it is necessary to define precisely 
what the end of the remission period is with respect to the UCP. 
What is really the point of no return regarding the UCP? An in-
vestigation of the results of the individual subjects (including 
all data) thus far obtained suggests that 3 successive UCP of 30% 
or less (of the predicted mean for a specific age) will not be 
followed by a spike above 30% but rather by a final decrease. 
Therefore, the first time there are three successive values of 
UCP of 30% or lower, this point in time is used to indicate the 
end of the remission with respect to the endogenous insulin 
reserve. The characteristics of the UCP course are depicted in 
table 5. VII. 
Urinary 
G-peptide 
[% J 
Figure 5.2. 
0 3 6 g 12 
Time [periods of q weeks] 
Comparison between the urinary C-peptide 
(expressed as percentage) in diabetic 
treated with CSII (0-0) and CT (1-8) 
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The initial UCP does not differ significantly between the 2 
groups. 
After the start of the treatments an increase of UCP - labeled 
according to previously mentioned criteria as peak - is observed 
significantly more often in the CSII group (7 vs 3 times). The 
duration of these peaks does not differ between the 2 groups. 
The decline of UCP in time reflected by the slope of the line, 
is significantly less steep in the CSII group. In 2 children with 
pump therapy no slope could be calculated because of insufficient 
samplings after the peak to fit a line. In 1 CSII patient no de-
cline but even an increase is observed during the first year. 
Whether this will continue during the second year remains to be 
seen. 
The maximal UCP does not differ significantly between the 2 
groups. Prediction of the point of time at which no UCP can be 
elucidated anymore (obtained ·through extrapolation of the Mood 
line) can not be made in the case of 3 CSII patients, either be-
cause of the increase of the Mood line or because of the impossi-
bility to draw a line. No significant difference is found between 
the two groups with respect to this point in time. 
The decrease of UCP below the critical level (~ 30%) is found 
after 15.3 ± 2. 1. months (range: 7->26 months*) in the CSII group 
and after 12.7 ± 2.3 months (range: 0->26 months*) in the CT 
group. These points of time do not differ significantly between 
the two groups. 
A significant correlation is found between the initial UCP va-
lues and those (not on the line) after 1 year. This relationship 
is found as well for all children as for the 2 groups separately. 
(All children: r= 0.55, p < 0.05; CSII group: r= 0.80, p < 0.05; 
CT group: r= 0.67~ p < 0.05). 
Glucagon tests 
The glucagon stimulation test has been performed in 23 chil-
dren (13 CSII and 10 CT children) after 6 months and in 27 chil-
dren (13 CSII and 14 CT children) after 1 year. Most of the chil-
dren who have not been tested after 6 months ( 12, 14, 16, 17, 
21, 26, 30) belong to the younger ones. In three of them (12, 14 
and 30) insertion of the intravenous catheter has failed. 
* For these results all data, obtained thus far, are used. For 
those children still having UCP above 30%, a normal sHbAl 
and an insulin dose below 0.5 U/kg /24 h bodyweight a maxi-
mal score (2 years) is used for the calculations. The mean 
values given are lower than they are in reality. Two CSII 
and 2 CT children have a UCP above 30% after 2 years of dia-
betes. One CSII treated child has an insulin dose below the 
limit of 0.5 U/kg bodyweight/24 h. Finally 4 CSII children 
still have a sHbAI in the normal range after 2 years of fol-
low-up. 
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At the beginning of this study, frequent execution of glucagon 
stimulation tests in very young children has not been considered 
acceptable. Hence, the frequency was reduced to twice during the 
entire study. The reduction of complaints during the stimulation 
test because of slow intravenous administration has changed our 
attitude and except for the first group of toddlers, youngsters 
also have been tested 4 times. One CT child has not been tested 
after 6 months because the appointment was mistakenly made too 
early (2 months after the onset). The difference in time is too 
great to include these results. After I year, 1 CSII child (3) 
has refused to participate in the test because of complaints he 
had during the previous test. For one child (14) the quantity of 
blood sampled was insufficient for the determinations. Finally, 
for one child (24) the insertion of the intravenous catheter fai-
led. Thus. the results of the tests given in table 5.VIII must be 
interpreted with care. 
Table 5.VIII Plasma C-peptide values before and after stimulation 
with _!_ mg glucago_n ___ ---- --
Fasting plasma 
C-peptide levels 
(nmo1/1) 
time 
(months) 
6 
12 
CSII group 
n 
0.22 ± 0.08 13 
0. 13 
.± 0.03 14 
CT group 
n 
0, 18 .± 0.04 10 
0. 12 .± 0.03 14 
---------------------------------------------------------------------
Peak value of 
plasma C-peptide 6 0.33 ± 0.04 13 0.38 .± 0.06 10 
after glucagon 
stimulation 12 0.25 ± 0.05 13 0.20 ± 0.05 14 
(nmo1/1) 
Plasma C-peptide 6 14.1 ± 2.1 13 14.5 .±. 2.5 10 
values during glu-
cagon stimula-
tion 12 10.7 .:!.. 2.0 13 8. I ± 1.6 14 
(AUC) 
Mean plasma 
C-peptide values 6 0.24 .:!:. 0.03 13 0.25 ±. 0.04 10 
during glucagon 
stimulation 12 0.18 :t. 0.03 13 0. 13 ±. 0. 03 14 
(nmo1/1) 
Although the CSII group has slightly higher plasma C-peptide 
levels after 1 year this difference is not significant. 
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Time 
.1ftcr 
onset 
(yc.lrs) 
P.1tient 
I 
2 
3 
' 5 
6 
7 
8 
' 
IO 
II 
I2 
13 
14 
IS 
In summary, the UCP course shows significantly more often a 
peak in the CSII group. Its path, as reflected by the slope of 
the Mood line, is also less steep in the CSII group. The variabi-
lity does not differ significantly between the 2 groups. The ini-
tial, nor the maximal UCP or the levels after 1 year differ sig-
nificantly between the 2 groups. The time at which no UCP is ex-
pected anymore (by extrapolation of the Mood line) and the end 
of the remission period (UCP ~ 30%) are not significantly 
different for the 2 groups. The glucagon stimulation test shows 
no significant differences between the groups. It must be stres-
sed, however, that not all the children have been tested. 
IMMUNOLOGICAL PARAMETERS 
At the onset of IDDM ICCA are detected in 60% (9 out of 15) of 
the CSII group and 67% (10 out of 15) of the CT group. ICCA-CF 
is found in 46% (7 out of 15) of the CSII group and 40% (6 out of 
15) of the CT group. In 42% of the CT group and 46% of CSII (6 
out of 14 in the CT group and 6 out of 13 in the CSII group) ICSA 
are detected. Of 3 patients ICSA has not yet been determined at 3 
different intervals because of practical problems (patients 1, 6 
and 20). 
The data concerning the islet cell antibodies are given in 
table 5.IX. 
Table 5.IX The immunological parameters 
CSII patients CT patients 
ICCA-CF ICSA ICCA ICCA-CF ICSA 
I 
! 
! 
,I I I Jfl i 0 \ I 0 l I 0 \ I 0 l I \ I 
' P.1ticnts I 
' 
I 
I 
I 
I ol 0 0 0 ' 0 0 0 - 0 - I 6 2 2 0 0 0 0 0 3 
' 3 3 3 3 2 2 0 0 0 I7 2 I 0 0 I 0 0 0 2 
0 0 0 0 0 0 0 0 0 18 3 2 I 2 2 I 0 0 0 
2 
' 
4 2 3 3 2 2 I I9 0 2 0 0 2 0 0 0 0 
3 3 I 4 3 2 3 3 3 20 2 4 4 2 I 2 - 0 -
0 2 0 0 2 0 - 0 - 2 I 2 2 2 0 2 I 3 2, I 
0 0 0 0 0 0 3 3 3 22 4 3 4 3 3 3 0 2 I 
2 0 0 2 0 0 0 0 0 23 0 0 0 0 0 0 0 2 0 
2 3 3 2 3 3 3 I 2 24 0 0 2 0 0 0 
' 
3 3 
2 2 2 0 0 2 0 0 0 25 0 I 0 0 0 0 3 0 2 
4 4 3 2 2 2 0 0 0 26 4 4 3 3 2 2 2 I 3 
3 3 2 0 2 0 I 0 I 27 3 2 3 2 2 2 3 0 0 
0 0 0 0 0 0 0 2 0 28 2 3 0 0 2 0 0 2 0 
' 
I 2 4 0 0 0 0 0 
" ' 
4 4 
' 
3 3 I 2 2 
0 3 2 0 2 2 I 0 0 30 0 0 0 0 0 0 0 0 0 
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No significant differences are found between the two groups with 
respect to these antibodies. 
IgGia levels do not differ significantly between the two 
groups at any point of time. They are given in table 5.X. 
Table 5.X Insulin antibody production 
time 
(weeks) 
0 
12 
24 
36 
48 
CSII patients 
IgGia (U /1) * 
0 
0.064 
.± 0.025 
0. 178 
.± 0.086 
0. 137 ..:t. 0.045 
0.13-1.± 0.040 
* Determined by the method of Christiansen 
CT patients 
IgGia (U /1) * 
0 
0.045 
.± 0.022 
0. 194 ..:t 0. 123 
0.384 .± 0.232 
0.470 .± 0.297 
One CT child (20) has an exceptional IgGia production (3.95 
U/1) explaining the large SEM. She is also the only child without 
HLA Dr 3 and/or HLA Dr 4. 
At onset no insulin antibodies (IgGia) were detected by the 
method of Christiansen, whereas with the more sensitive method in 
5 of 15 CT children (33%) and in 4 of 13 CSII children (31%) in-
sulin antibodies were found. The percentage bound insulin antibo-
dies varies in the CT group between 0.3 and 2.8% and in the CSII 
group between 0.3 and 0.9%. 
In summary, the 2 groups do not differ with respect to the 
presence of the immunological factors studied. 
REMISSION PERIOD 
If the 3 parameters- insulin dose (<0.5 U/kg/24h), UCP 
(~30%) and sHbAI (>9.0%) are taken into account to calculate 
the duration of the remission, a significant difference is found 
between the two groups regarding the duration of the remission 
phase. The remission period in the CSII group lasts significant-
ly longer than in the CT group (7.5 ± 2.0 versus 3.3 ± 1.5 months 
respectively). After one year, 3 of the CSII treated children 
(20%) and none of the CT children (0%) are still in remission. No 
remission is seen in 16 children (1 I of the CT group and 5 of the 
CSII group). 
In search of factors, possibly influencing the remission 
period • the relationship between several factors and the remis-
sion period has been·analysed. 
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Characteristics of the patients 
In this group of patients the duration of the remission period 
shows no relation with the age of the children. Although the boys 
show a slightly longer remission period (5.5 ± 1.5 months in the 
boys; 4.7 ~ 1.8 months in the girls), this difference is not 
significant. 
The HLA Dr types (HLA Dr 3,x; HLA Dr 4,x; HLA Dr 3,4) do not 
differ with respect to the duration of the remission period. One 
girl with HLA Dr 1,8 had no remission at all. 
The socioeconomic background of the children does not seem to 
play a role either as is suggested by the not significant dif-
ferences between the socioeconomic classes. 
The 3 children who needed an intravenous administration of 
fluids and insulin show no remission period. The insulin doses 
of these 3 children exceed 0.5 U/kg bodyweight/24h from the 
first month onwards. The UCP of one of these children decreases 
rapidly below the limit of 30%. In the other 2, this limit has 
been passed at 11 and 16 months. 
Presence or absence of ketonuria at onset does not result in a 
significantly different duration of the remission period (pH < 
7.2 (n=l): no remission;ketones: positive but pH~ 7,2 (n=24), 
mean duration of the remission: 5.2 ± 1.4 months; ketones negati-
ve (n=5): 6.0 ~ 2.3 months). 
Finally, no relationship is noted between the duration of the 
remission period and the duration of the symptoms before the 
overt onset of the disease. 
Immunological factors 
A clear relationship between the remission period and any of 
the determined immunological parameters has not been detected. 
Neither their presence at onset nor their course reveal any 
indication of a direct influence by them on remission. 
The individual parameters 
The Pearson contingency coefficient has been calculated for 
the individual values of sHbAI and UCP in order to obtain infor-
mation on a possible constant relationship between the metabolic 
control and endogenous insulin reserve. This results in distinct 
coefficients, varying from 0.0 to 0.51. Thus no fixed associa-
tion exists between the sHbAl and UCP. 
The 4 children with a sHbAI still in the normal range after 2 
years all have a UCP above the lower limit (in total 7 children 
have a UCP above 30% after two years of overt diabetes). Only in 
child the decrease in UCP below 30% precedes the increase in 
sHbAl. In the other children an increase in sHbAI above 9.0% is 
observed before the decrease in UCP. It is evident that the gly-
caemic control is not the only important factor. Nevertheless its 
influence can certainly not be excluded. 
The relationship between insulin doses and endogenous insulin 
reserve has not been calculated through the Pearson contingency 
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coefficien~, because ~he insulin dose is often constant for se-
veral mon~hs. A possible correlation has been sought by calcula-
ting ~he Spearman coefficien~ of correlation for the insulin dose 
(at 6 months and 1 year) and the UCP (at 6 months and 1 year). 
For UCP the points on the Mood line have been taken, since they 
are influenced by all values. 
A significantly negative correlation is detected at both 
points in time and in both groups (6 months: all children, n =28, 
r = - 0,68; CSII group, n=l3, r ==- 0,72; CT group, n = 15; 
r = - 0,52; 1 year: all children, n = 28, r = - 0,59; CSII 
group, n = 13, r = - 0, 76; CT group, n = 15, r = - 0,57 (p < 
0.05)~ The differences between the correlation coefficients of 
the CT and the CSII group are not significant. 
Analysis of the data, looking for a possible relationship 
between age, HLA types and antibody formation (either against the 
islet cell or against insulin), does not reveal a relationship. 
The presence of ICCA, ICCA-CF, ICSA and IgGia nor their course 
show a relationship with the sHbAl, insulin dose or UCP. The pre-
sence of IgGib, however, shows a significant negative correlation 
with UCP (on the Mood line) after I year. The patients with de-
tectable IgGib at onset have a significantly lower UCP after 1 
year (IgGib positive patients UCP: 10.4 + 5.5%, IgGib negative 
patients UCP: 32. I ~ 4.5%). They also reach, significantly ear-
lier, the point of-no return (UCP ~ 30%) (IgGib positive group: 
2.7 ±... 0.7 months; IgGib negative group: 5.8 ±. 1.4 months). Thus 
detectable IgGib at onset is associated with a faster decrease of 
UCP. At onset patients with and without IgGib do not differ sig-
nificantly with respect to UCP (IgGib positive group: 60.1 £ 
24.4%; IgGib negative group: 79.0 ~ 12.0%). 
Summarizing, although no fixed relationship can be 
demonstrated between UCP and sHbAl, a possible role of a normal 
metabolic control on the residual beta cell function can not be 
excluded. The insulin dose shows a linear relationship with UCP. 
This relationship seems to be more obviously present in the CSII 
group. Of the other parameters, only the presence of IgGib at 
onset (negatively) influences the residual beta cell function. 
SUMMARY 
Pump therapy, started from diagnosis onwards in newly 
diagnosed diabetic children is very well feasible. The remission 
period lasts about 4 months longer in CSII patients. The glycae-
mic control is significantly better in the CSII group with 
respect to sHbAl values. 
A significant relationship is found in both groups between 
UCP and insulin doses after 6 and 12 months. UCP at onset shows a 
significant correlation with UCP after I year. 
The presence of insulin antibodies (IgGb) before the start of 
insulin therapy shows a significantly negative association with 
the endogenous insulin production. 
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Further this summary serves to answer questions, raised in the 
previous chapter. 
J. CSII treatment is feasible in previously randomized newly di-
agnosed children. 
- Four children "dropped out": 2 because of their age (~ 5 
years) and the pumps available at that time ; 1 because of 
her social background and 1 because of her family history. 
- The patients nor the parents require more attention as is 
reflected by phone calls and home visits from a nurse prac-
titioner (rather the contrary). 
- The treatment and its consequences have been remarkably 
well accepted up to now by most patients and parents. One 
child (adolescent girl) has expressed the wish to stop the 
treatment and has done so. The other children want to con-
tinue the treatment. even after the end of the study peri-
od. 
- The problems occurring during CSII therapy are mild and do 
not necessitate termination of this therapy. 
- It is not yet possible to answer the question whether CSII 
reduces any possible negative effects of IDDM on the 
psychological functioning of the child since the data are 
incomplete. A marked difference is found between the 2 
groups with respect to their physical complaints (much 
higher frequency in CT children). As for the social activi-
ties and contacts, the 2 groups do not differ significant-
ly. This suggests that CSII does not form an impediment for 
children in their social life. 
2. The children, treated with CSII achieve a significantly bet-
ter metabolic control with respect to sHbAl. 
- Four of the CSII children continue (after 2 years) to have 
a sHbAI percentage in the normal range, whereas after 11 
months none of the CT children has a sHbAI in the normal 
range. The variability index does not differ between the 
2 groups. Neither intermediary metabolites nor cholesterol 
and HDL Cholesterol (after I year) differ significantly be-
tween the two groups. 
- The numbers of blood glucose measurements provided by the 
diaries of the children (incomplete) suggest a similar fre-
quency in the two groups. According to the information 
(also incomplete) obtained from the insurance companies. 
the frequency of blood glucose measurements seems to differ 
significantly. 
- The insulin dose of the 2 groups does not differ signifi-
cantly. The moment at which the critical level of 0.5 U/kg 
/24 h is exceeded, does not differ significantly either. 
3. CSII therapy results in a significant - however temporary 
prolongation of the remission period of about 4 months. 
- Although the endogenous insulin production (UCP) is higher 
most of the time in the CSII group, this difference is not 
significant. A peak in UCP is observed significantly more 
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often in the CSII group, together with a less steep decrea-
se. 
Neither initial nor maximal values differ significantly be-
tween the 2 groups, nor does the moment at which the criti-
cal level (UCP ~ 30%) is passed. 
A significant correlation is found between the initial UCP 
and the UCP after 1 year. Although the correlation coeffi-
cients of the 2 groups differ considerably, this difference 
is not significant. The data of the glucagon stimulation 
tests (although incomplete) suggest the same: although the 
CSII group has slightly higher values, this difference is 
not significant. 
No fixed association has been found between sHbAl and UCP. 
The existence of a critical level of sHbA1 can not be ex-
cluded, since only for one child a period was found with a 
sHbA1 in the normal range and the UCP below 30%. (Most 
children demonstrate first an increase in sHbA1 and subse-
quently a decrease of UCP). From these data, however, no 
definite conclusions can be drawn. 
The insulin doses show a significant relationship with UCP 
(after 6 months and 1 year). Although this association 
seems more outspokenly present in the CSII group, the dif-
ference between the 2 coefficients is not significant. 
None of the characteristics of the patients shows a rela-
tionship with the remission period and/or its individual 
parameters. 
Neither the presence nor the course of islet cell antibo-
dies reveal a relationship with the remission period and/or 
its individual parameters. 
A significant negative association is found between the 
presence of insulin antibodies (IgGib) at onset and UCP 
after 1 year. The presence of these antibodies is also as-
sociated with a significantly faster decrease in UCP 
levels. 
No difference is found in insulin antibody production 
(IgGia) of the two groups. An extraordinary concentration 
(up to 3.95 U/1) is found in aCT girl with a particular 
HLA-Dr type: HLA-Dr 1,8. Antibody production certainly oc-
curs in spite of treatment with human insulin, suggesting 
that other factors are important besides the purity of the 
insulin. 
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CHAPrER6 
EVALUATION AND RECOMMENDATIONS 
FEASIBILITY AND PSYCHOLOGICAL IMPACT OF CSII IN 
NEWLY DIAGNOSED DIABETIC CHILDREN 
Feasibility 
The findings of this study suggest that CSII therapy is feasi-
ble in not selected newly diagnosed diabetic children (age:. I -
16 years) who were consecutively referred to the SKZ. The pre-
sence of patient (and parent) education, self-monitoring, 24 
hours telephone service and, last but not least, a home visiting 
nurse practitioner are necessary conditions for the execution of 
this prospective randomized study in children. 
The feasibility of CSII therapy has been evaluated by taking 
the following factors into account: 
- the acceptation of CSII by patient and parents 
- the problems, encountered with CSII therapy (patient- or pump-
related) and possible consequent metabolic disregulations (se-
vere hypoglycaemia or ketoacidosis, requiring hospitalization) 
- the time cost (frequency of phone calls to and home visits by 
the nurse practitioner) 
Regarding the acceptation of CSII~ our results are consistent 
with some and inconsistent with other studies (Van Ballegooie· 
1984, Becker 1984, Bougneres 1984, Schiffrin 1984). Of our 15 
CSII patients only one, an adolescent girl~ has stopped CSII the-
rapy after 28 months. Becker obtained an entirely different re-
sult. In order to evaluate the long-term efficacy of CSII, 16 
adolescents Cage: 14 - 19 years, duration of IDDM: 3. 75 - 14.5 
years) started with CSII therapy. Twelve stopped with CSII from_ 2 
weeks to 2 years after onset and 1 patient has died. Becker 
concludes that adolescents are unable to comply with the rigorous 
demands necessary to maintain euglycaemia with CSII. Schiffrin 
suggests that for diabetic adolescents CSII is more effective and 
acceptable than intensified conventional treatment. Van Balle-
gooie has studied the use of CSII in pregnant women and 
concludes that most patients will continue with CSII after the 
birth of their child. Bougne-res, studying CSII in youngsters, 
(age: 17-53 months) also describes a good acceptation of CSII. 
One of the differences between these studies and ours is the 
moment at which CSII is started. The lack of a "diabetic" past 
(discussed further on in this chapter) may contribute to the good 
acceptation of CSII. Further, a very trivial factor may contri-
bute to the acceptation of CSII in Holland: its rather cool 
climate! MOst hesitations towards continuation of CSII have been 
expressed during the summer (especially during periods of hot 
weather). Visibility and increased activities such as swimming, 
beach visits etc. may be involved. 
Only once a serious practical problem has occurred with CSII: 
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the detachment of the needle from the catheter, necessitating 
surgical removal of the needle. This did not result in metabolic 
disregulation. Considering the problems and risks described by 
other authors, the incidence of problems in our CSII group is low 
(Anonymous 1985, Fishman 1981, Teutsch 1984). No differences are 
found between the CT and CSII group regarding the metabolic dis-
regulations, including severe hypoglycaemia (once in both groups) 
and ketoacidosis requiring hospitalization (none in both groups). 
Data on the risks of metabolic disregulations associated with 
CSII treatment are conflicting (KROC Collaborative Study Group 
1985, Mecklenburg 1982, MUhlhauser 1985, White 1983). Mecklenburg 
and MUhlhauser find a relatively low incidence of severe hypogly-
caemia in CSII patients (respectively 3 times in 100 patients 
during 500 patient-months and 12 times in 8 of 50 CSII patients 
during 1093 patient-months), which is more or less consistent 
with our results (I time in more than 360 patient-months). MUhl-
hauser mentions the mismanagement of insulin therapy as main rea-
son for the occurrence of the hypoglycaemic episodes. In our 
study this has also been the cause (too early administration of 
the insulin bolus). It stresses the importance of intensive pa-
tient (and parent) education. In CT patients the frequency of hy-
poglycaemic periods also seems to decrease with increased patient 
education (Casparie 1985). This suggests that the intensive pa-
tient education (by the nurse practitioner) and care may play an 
important role in the relatively low incidence of problems with 
CSII therapy and metabolic disregulations. 
White describes 48 occasions of severe hypoglycaemia in 8 of 
22 CSII patients during 467 patient-months, mostly between 01.00 
and 05.00 hours and seemingly unrelated to patient error or pump 
malfunction. These hypoglycaemic episodes may be due to an insuf-
ficient glucose counterregulation (Cryer 1983, Madsbad 1982a). 
Madsbad describes an impaired reaction to glucagon in diabetic 
patients (adults) without residual insulin production. Although 
only the combination of an impaired reaction to glucagon and an 
insufficient production or effect of epinephrine will provoke an 
impaired counterregulation, the influence of the duration of IDDM 
can not be excluded (Madsbad 1983). 
Contrary to other studies, the pump children in our study are 
studied dUring the first 2 years of IDDM. CSII has never before 
been started in unselected newly diagnosed diabetic children. The 
difference in duration of IDDM may explain the difference between 
the incidence of hypoglycaemia in the study of White and our stu-
dy. 
The KROC Collaborative Study Group finds an increased inci-
dence of ketoacidosis in CSII patients. Since only regular insu-
lins are used in CSII this may possibly be due to a lack of insu-
lin depot. Pump failure, for example, (or patients' mismanage-
ment) may thus provoke a ketoacidosis in a relatively short pe-
riod of time. The difference between the KROC study and our 
study may be explained by the difference between the duration of 
IDDM among the participating patients. Madsbad has demonstrated, 
that the presence of an endogenous insulin production is associa-
ted with a later appearance of ketonbodies in insulin withdrawal 
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studies, thus delaying the development of a ketoacidosis and pro-
viding time for intervention (Madsbad 1979, Madsbad 1982b). Most 
of the children, participating in this study will have some C-
peptide production left, since they only have been diabetics for 
a short period of time. 
It can not be excluded that the age of the patients plays a 
role in the relatively low incidence of problems and metabolic 
disregulations. Children are more closely watched by parents and 
their family. This may result in earlier intervenlion in case of 
imminent ketoacidosis. 
The time cost or required attention, assessed by the frequency 
of pho;e--calls and home visits made by the nurse practLtloner, 
does not differ between the 2 groups. During intercurrent infec-
tions CSII patients (or parents) request slightly less attention 
(compared with the CT children). This suggests that CSII indeed 
facilitates adjustments. Our observation is contrary to other 
studies, which emphasize the extra time-consuming aspect of CSII 
in children (Becker 1984, Bougneres 1984). Both studies descri-
be CSII use in selected patients (adolescents and youngsters 
respectively) with a longer duration of IDDM (3. 75- 14.5 years 
and 5- 27 months). The participants of our study are unselected, 
of all ages (J - 16 years) and treated from diagnosis onwards 
with CSII. Absence of selection may be accompanied by a lack of 
motivation and motivation has been mentioned as an essential fac-
tor to successful CSII therapy (Raskin !982, Stein 1982). One has 
to realize that the selection of patients is often based on poor 
metabolic control, brittleness and threat of complications. Such 
criteria indicate that the patients have already been through a 
considerable number of problems. Sometimes lack of alternatives, 
insufficient amelioration by intensified injection therapy, leads 
to the start of CSII. CSII may even be mentioned as "the last 
possibility". It is evident that despair and high-pitched expec-
tation can influence the outcome of the therapy, the acceptation 
and the time cost. Our patients start with CSII at onset. During 
the first weeks, newly diagnosed patients, whether treated con-
ventionally or by pumps, require an intensive training program. 
The acquisition of the technical aspects, activities and adjust-
ments surrounding CSII therapy, may proceed more easily at this 
point of time. Getting used to things when one is young makes it 
easier when one gets older. Thus, starting at onset of IDDM with 
CSII is probably contributing to the low incidence of problems, 
disregulations, the good acceptation and the absence of an in-
creased time cost. 
In summary, CSII therapy is feasible in unselected newly diag-
nosed diabetic children. Three important factors, which pro-
bably contribute to this, are intensive patient education, the 
moment at which therapy is started (presence of endogenous insu-
lin production and the absence of a burdened past) and the age of 
the patients. To what extent the presence of an endogenous insu-
lin reserve or the lack of a "diabetic past" contribute remains 
to be elucidated. A careful follow-up of the participating chil-
dren regarding these 3 aspects may give in time a further clari-
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fication. 
Psychological impact 
The results of the psychological tests give no reason for not 
continuing CSII in unselected newly diagnosed diabetic children. 
Since these tests have been taken by only 15 children (having 
completed the 2 years of follow-up), the results are preliminary 
and have to be evaluated with caution. 
A significant difference in age is found between the tested 
children of the 2 groups (CT group: 14.9 ± 1.0 years; CSII group: 
9.3 ± 1.2 years). A possible explanation for the increased diffe-
rence is that only the first part of the children has been tes-
ted. At that time, 2 youngsters (2 and 5 years of age) dropped 
out because of the size of the available pump (Autosyringe AS6C). 
This difference in age implies a discrepancy between the level of 
psychological development and maturation and varying age-related 
problems. 
Although the difference in age is considerable and possibly 
influenced by the 2 drop outs, the intelligence of the 2 groups 
of children is not different. 
The Junior-Dutch Personality Test reveals no differences be-
tween the 2 groups regarding its 5 items: inadequacy, recalci-
trance, dominance, perseverance, social inadequacy. The normal 
scores of both groups for social inadequacy suggest that neither 
of the treatments has formed an impediment for the social con-
tacts and activities of the children. Compared with normal chil-
dren the CSII group scores high for recalcitrance and dominance. 
Recalcitrance (related to negative feelings and distrust towards 
others) may form part of the (normal) coping response and accep-
tation process (Van den Burg 1985). Kovacs concludes in her 
recent publication that the acceptation process of IDDM in 
children lasts about 9 months (Kovacs 1985). Her results suggest 
that this acceptation process may be prolonged by CSII therapy. 
One can not omit however that a high score for recalcitrance 
points towards an increased feeling of inferiority. Considering 
the concern of healthy adolescents for their body and self-image, 
it may not be surprising that the onset of IDDM and a constant 
confrontation with the disease through the (visible) pump inter-
feres with this process in a negative manner (Sullivan 1978). 
However, because of its easy adjustments, CSII therapy permits 
participation in most activities of the peer group and imposes 
less strict rules for day-to-day life. Therefore this may lead to 
a more complete self-image (Seigler 1982, Stein 1982). The high 
scores of the CSII group, when compared with reference values, 
for dominance (suggesting self-confidence and a tendency to bos-
siness) may support this point of view. 
The use of CSII has no negative influence on the family or its 
functioning, as is assessed by the Family Relation Test (FRT), 
(looking through the eyes of the child) and the Family Environ-
mental Scale (giving the parents' opinion (FES)). The CSII 
children express more negative feelings towards their mothers. 
Although the parents score in the normal range for the FES, they 
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do differ with respect to each other on two items. The mothers of 
the CSII group have the impression that they exert less control 
on the family, whereas the fathers of the CSII group experience 
more structure and organization in their family. These results 
may induce the speculation that age plays an important role. For 
the CSII children the beginning of the stormy period of adoles-
cence, the striving for independence and liberation from emotio-
nal childhood is complicated by the onset of a chronic disease. 
Normal conflicts with the parents may be intensified because of 
the restrictions caused by IDDM. The more outspoken negative 
feelings of the CSII children towards their mothers as well as 
feeling of "lack of control" of the mothers may be provoked by 
the fact that mothers are more often involved in every day life 
including the diabetes regime. 
The Diabetes Questionnaire, specifically designed for the 2 
groups of diabetic children, reveals a significant difference 
regarding the incidence of physical complaints. The CSII group 
suffers less from physical complaints. This may stimulate their 
activities. The test confirms the lack of difference between the 
2 groups with respect to their social activities and friends. 
The Assessment of Acceptation Scale reveals a difference 
between the 2 groups concerning the physical health and metabolic 
control. The CSII group is considered to have a better metabolic 
control and a better physical health. The acceptation of the di-
sease is considered similar by the parents. Compliance to advices 
of the diabetes team is only considered better in the CSII group 
by the fathers. Mothers and diabetes team members (2 of the 3) do 
not endorse this point of view and suggest that compliance does 
not differ. As for the psychical health of the children the ob-
servers present differing opinions. 
It is evident that more data are necessary to evaluate the 
psychological impact of CSII. The data obtained thus far clearly 
indicate that CSII does not impede the children in their social 
activities and contacts. This is in accordance with the prelimi-
nary data on the psychological influence of pump therapy, descri-
bed by Shapiro (Shapiro 1984). The physical well-being of the 
CSII group is significantly better. To what extent CSII contribu-
tes to psychological development remains to be elucidated in the 
following years. 
Recommendations 
First of all, the rema~n~ng children who have not completed 
the 2 years of the study, must be tested psychologically before 
more definite conclusions can be drawn. 
In order to obtain information considering the long-term fea-
sibility of CSII, a careful follow-up of the 30 children after 
the 2 years of the study is necessary. The psychological impact 
of long-term CSII therapy, started from diagnosis onwards, has to 
be evaluated by testing the children after 5 and 10 years. 
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METABOLIC CONTROL 
The diabetic children, treated from diagnosis onwards with 
CSII, have a significantly better metabolic control when compared 
co the CT group with respect to sHbAI values. The CSII group 
obtains sHbAJ levels in the near normal ~Intermediary meta-
bolites, nor the other parameters for the metabolic control 
differ significantly. A possible explanation for this difference 
in sHbAl is the more physiological way of administering insu-
lin. The ease with which insulin administration can be adjusted 
with CSII may shorten hyperglycaemic periods and thus improve the 
control. Our finding is in accordance with the data of Madsbad, 
who studied the effect of CSII in newly diagnosed diabetic 
adults (Madsbad 1985). Whether this difference will persist in 
time remains to be studied. Mecklenburg states that the improve-
ment of the metabolic control can be maintained in long-standing 
diabetics with long-term CSII therapy (Mecklenburg 1985). How-
ever, data concerning long(er)-term efficiency of CSII therapy in 
long-standing diabetics are conflicting (Becker 1984). Contrary 
to Mecklenburg, Becker demonstrates only a temporary improvement 
of metabolic control in long-standing diabetic adolescents. Al-
though the data we have accumulated so far suggest a continuati-
on of the better metabolic control (with respect to sHbAI), long-
term efficacy of CSII remains to be proven. The importance of 
poor metabolic control with respect to the development of major 
diabetic complications remains uncertain. It has been demonstra-
ted in an animal model that intensified insulin therapy reduces 
the development of retinopathy (Deneault 1980). The use of CSII 
therapy, from diagnosis onwards, may offer the opportunity to 
evaluate the influence of near normoglycaemia on the development 
of complications in human subjects. 
Especially with respect to major complications and the possi-
ble beneficial effect of near normoglycaemia, it is important to 
focus on a special category of children: the very young diabetic 
children (5 years of age and younger). In these children major 
complications are likely to become manifest before the age of 40. 
It is very difficult to obtain even an acceptable metabolic con-
trol in these children. An explanation for this may be found in 
the age-related problems: 
long overnight pauses (19.00- 07.00) without food intake 
a relatively high insulin sensitivity (Rosenbloom 1975) 
lipodystrophic injection sites 
- frequent intercurrent diseases 
- unpredictability of their activities. 
Overnight metabolic profiles of these children add, as an extra 
problem, an even more outspoken early morning rise of blood glu-
cose levels, or the so-called dawn phenomenon, when compared to 
diabetic adults (De Beaufort 1985). Regardless of its cause, it 
certainly contributes to the poor metabolic regulation of these 
children. Considering the age-associated problems and the night-
profiles (referred to above) it may be possible to obtain an im-
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provement in their metabolic control by using CSII therapy. The 
recent publication of Bougneres, studying CSII therapy in 
youngsters, demonstrates an improvement of their metabolic 
control (Bougneres 1984). An evaluation of the metabolic con-
trol in the 4 youngsters of our study (two of I year of age and 
two of 3 years of age: one of each in both groups) reveals a 
clear difference between the mean sHbA1 values of these children 
during the first year (excluding the first 2 months (CSII group: 
9.3 and 9.4%; CT group: 11.5 and 12.3%)). This together with the 
results of Bougneres suggests that near normoglycaemia may be 
obtained in very young diabetic children by the use of CSII. Al-
though a careful follow-up of these children is necessary to ob-
tain information on the long-term effects of CSII on metabolic 
control and to evaluate its psychological impact, CSII therapy 
can be recommended for toddlers in order to obtain good metabolic 
control. 
Improved metabolic control is not associated with an increa-
sed frequency of home blood glucose measurements. Regarding the 
quantity of test str~ps declared to the insurance companies, 
the suggestion is raised that the CSII group performs slightly 
less blood glucose measurements at home. Although the course of 
the sHbAI does not show a significant difference between the 2 
groups with respect to the variations in these sHbA1 percenta-
ges, the tendency towards less measurements may point to a more 
stable control. Since the data are incomplete, no definite con-
clusions can be drawn. 
The intermediary metabolites are slightly increased in both 
groups when compared to healthy subjects. The 2 groups do not 
differ with respect to each other. Tamborlane describes a total 
normalization of the intermediary metabolites in children during 
the use of CSII (Tamborlane 1979). The difference may be explai-
ned by the fact that his study was performed in the hospital and 
lasted only 2 weeks. 
The insulin doses do not differ between the 2 groups. This 
suggests that the-sa;e doses, administered in different ways, 
must exert a distinct influence on the metabolic control. One 
realize, however, that insulin dosage is not necessarily the same 
as insulin requirement. With the conventional therapy one is 
limited to increasing the insulin dose. It may reduce the hypo-
insulinaemic periods but at the cost of an increased frequency of 
hyperinsulinaemia and hypoglycaemic periods. 
The difference between the CT and CSII group regarding the re-
lationship between insulin dose and insulin effect is also sug-
gested by the difference in relationship between the insulin dose 
and the endogenous insulin reserve. It is uncertain which factors 
are involved in this relationship. Although the difference is not 
significant it suggests a better as-sociation in the CSII group 
between the endogenous production and the exogenous administrati-
on of insulin. In other words, they may be better attuned to each 
other. Insulin resistance may contribute to the difference 
between the two groups. 
The importance of insulin resistance in IDDM has been stres-
sed by DeFronzo (DeFronzo 1982). By employing the insulin clamp 
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technique he demonstrates a diminished insulin-mediated glucose 
metabolism in 19 insulin requiring diabetics compared with age 
and weight matched controls. Rizza and co-workers demonstrate 
(using the euglycaemic clamp technique) that hyperinsulinaemia, 
produced by the infusion of insulin, can create insulin resistan-
ce in man. He suggests that the decrease in insulin action proba-
bly occurs at a post receptor site (Rizza 1985). Although this 
study has been performed with healthy subjects, a possible impli-
cation is that hyperinsulinaemia, induced more outspokenly by 
conventional injection therapy, may impair insulin action, thus 
contributing to the difference in relationship between insulin 
dose and insulin effect. Conflicting with this is the study of 
Pernet, comparing insulin resistance in insulin requiring 
subjects and healthy controls. He suggests that impaired insulin 
sensitivity in IDDM is dependent on the insulin concentration. 
Using the euglycaemic clamp technique he demonstrates that at 
physiological insulin concentrations insulin requiring diabetic 
patients are resistant to insulin when compared with non-diabetic 
subjects. Supraphysiological levels of insulin, however, result 
in a disappearance of the difference between the diabetic and the 
healthy subjects (Pernet 1984). This suggests that hyperinsu-
linaemia may reduce insulin resistance. The conflicting data re-
garding insulin resistance emphasize the importance of further 
investigation. 
Other studies suggest that not only hyperinsulinaemia but also 
hyperglycaemia may be involved in insulin resistance. Unger pos-
tulates that hyperglycaemia can impair peripheral insulin-media-
ted glucose transport (Unger 1985). This may also play a role in 
our study, since the CT patients have higher sHbAI values and 
thus can be expected to have higher blood glucose values. Two 
studies describe an increased insulin sens~t~v~ty (using the 
clamp technique) after the start of CSII therapy and the achieve-
ment of an improvement in metabolic control (Beck-Nielsen 1984, 
Lager 1983). To what extent these factors (hyperinsulinaemia and 
hyperglycaemia) interrelate in insulin resistance in insulin re-
quiring diabetic children remains to be elucidated. 
It can be argued that part of the insulin resistance is due to 
circulating antibodies against insulin. DeFronzo finds no re-
lationship between the presence of antibodies and insulin resis-
tance (DeFronzo 1982). In our patients no relationship has been 
found between the presence of antibodies and metabolic control or 
the insulin dose. The presence of antibodies which interfere with 
the insulin receptor has not been studied (Maron 1983). Maron 
describes the presence of IgM antibodies at onset of IDDM in 
childhood, which exert an insulin blocking or an insulin-like ef-
fect on fat cells. These antibodies may alter the effect of a 
certain insulin dose. 
Taken together, CSII therapy in newly diagnosed diabetic chil-
dren-re5ults in a better metabolic control with respect to sHbAI. 
A more physiological administration of insulin and faster 
adjustments of hyperglycaemia may contribute to this difference. 
Since in small children (age: 5 years or younger) specific 
problems are present, which complicate the achievement of a good 
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metabolic control, CSII therapy is recommended for this group of 
children. The lack of difference in insulin doses used by the 2 
groups may be explained by the fact that insulin dose is not the 
same as insulin requirement. This finding, in combination with 
the not significant, but suggestive difference between the 2 
groups in relationship between insulin dose and endogenous insu-
lin production, may point towards an increased insulin resistance 
in the CT group. To what extent hyperinsulinaemia, hyperglycae-
mia, ~unological factors or yet unknown factors contribute to 
the occurrence of insulin resistance must still be found out. 
Recommendations 
Prevention of the late complications of diabetes in man by the 
near normalization of blood glucose concentrations has not yet 
been demonstrated since until recently, normoglycaemia could not 
be sustained from onset of IDDM onwards with the available 
methods of treatment (Tchobroutsky 1978). It has been shown that 
progression of present retinal abnormalities can not be prevented 
nor delayed by near normoglycaemia (Van Ballegooie 1984, KROC 
Study Group 1984, Lauritzen 1983, Tamborlane 1982). With these 
studies however, a point of no return was possibly passed alrea-
dy. Elevated albumin excretion has declined during CSII treatment 
toward the normal range, suggesting that an intensified treatment 
may retard progression of clinical nephropathy (KROC Collabora-
tive Study Group 1984, Viberti 1979). 
A careful long-term follow-up of the participants of the ptunp 
these study may provide information on the effect of CSII on 
complications. To obtain significant differences between the two 
groups in such a long-term study is probably not possible consi-
dering the small number of participants. 
Parameters for metabolic control and endogenous insulin pro-
duction as well as early detection methods for the onset of 
chronic complications have to be determined at regular intervals. 
Since the children will leave the Diabetes Clinic at about 18 
years of age this interval can not be too small. 
It seems feasible to obtain annually 24 hours urine for the 
determination of UCP and blood for the measurement of sHbAI and 
lipid metabolites (HDL cholesterol and cholesterol as possible 
parameters for macroangiopathy). 
For an early detection of retinopathy several techniques can 
be applied by the ophtalmologist. Fundus photos and fluorescein 
angiography may provide useful information on the development of 
early retinal abnormalities. Since the first signs of retinopa-
thy are usually not seen until after 10 years of diabetes an 
ophtalmological test after 5 years of IDDM seems justified. 
It is evident that the development of any reliable tool for 
early (or earlier) detection of complications has to be evaluated 
and, if possible and useful, applied. 
The development of nephropathy can be studied by the measure-
ment of micro-albuminuria and bloodpressure (Mogensen 1984). 
These parameters in combination with plasma creatinin and ureum 
concentrations will give further information on the development 
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of possible complications. 
Neuropathy may occur at different periods of time after cli-
nical onset. In adults it may even be the first symptom of IDDM. 
A relationship between neuropathy and the metabolic control has 
been suggested in several studies (Greene 1985, Young 1983). This 
is confirmed by others who show a reduction of the neuropathic 
symptoms after an important improvement in metabolic control (Van 
Ballegooie 1984, Spijker 1984). Tendon reflexes, position sense 
(position of the big toe) and vibrations sense can easily be tes-
ted during a visit to the Diabetes Clinic. Polyneuropathy, espe-
cially of the long sensible nerves of the legs, is often one of 
the first symptoms of neuropathy. The measuring of nerve conduc-
tion velocity is an established method to evaluate the neuro-
pathy, an unpleasant one however, especially for children. Re-
cently a new method has been developed by the neurologists of the 
Free University of Amsterdam. With their method the temperature 
sense is tested in a very sophisticated way (Bertelsmann 1985). 
It provides information on the functioning of the long thin sen-
sible nerve fibers. Since this test is not painful and requires 
no extra injections etc. it is included in the parameters for the 
evaluation of neuropathy, together with the tendon reflexes, 
position sense and vibration sense. These parameters also ought 
to be determined once a year. 
Thus for the follow-up of the part~c~pants of the pump study -
in order to obtain information on the influence of CSII on the 
chronic complications - the following is suggested: 
the determination, at least once a year, of: 
- sHbAl, plasma HDL cholesterol, plasma cholesterol levels 
- UCP (until no UCP is detected anymore, then the measurement can 
be stopped) 
- Fundus photos 
Fluorescein angiography of the retina 
- Blood pressure 
Plasma ureum levels 
Plasma creatinin levels 
Micro-albuminuria 
Tendon reflexes 
Position sense 
Vibration sense 
Temperature sense 
The non-significant, but suggestive difference between the 
CSII and CT group with respect to the relationship between exoge-
nous insulin administration and endogenous insulin production may 
raise the question to what extent this difference is caused by 
insulin resistance. In children its relevance has not been stu-
died since the accepted method to study insulin resistance in vi-
vo is the clamping technique. This can not be done with children 
(one has to l3y calmly on a bed for at least 4 - 8 hours!). Al-
though not providing the same quality of information the i.v. 
glucose tolerance test may be useful. The evaluation of the data 
obtained through this test, will provide information on the ef-
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of a glucose load on the plasma glucose levels in the pre-
of a certain insulin concentration (Srikanta 1983). C-pep-
levels provide information on the residual beta cell acti-
To evaluate the influence of immunological factors on the 
relationship insulin dose versus effect, antibodies, interfering 
with the effect of insulin on the fat cell, can be studied. Now 
the insulin receptor has been synthesized, the presence of these 
antibodies can be demonstrated by an insulin receptor assay or 
by bioactivity in the fat cell (Maron 1983). Separation and puri-
fication of the relevant IgM and IgG fractions may lead to the 
identification of these antibodies and elucidate their contribu-
tion to insulin resistance or even their possible involvement in 
the remission period. 
REMISSION PERIOD AND ITS INDIVIDUAL PARAMETERS 
The individual parameters of the remission period 
An analysis of the individual parameters which characterize 
the remission period, reveals that only sHbA1 and the moment at 
which it deteriorates differ significantly between the 2 groups. 
The decrease in UCP and the increase in insulin dose past their 
critical values ~not occur at significantly differing points 
of time. This confirms the preliminary data of a randomized 
trial with CSII in adults, recently presented by Madsbad (Madsbad 
1985). The differences between our data and those of Mirouze may, 
next to the difference in age, be based on the randomization (Mi-
rouze 1978). Mirouze studied a non-randomized group of adults. 
The variability in UCP does not differ significantly between 
the 2 groups. UCP in time does not differ significantly between 
the 2 groups. One may speculate that the better glycaemic control 
in the CSII group causes suppression of the endogenous insulin 
production. Although this can not be excluded, the relationship 
between stimulated plasma C-peptide values and the urinary C-
peptide excretion suggests a maximal functioning of the residual 
beta cells. The association between exogenously administered 
insulin and endogenous insulin production (on the Mood line) does 
not suggest a suppression either. CSII therapy results in a sig-
nificantly less steep decline of UCP estimated through the slope. 
It is associated significantly more often with a peak (7 versus 3 
times). The presence or absence of a peak in the initial course 
of IDDM does not show any relationship to the remission period. 
It is questionable whether this phenomenon has any importance at 
all, since no relationship with any of the other parameters for 
UCP has been detected. Peaks do not indicate a better residual 
beta function since the maximal UCP does not differ between chil-
dren with or without peaks. A peak signifies that the course of 
UCP during the first year can not be characterized by simply 
drawing the Mood line. The presence of such a peak may contribute 
to the difference in the slope of the lines since - in the pre-
sence of a peak - the Mood line will be drawn from the end of the 
peak onwards. 
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A significant relationship is found between UCP at onset and 
after 1 year. This confirms the data of Koivisto, suggesting that 
the moment at which IDDM is diagnosed is vital for the course of 
the disease (Koivisto 1984). Although the coefficients of corre-
lation of the 2 groups are not significantly different, the 
better correlation ~n the CSII group may suggest less 
interference by other factors (therapy related?). The presence of 
this relationship stresses the importance of an early diagnosis 
in order to start with as much endogenous insulin as possible. 
Distinct to several other studies we could not identify a 
fixed relationship between the endogenous insulin production and 
the metabolic control (sought by the Pearson Contingency coeffi-
cient) (Ludvigsson 1977, Madsbad 1980, Schober 1980). It is inte-
resting however, that only in one child sHbAl within the normal 
range is not combined with UCP above 30%. In all other children 
an increase in sHbAl (during a longer or shorter timespan) went 
with a decrease in UCP. Thus, the influence of (near) 
normoglycaemia on the preservation of the beta cell function can 
not be excluded. 
The significant negative correlation between UCP (on the line) 
after 6 and 12 months and the insulin dose at these points of 
time has been discussed in the previous paragraph. 
The remission period in IDDM has been defined in this study as 
a period, occurring after the onset of IDDM, with a near normal 
glycaemic control (sHbAI ~9.0%), an insulin dose below 0.5 U/kg 
bodyweight/24h and an endogenous insulin production resulting in 
a UCP above 30%. Pump therapy results in a significant 
prolongation of the remission period when compared to CT. 
This effect is temporary however, and seems only to be "put-
ting off the evil moment" for a short while (4 months). Evidently 
CSII therapy in children does not check the process causing IDDM. 
It may only create a little more time between the overt onset of 
the disease and the moment at which the child is totally depen-
dent on exogenously administered insulin. 
What causes this delay and can we identify any factors rele-
vant for the continuation of the ongoing process? 
The characteristics of the two groups of children differ only 
with respect to the age at onset. The children in the CSII group 
are significantly older (9.5 ± I. I years in the CSII group vs 7.0 
± 0. 9 years of age in the CT group). As mentioned prev-iously this 
may be provoked by the 2 drop outs in the beginning of the study. 
Two young children (2 and 3 years of age) have not started with 
CSII because the pumps available at chat point of time were too 
large for them. 
The evaluation of the relationship between age at onset and 
the remission period and its individual parameters does not re-
Knip veal an association, distinct to other studies (Eff 1978, 
1982, Ludvigsson 1977). 
One has to realize that criteria for remission differ conside-
rably between different studies. Knip and Ludvigsson have, for 
example, not included a parameter for endogenous insulin produc-
tion. Metabolic control is assessed by the presence or absence of 
glucosuria. Next to the different criteria the difference may be 
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explained by the relative young age of our participants. The 
course of IDDM may be less directly related to the age at onset 
if the disease starts before a certain - critical - age (Deckert 
1978). 
Contrary to other studies, we could not demonstrate any rela-
tionship between the characteristics of the participating chil-
dren (age, sex, HLA-Dr types) and the remission period or its in-
dividual parameters (Eff 1978, Knip 1982, Ludvigsson 1984, Lud-
vigsson 1985, Madsbad 1983). The combination of age and HLA-Dr 
types or sex and HLA Dr-types does not show a significant asso-
ciation either. It is possible that the number of children 
studied is too small to demonstrate these associations. Ludvig-
sson shows a relationship between a slower course of IDDM and 
HLA-Dr3 in a multicentre trial with over 700 patients. It is not 
surprising that this is not observed in our small group of pa-
tients. 
Symptoms at onset, not differing between the 2 groups, show no 
association with the remission period or its individual parame-
ters. This dissents from the retrospective studies of Ludvigsson 
and Knip who demonstrate a negative relation between the severi-
ty of the symptoms at onset and the remission period (Knip 1982, 
Ludvigsson 1977). Once again, the differences in definition may 
be involved. The explanation may also be sought in the relative 
mild symptomatology at onset in the present survey. Only one 
child had a serious ketoacidosis (pH< 7.2) at onset and two 
(other) children came to the hospital with a dehydration, requi-
ring the infusion of fluids and electrocytes (however without a 
serious ketoacidosis). These three children have had no remission 
period. 
Regarding immunological parameters, the 2 groups differ 
neither at onset, nor during the first year. The presence of 
ICCA, ICCA-CF and ICSA at onset, nor their course during the 
first year reveals any relationship with the remission period or 
its individual parameters, distinct to other studies (Mustonen 
1984). Our data do not provide any further information on the 
possible role these antibodies play in the pathogenesis or course 
of IDDM. 
The levels of insulin antibodies (IgGia) determined with the 
method of Christiansen do not differ after 1 year of therapy. 
The human semisynthetic insulins clearly induce an antibody pro-
duction. No difference can be found between the two treatments or 
between the use of only soluble insulin vs combinations of 
soluble with zinc or isophane insulins. Neither could an associa-
tion be demonstrated with the HLA-Dr types and the antibody 
production (Reeves 1984). An interesting fact however is that the 
only child without HLA-Dr 3 and/or· Dr-4 has an extraordinary high 
antibody titer. It is evident that more factors than insulin pu-
rity alone are involved in the development of insulin antibodies. 
The presence of insulin antibodies shows no relation to the meta-
bolic control. This is in keeping with other studies (Asplin 
1981, Peacock 1983). 
Discriminating, however, is the presence of insulin antibodies 
(IgGib, measured by the more sensitive method) in 9 children of 
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the 28 tested previous to therapy with insulin. Although a role 
of these auto antibodies in the pathogenesis of IDDM is uncer-
tain, they may be marker of autoimmune beta cell damage, 
detectable before the overt onset of the disease (Asplin 1983, 
Kaplan 1984, Palmer 1983). In keeping with this is our finding 
that the children with IgGib at onset show a significantly 
faster decrease of the UCP and a significantly lower UCP 1 year 
after onset of IDDM. This association suggests that these antibo-
dies may indeed be involved in or are a marker for the ongoing 
beta cell destruction. To evaluate whether these antibodies are 
involved in or are markers for autoimmune beta cell destruction 
further in vivo and in vitro studies are necessary. 
Summarizing, although none of the parameters of the study can 
be directly related to the remission period, the presence of 
IgGib at onset and the UCP level at onset show a significant cor-
relation with the endogenous insulin reserve after 1 year. The 
influence of the glycaemic control on the endogenous insulin 
reserve remains to be clarified. 
Recommendations 
The follow-up of the studied children during the second year 
and after the end of the study, as described in the previous 
paragraph, may reveal further information on the course of IDDM 
and the importance of near normoglycaemia regarding the preser-
vation of beta cell function. 
In the long-term more information may 
the relationship between normoglycaemia 
insulin production and the development of 
cations. 
be obtained regarding 
and/or an endogenous 
major diabetic compli-
The significant relationship between the endogenous insulin 
production at onset and after 1 year stresses the importance of 
earlier detection of IDDM in order to start with a considerable 
endogenous insulin reserve. 
The role of IgGib in IDDM must be studied in in vivo as well 
as in in vitro studies. Our demonstration of a negative relation-
ship between IgGib at onset and UCP after l year has to be 
confirmed by other studies (with larger samples). Further it 
would be very interesting to test the effect of positive serum 
samples on perifused islets of Langerhans in the absence and 
presence of complement to evaluate if the function of the beta 
cells is altered by these antibodies (Kanatsana 1981, Ziegler 
1972). A purification of the serum fraction with IgGib may 
allow a further characterization of these auto antibodies and 
their role in the pathogenesis of IDDM. 
GENERAL DISCUSSION 
Feasibility aspects and psychological impact of CSII in 
randomized newly diagnosed diabetic children do not form an im-
pediment for the continuation of this method of insulin admini-
stration, but rather the contrary. Metabolic control is impro-
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ved with respect to sHbAI. The remission period lasts about 4 
months longer. Prolongation of the remission period is only tem-
porary. The initial endogenous insulin reserve shows a signifi-
cant correlation with the production after I year, suggesting no 
direct benefit of CSII therapy. Although the time costs of CSII 
are relatively low, the financial costs are considerable. 
These results of the pump study evoke the question whether it 
is worthwhile to start with CSII in all newly diagnosed diabetic 
children, provided that the setting fulfills certain requirements 
(24 hours telephone service, education program, self-monitoring 
and a home visiting nurse practitioner). 
Although it has not yet been proven that chronic complications 
can be prevented or delayed by good metabolic control (from onset 
onwards), CSII may contribute to a reduction of some chronic 
complications. No results from studies are available evaluating 
the effect of good metabolic control from diagnosis onwards. Most 
studies investigating the relationship between chronic compli-
cations and CSII are performed only after the first signs of com-
plications have become manifest. One may think: too late already. 
In time our pump study may answer, or at least give an indication 
(because of the small number of participants) of the effect of 
CSII, started in an earlier phase, on the microvascular complica-
tions. A careful follow-up of the two groups regarding chronic 
complications is necessary and may provide relevant information 
concerning this. 
At this point of time the results of the study do not justify 
the starting of CSII in all newly diagnosed diabetic children, 
however with 2 exceptions. 
Firstly, 1 category of newly diagnosed diabetic patients ought 
to start with CSII, namely the youngsters with an age at onset of 
5 years or younger. Their age-related problems contribute to the 
usually poor metabolic control. Considering the reduced life ex-
pectancy, the age at which the chronic complications may arise 
and taking account of the possible benefit of a good metabolic 
control, the use of CSII treatment as early as possible seems 
justified in this group of patients. 
Secondly, if further development of the knowledge of the 
pathogenesis of IDDM results in the production of an adequate in-
tervention therapy, CSII may be useful as interim therapy to ob-
tain good metabolic control and to prolong the remission period 
temporarily. 
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APPENDIX I 
Request for confirmation of the parents' oral consent for par-
ticipation of their child in the pump study--
Dear Parents, 
We would hereby like to thank you for your willingness to par-
ticipate in the diabetes study. 
For the sake of clarity and perhaps superfluously, we would 
like to briefly inform you of what it is about. 
Every diabetes patient must have insulin administered his 
entire life. Until now the insulin used has been prepared from 
porcine or bovine. In the past few years, semi-synthetic human 
insulin has been produced abroad. Although this has been used, 
amongst others in the U.S. and Denmark, it is not yet available 
in the Dutch pharmacies. 
We think that this insulin might be superior. In order to 
confirm this, research is necessary. All children participating 
in this research project will be treated with human insulin. 
Another part of this research project involves the method of 
administering the insulin. In order to imitate the normal situa-
tion as much as possible, there are currently pumping devices 
which provide a constant release of insulin into the body over a 
period of 24 hours. This method would provide a close imitation 
of a normal condition. However, research regarding this is neces-
sary first. At random is determined which patient (in the event 
permission is granted for participation in the project) receives 
the conventional treatment (J x or 2 x an insulin injection dai-
ly) and which patient receives the pump treatment. Small children 
may not be considered for the pump treatment. 
Participation in this project means that blood sampling will 
take place more frequently, to wit: 
1st month 1 x per week 
2nd month 2 x per month 
3rd month 2 years: 1 x per month. 
Once every month 24 hours urine has to be collected on ice. 
At any time you can approach us with further questions (phone 
number: 010 - 656566, ext. 1110). 
We would kindly request you to notify your approval of 
project and the participation of your child in this project 
signing the enclosed paper. 
the 
by 
It is emphasized once again, that you have the right to stop 
this participation at any time during the study, with no explana-
tion required. 
Roping to have informed you sufficiently 
again, we remain, 
yours sincerely 
C.E. de Beaufort 
G.J. Bruining (pediatrician/endocrinologist) 
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and thanking you 
APPENDIX I (continued) 
Undersigned: Born: 
Parent(guardian) of: Born: 
declares to have taken note of the participation of 
in a study in which human insulin and/or insulin pumps are stu-
died. 
Undersigned has been notified of the fact, that all patients will 
use human insulin, but that at random is determined which child 
starts with the pump and which with the conventional injection 
therapy. 
Small children may not be considered for the pump treatment. 
Children and/or parents (guardian) have the right to stop the 
participation at any time during the study, with no explanation 
required. 
The duration of the study and the possible risks and disadvanta-
ges of the study have been clearly explained before the start of 
the study. 
C.E. de Beaufort 
G.J. Bruining (pediatrician/ 
endocrinologist) 
child ( >12 years) 
parent/guardian 
!05 
APPENDIX II 
Costs of the requ~s1tes for pump treatment ~ and Jb) and 
~ntiOnar-treatment (2) 
Requisites (per month = 30 days) 
Ia Pump therapy 
I 1/2 ml syringe+ needle 
Opsite (Hfl 8. 10 - Hfl. 18.89) * 
Infusion set (Hfl 58.60- Hfl 117.20) * 
Stopcaps (30 a 50) 
Insulin (actrapid) (H£1 19.60 - Hfl 78.42) 
Medium (diluting solution) 
Diaburstrips 0 (50) 
Keturstrips 0 (50) 
Hemoglucotest strips 0 (25) 
Monolets prickers 0 (25) 
Glucagon infusion set o ( I) 
Range H£1 
Initial expense for the 
Pump + charger + batteries (3) 
(expected life span ~ 6 years) 
280.61 -
Costs. as calculated 
by the purchase de-
partment of the SKZ 
CPI Betatron 9204 
H£1 90.44 
Hfl 18.89 
Hfl 117.20 
Hfl 23.20 
H£1 78.42 
H£1 9.67 
H£1 10.62 
Hfl 35.04 
H£1 15.82 
Hfl 18.80 
------------
H£1 418. 10 
Hfl 6.090.00 
* 
Dependent on the frequency with which the 
changed (5-7 days). 
infusion set: is 
o Requisites for blood glucose monitoring at home, not paid by 
the project budget. 
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APPENDIX II (continued) 
Requisites (per month = 30 days) 
for 
lb Pump therapy 
3 ml syringe (luer lock) 
2 ml syringe 
Needle 
Opsite (Hfl 8. 10 - Hfl 18.89) * 
Infusion sets (Hfl 58.60- Hfl 117.20) * 
Stop cap (30 a 50) 
Insulin (actrapid) (Hfl 19.60- Hfl 78.42) 
Medium (diluting solution) 
Diaburstrips o 
Ketur strips o 
Hemoglucotest strips o 
Monolets prickers o 
Glucagon infusion set o 
Range: 
(50) 
(50) 
(25) 
(25) 
( 1 ) 
Hfl 212.77-
Initial expense for the pump 
+ Charger + 2 batteries 
(expected life span: 3 years) 
Costs as calculated 
by the purchase de-
partment of the SKZ 
Autosyringe AS6C 
Hfl 12.32 
Hfl 3.60 
Hfl 6.68 
Hfl 18.89 
Hfl 117.20 
Hfl 23.20 
Hfl 78.42 
Hfl 9.67 
Hfl 10.62 
Hfl 35.04 
Hfl 15.82 
Hfl 18.80 
-------------
Hfl 350.26 
Hfl 5.192.00 
* Dependent on the frequency with which the infusion set is 
changed (3-7 days). 
o Requisites for blood glucose monitoring at home, not paid by 
the project budget. 
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APPENDIX II (continued) 
Requisites (per month = 30 days) 
for 
2. Conventional injection therapy 
2 ml syringe (60) 
Needles (60) 
Diabur teststrips 0 (50) 
Ketur tests trips 0 (50) 
20/800 hemoglucotest 0 (25) 
Monolets 0 (25) 
Glucagon infusion set ( 1) 
Insulin (Monotard) (Hfl 14.36 - Hfl 
Actrapid (Hfl 13.04 - Hfl 
Range: Hfl 128.25 
64. 82) 
19.56) 
Costs as calcula-
ted by the purcha-
se department of 
the SKZ 
Hfl 7.30 
Hfl 3.60 
Hfl 9.67 
Hfl 10.62 
Hfl 35.04 
Hfl 15.82 
Hfl 18.80 
Hfl 64.82 
Hfl 19.56 
Hfl 185.23 
o Requisites for blood glucose monitoring at home, not paid by 
the project budget. 
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APPENDIX ill 
Items of the Dutch Personality Test for Juniors 
Item 
l. Inadequacy 
2. Perseverance 
3. Social Inadequacy 
4. Dominance 
5. Recalcitrance 
Interpretation 
- high score: anxious, sense of inferio-
rity, usually difficult in 
social contacts 
- high score: calm, conscientious child, 
positive attitude towards 
work and with perseverance 
- high score; withdrawing from their peer 
group, inadequate in main-
taining social contacts 
- high score: self-confident (apparently 
sometimes dominating), not 
easily influenced by others 
-high score: negative and suspicious at-
titude towards others 
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APPENDIX IV 
Items of the Family Environment Scale 
Item 
Cohesion 
Expression 
Norms and values 
Organization 
Control 
Conflict 
Social orientation 
Recreation 
Ambition 
Interpretation 
Concern of the family members for 
each other 
Possibility to express feelings and 
opinions freely and directly 
The attitude of the family members 
towards norms and values 
The way in which rules, 
duties are handled within 
ly 
tasks or 
the fami-
The control exerted by the family 
towards family members 
The expression of anger and aggres-
sion within the family 
Concern of the family for the poli-
tical and social sides of life 
Participation by family members in 
recreational activities indoors and 
outdoors 
The ambitions of family members 
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APPENDIXV 
Items of the Diabetes Questionnaire 
Items 
Physical complaints 
Social contacts 
Injection fear 
Socially restricted 
Physically restricted 
Attitude outsiders 
Attitude parents 
Dietary problems 
Wish to have children 
when grown up 
Ill 
Max. ~ Interpretation 
7 
7 
7 
9 
6 
5 
8 
5 
2 
- poor metabolic con-
trol 
- has poor social con-
tacts 
- is afraid of injec-
ting itself 
the diabetes impedes 
its activities and 
social contacts 
- the diabetes impedes 
physical activities, 
such as sports 
- outsiders are afraid 
of IDDM/injections, 
as observed by the 
child 
- parents are not o-
verly concerned nor 
consider the child 
as pitiful 
difficulties in ac-
cepting and comply-
ing to dietary rules 
wish to 
children 
up 
have no 
when grown 
APPENDIX VI 
Diabetes Questionnaire 
Name: 
1. Sometimes I feel sick. 
2. I often feel strange. 
3. I often have a tummy ache. 
4. I often wake up in the middle of the night. 
5. Then I have to go to the bathroom. 
6. I am then very very thirsty. 
7. When I wake up in the morning I often have a 
headache. 
8. I often have a runny bm (=bowel movement). 
9. I have a lot of friends. 
10. I often play with my friends. 
II. Most of all I like to play by myself. 
12. I often argue with my friends. 
13. I like animals more than people. 
14. Other children think I'm a nuisance. 
15. I often dream about needles. 
16. I think injections are terrible. 
17. My father says, that I should be brave when I 
get an injection. 
18. I think a prick in the finger is much worse 
than the injection. 
19. My mother doesn't mind the injections. 
20. My parents feel sorry for me because I have 
to have injections. 
21. My friends don't mind the injections. 
22. I never want anyone to see me getting an 
injection. 
23. My friends always like to see me getting 
an injection. 
24. I don't like to play at a friend's house if I 
still have to have an injection. 
25. I can never play for very long _at a friend's 
house, because of my injections. 
26. My mother doesn't like my friends to see me 
getting my injection. 
27. I am always hungry. 
28. I like sweets and candy a lot. 
29. My mother is a real good cook. 
30. My mother feels sorry for me. 
31. I get more presents because I have to have 
injections. 
32. My mother gets mad at me, if I eat a piece 
of candy. 
33. I'm never allowed to eat nice food. 
34. My parents think it is pretty terrible be-
cause I can not eat just anything. 
35. My father thinks that injections are just 
terrible. 
36. My mother thinks that I am real brave. 
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Yes No 
APPENDIX VI (continued) 
37. Children, who have to have injections, should 
get a lot of presents. 
38. I want a lot of children when I grow up. 
39. I will never want children of my own. 
40. Injections are worse for children than for 
grown-ups. 
41. Grown-ups think injections are terrible too. 
42. My teacher thinks injections are real fright-
ful. 
43. I don't like parties at all. 
44. I'm always invited to my friend's parties. 
45. I don't want to throw a party. 
46. I don't like to treat other children to sweets. 
47. When children are treated to sweets, I always 
get something else. 
48. I wish no one knew that I need injections. 
49. I am often afraid of getting an injection. 
50. My parents love me the most. 
51. I don't like to eat at my friend's house. 
52. I often tease other children. 
53. I like to swim a lot. 
54. I like PE (Physical Education). 
55. At home I like to wear my gym clothes. 
56. I don't like to swim. 
57. I don't like putting on my swimming suit 
at the swimming pool. 
58. I don't like getting dressed for PEat 
school. 
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APPENDIX VII 
Assessment of acceptation scale 
Name of the critic: 
Name of the child : 
1. Indicate to what extent the child accepts its diabetes. 
very good 
I 
good 
2 
moderate 
3 
bad 
4 
poor 
5 
2. Give your opinion on the metabolic control of the child. 
very good 
I 
good 
2 
moderate 
3 
bad 
4 
poor 
5 
3. Give your opinion on the physical condition of the child. 
very good 
I 
good 
2 
moderate 
3 
bad 
4 
poor 
5 
4. Give your opinion on the capacity of the parents to effectuate 
advices, given by the diabetes team. (This comprises as well 
the compliance of the parents as the influence of the parents 
on the child). 
very good good moderate bad poor 
I 2 3 4 5 
5. Give your opinion on the psychological health of the child. 
very good good moderate bad poor 
I 2 3 4 5 
I 14 
APPENDIX VIII 
Letter to the insurance companies, 
~ed blood test strip pots 
Dear Colleague, 
concerning the quantity 
We kindly request your attention for the following. 
of 
In the past four years research has been conducted in the SKZ 
regarding the influence of CSII treatment on residual insulin 
production of insulin dependent diabetic children. For this 
purpose 30 newly diagnosed children have at random started with 
either CSII or conventional therapy. Besides the above mentioned 
we are particularly interested in the effect of CSII on metabolic 
control. Better metabolic control could lead to less frequent 
blood testing. In order to investigate the difference in use of 
blood sugar strips between the two groups, we kindly request your 
cooperation. 
We would like to know if it is possible that you fill in the 
enclosed form as to how many pots of blood test strips have been 
declared by the patient (parents) during the relevant months. 
Hoping that you can and will fulfill our request, and thanking 
you for your cooperation, 
we remain 
yours sincerely~ 
C.E. de Beaufort 
G.J. Bruining (pediatrician) 
NAME 
Month 
I 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
Total 
Blood. strip pots Month 
I 
2 
3 
4 
5 
6 
7 
8 
9 
10 
II 
12 
liS 
Blood strip pots 
SUMMARY 
The influence of CSII on the remission period of newly 
diagnosed insulin dependent diabetic children is the central 
theme of this thesis. An answer is sought for following questi-
ons: 
- Is CSII feasible in not selected newly diagnosed diabetic 
children? What is the psychological impact of the therapy? 
-What is the influence of CSII on the metabolic control? 
Does CSII prolong the remission period of diabetic children? If 
so, which factors contribute to this? 
In Chapter I motives and purposes of the study are briefly 
described. Progressive loss of insulin producing beta cells re-
sults in a metabolic disregulation. This leads to a lifelong 
dependency on insulin administration. Shortly after the start of 
insulin therapy a remission period may occur. The remission pe-
riod is characterized by a good (near normal) metabolic control 
with a relatively low insulin dose. Some beta cells seem to re-
cover temporarily. However, after several weeks or months insu-
lin requirements increase once again. In insulin withdrawal 
studies the presence of a residual beta cell activity is 
associated with a later onset of metabolic disregulations. 
Chronic complications have often been suggested to occur less in 
patients with a residual beta cell activity. This has led to 
intensive research into possibilities to influence and/or prolong 
the remission period. Retrospective studies suggest a beneficial 
effect on this period of a rapid normalization of metabolism 
after the onset of IDDM. To obtain a good metabolic control in 
children often raises problems. In general, several injections 
per day Cat least 2) are necessary, which is not always easy in 
children. The availability of CSII, however, offers new possi-
bilities. 
In order to evaluate the influence of CSII on the metabolic 
control and the remission period of newly diagnosed diabetic 
children, a prospective randomized study has be·en undertaken. 
Since CSII has never before been used in a group of not selected 
newly diagnosed diabetic children, the feasibility of this the-
rapy has to be studied. The feasibility for the child, its 
parents and the medical staff are included. 
In Chapter 2 IDDM, the pathogenesis and possible causes are 
discussed. Hereditary susceptibility, combined with a viral or 
environmental agent~ may cause a disturbance of the immune sys-
tem, possibly resulting in the autoimmune destruction of beta 
cells. For the patient it implies a lifelong dependency on insu-
lin injections. Ten to 15 years after the onset of IDDM chronic 
complications may occur (nephropathy, retinopathy, neuropathy and 
cardiovascular abnormalities). It may not be surprising that this 
chronic disease exerts an influence on the psyche of the 
patients. Many factors - however - will be involved in the coping 
responses. 
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The remission period is discussed in more detail in the 2nd 
paragraph. During this period, occurring shortly after the start 
of insulin therapy, a good metabolic control is obtained with a 
relatively low insulin dose. In this thesis the remission period 
will be characterized by 3 parameters. 
- a near normal metabolic regulation (sHbA, within the normal 
range) 
a near normal endogenous insulin production (urinary C-peptide 
excretion within the normal range) 
- an insulin dose below 0,5 U/kg/24 hours 
Morphological studies demonstrate beta cell hyperactivity and 
regeneration during the remission period. The metabolic disre-
gulation, present at onset, is almost normalized. To maintain a 
good (near normal) metabolic control, a relatively low insulin 
dose is needed. This suggests either a recovery of insulin produ-
cing beta cells or an increased insulin sensitivity of the tis-
sues. To what extent therapy contributes to the occurrence of the 
remission period remains to be clarified. The discovery of C-pep-
tide (a peptide, which is secreted by the pancreas in equimolar 
quantities as insulin) and the development of an assay to measure 
it, offers the possibility to assess the endogenous insulin 
production. The relevance of an endogenous insulin production has 
been suggested by several studies. As mentioned before, a later 
onset of metabolic disregulation in insulin withdrawal studies as 
well as less chronic complications have been described in asso-
ciation with the presence of an endogenous insulin production. 
Rapid normalization of metabolism after the onset of IDDM is 
suggested to result in an increased occurrence and longer dura-
tion of the remission period. An association between age and 
seriousness of metabolic disregulation at onset and the occur-
rence of a remission period has also been described. To what 
extent other factors, such as immunological disturbances, are 
involved remains to be elucidated. 
The aim of the pump study is to evaluate the influence of CSII 
on the metabolic control and on the remission period of diabetic 
children. 
In Chapter 3 the aim of the treatment of IDDM children in the 
Sophia Childrens' Hospital (part of the University Hospital Rot-
terdam, Rotterdam) is described as well as the methods used to 
pursue this aim. In the Sophia Childrens' Hospital the diabetes 
team, consisting of a pediatric endocrinologist, a pediatrician, 
a nurse practitioner, a dietician and - during this study - a 
research fellow, takes care of about 150 diabetic children. The 
purpose of the treatment is achieving a good metabolic control, 
without hypo- or hyperglycaemic periods, and a normal 
development. Patient (and parent) education and self monitoring 
form the basis of the therapy. Hospitalization is reduced as much 
as possible. A 24 hours telephone service is imperative on offe-
ring children and parents the possibility to consult one of the 
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team members at any time. After the clinical onset of IDDM 
practical and theoretical instruction given by the nurse 
practitioner, if possible at home. This depends on the serious-
ness of metabolic disregulation, the social background~nter alia 
presence of a telephone) and the availability of the nurse prac-
tltloner. Later on home visits will be made for several purposes 
(a repetition of practical skills, instruction for holidays. pe-
dagogical or psychological problems). Once a year parents of re-
cently diagnosed children are invited to participate in a "re-
fresher" course in the hospital (5 evenings). 
At the start of this study only for I child a pump had been 
used. CSII is expected to imitate more or less the physiological 
insulin production (although insulin is still administered in the 
wrong place). Further experience with this therapy- however- is 
needed. 
In Chapter 4 the design and protocol of the study are 
described in more detail. In a prospective randomized study 30 
newly diagnosed diabetic children - consecutively referred to the 
Sophia Childrens' Hospital- are treated either with CSII or with 
CT. In both groups semisynthetic human insulin is used. Oral and 
written consent is obtained from parents (and children of 12 
years of age or older). During 2 years the children visit the 
outpatient clinic monthly. The first 3 months these visits are 
more frequent. After 2 years of follow-up the children are tested 
psychologically. In this thesis the results after 1 year of fol-
low-up are given. Since the psychological tests are only perfor-
med after 2 years of follow-up, these data are preliminary and 
incomplete. 
At onset the seriousness of the metabolic disregulation is 
assessed by blood glucose levels, blood pH and ketonuria. HLA 
typing and virusserology have been performed to study their re-
lationship with IDDM and its remission period. The feasibility of 
CSII in not selected diabetic children is assessed by 4 parame-
ters: 
- acceptation of the therapy by child (and parents) 
- practical problems (and their possible consequences on the 
metabolic disregulation) 
frequency of telephone calls 
frequency of home visits by the nurse practitioner 
Main parameter for the metabolic control is the monthly 
determined stable glycosylated hemoglobin (sHbAI). After 6 months 
and 1 year intermediary metabolites are measured. The frequency 
of blood glucose measurements at home and of hypoglycaemic 
periods are also included as parameters for the metabolic 
control, as well the insulin dose. Monthly determined 24 hours 
urinary C-peptide excretion is the main parameter for the endoge-
~ insulin production. The glucagon stimulation test is 
performed once every half year to obtain information on the beta 
cell function after stimulation. The relationship between these 2 
methods is discussed. A 95% reference interval for 24 hours uri-
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nary C-peptide excretion has been calculated for healthy chil-
dren of different ages. Islet cell cytoplasmic antibodies, com-
plement or not complement binding, and islet cell surface anti-
bodies have been determined at onset and after 6 and 12 months. 
Insulin antibodies have been measured by 2 methods at onset, 
Three, 6, 9 and 12 months after the onset they have been mea-
sured by 1 method (the slightly less sensitive "classical 11 one). 
Finally the statistical analysis is described. 
In Chapter 5 the results of the study are given. Of the 34 
consecutively referred children 4 dropped out. Two children were 
too small for the pumps available at that moment (the AS6C; the 
CPI betatron became available after about 1 year). One child got 
CSII instead of the planned CT, because of a pos~t1ve family 
history. Finally one girl was created conventionally instead of 
by CSII because of her social background. Age at onset differs 
significantly between the 2 groups. The children of the CSII 
group are older. The metabolic disregulation at onset does not 
differ significantly between the 2 groups. Pump therapy is well 
accepted. Only one girl has changed after 28 months from CSII to 
CT. Practical problems resulting in serious metabolic disregula-
tions have not occurred. The CSII group has paid slightly less 
telephone calls. The frequency of home visits does not differ 
between the 2 groups. Only 15 children have been tested psycho-
logically. With respect to physical complaints the 2 groups 
differ significantly. The CSII group expresses less physical 
complaints compared with the CT group. A significantly better 
metabolic control is found in the CSII group with respect to 
sHbA1. Intermediary metabolites do not differ. Blood glucose 
measurements are performed about as often in both groups. Hypo-
glycaemia is seen with equal frequency in both groups. Insulin 
doses do not differ either between the CSII and CT group. The 
urinary C-peptide excretion nor the stimulated plasma C-peptide 
values show a difference between the 2 groups. The C-peptide 
excretion at onset is significantly related with the C-peptide 
excretion after 1 year. The remission period lasts about 4 months 
longer in the CSII group. Age or degree of metabolic disregula-
tion at onset, nor the presence of islet cell antibodies show an 
association with the occurrence of a remission period. A signi-
ficant negative relationship is found between the presence of 
insulin antibodies (IgGb) before the start of therapy and the C-
peptide excretion after 1 year. No fixed relationship has been 
found between sHbAI and C-peptide excretion. Interesting is 
- however - that only once a decrease in C-peptide excretion is 
not preceded by an increase in sHbAI. Urinary C-peptide ex-
cretion and insulin dose show a significant correlation in both 
groups after 6 months and I year. The coefficients of correlation 
in the 2 groups show a suggestive, but not significant differen-
ce. 
In Chapter 6 the results are discussed and compared with other 
studies. Recommendations for further research are given. 
Pump therapy has not before been used in not selected newly diag-
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nosed diabetic children. Most studies describe the use of CSII in 
selected populations of diabetic patients with a longer duration 
of IDDM. Differences between the results, described in this the-
sis and the data of other studies are the time requirements (for 
the medical staff), the acceptation of the therapy and the 
occurrence of metabolic disregulations (hypo- and/or hypergly-
caemia). Partly these differences can be ascribed to the moment 
at which therapy is started. The 30 participating children do 
not yet have a "diabetic" past. The presence of an endogenous 
insulin production may also play a role in the less frequent oc-
currence of metabolic disregulations. Further, the patients stu-
died are children. Possibly the attention paid by the parents may 
contribute to an earlier intervention in imminent disregulation. 
The follow-up of the 30 children after the 2 years of the study 
may provide further information on these 3 factors and their in-
dividual importance. 
Analysis of and discussion concerning the psychological tests 
are complicated, since the data are preliminary. CSII - however -
does not seem to form an impediment for the children and their 
(social) act~v~t~es. The role of an intensive education in the 
prevention of metabolic disregulations is widely accepted. 
Regarding the metabolic control the CSII group shows a 
significantly lower sHbAl. In youngsters (~ 5 years) this impro-
vement is considerable. Because of age dependent problems achie-
vement of an acceptable control is very difficult in these chil-
dren. CSII is of benefit for this group, since it offers the 
possibility to adjust more frequently and more adequately the 
insulin dose without increasing the injection frequency. The 
frequency of blood glucose measurements is significantly higher 
in most studies. The relatively low frequency of 5 measurements 
per week is not associated with an increase in metabolic disregu-
lations. The moment at which the children are studied may also 
play a role in this difference. 
Of interest are the same insulin doses of the 2 groups. One 
has to realize - however - that insulin dose and insulin require-
ments are not the same. Especially in the CT group the insulin 
dose can not always be augmented in order to reduce hyperglycae-
mia, for this may result in an increased occurrence of hypogly-
caemic periods. To what extent a difference in insulin sensiti-
vity is involved is unknown. Several studies suggest a better 
insulin sensitivity in CSII patients. Further (in vivo and in 
vitro) studies are needed to study this phenomenon in children. 
The follow-up of the children after the 2 years of the study may 
provide in due time information on the relationship between the 
occurrence of a remission period, the metabolic control and the 
onset of chronic complications. One must not forget - however -
that only a small number of patients is studied. 
No difference is found between the endogenous insulin 
production of the 2 groups. The significant relationship between 
the C peptide excretion at onset and after 1 year has also been 
described by another study. It stresses the importance of an 
early diagnosis and start of therapy. The presence of insulin 
antibodies before the start of insulin therapy shows a negative 
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association with the C-peptide excretion after l year. Whether 
these antibodies are actively involved in the ongoing destructi-
on of beta cell mass or are just "markers" for beta cell destruc-
tion is unknown. 
The remission period lasts significantly longer (4 months) in 
the CSII group. Contrary to retrospective studies no association 
has been found between age and metabolic disregulation at onset 
and the occurrence of a remission period. This may be explained 
by the different definitions and criteria which are used. It 
can not be excluded that age only plays a role below or above a 
certain critical level. For the lack of association between the 
metabolic disregulation and the remission period the same expla-
nation may be given, especially considering the fact that the 3 
children, who needed intravenous administration of fluids and 
insulin have no remission period. None of the determined 
parameters shows a significant relationship with the remission 
period. 
SHbAl and C-peptide excretion show no fixed relationship. 
Still, only in I case a decrease of C-peptide excretion is not 
preceded by an increase in sHbAl. The relationship between insu-
lin dose and endogenous insulin production differs slightly 
between the 2 groups. One could speculate that this difference 
suggests a different insulin sensitivity in the 2 groups. Insulin 
administered with CSII may be more effective (considering the 
lower sHbAl percentages). Several other studies describe a higher 
insulin sensitivity in patients with CSII. 
Finally, 2 indications for the use of CSII in newly diagnosed 
children are given. First of all, the youngsters (< 5 years) are 
considered as candidates for CSII therapy. Secondly, if methods 
are developed for intervention in the ongoing destruction of beta 
cells, CSII may be useful as interim therapy until intervention 
therapy is started. 
Returning to the questions, mentioned at the beginning of the 
summary, following answers have been found: 
- CSII is feasible in not selected newly diagnosed diabetic chil-
dren. Thus far, preliminary results of the psychological tests 
do not show a negative influence of CSII on newly diagnosed 
diabetic children and their social activities 
with respect co sHbAl the metabolic control in the CSII group 
is significantly better. The other parameters for the metabolic 
control including the insulin dose show no significant diffe-
rences between the 2 groups 
the remission period lasts about 4 months longer in the CSII 
group. 
No factors have been found, which show a significant relationship 
with the occurrence of the remission period. However, the C-pep-
tide excretion at onset as well as the presence of insulin anti-
bodies before therapy are significantly related to the endogenous 
insulin production (one of the individual parameters for the 
remission period) after 1 year. 
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SAMENVATTING 
De invloed van continue subcutane insuline infusie (CSII) op 
de remissie periode van insuline afhankelijke diabetes mellitus 
(IDDM) op de kinderleeftijd staat centraal in dit proefschrift. 
Getracht wordt om de volgende vragen te beantwoorden: 
Is CSII toepasbaar bij nieuwe niet geselecteerde kinderen met 
IDDM? Wat is de psychologische invloed van deze behandeling? 
- Resulteert CSII in een betere metabole regulatie van deze kin-
deren? 
Belnvloedt CSII de remissie periode? Zo ja, welke factoren 
spelen daarbij mogelijk een rol? 
In hoofdstuk 1 wordt weergegeven hoe en waarom dit onderzoek 
tot stand is gekomen. 
Progressief verlies van insuline producerende beta cellen 
leidt door insuline deficiencie tot uitgebreide stoornissen in 
onder andere glucose en vet metabolisme. Insuline injecties wor-
den - levenslang - noodzakelijk. Snel na de start van deze thera-
pie treedt in sommige gevallen een remissie periode op. Deze pe-
riode wordt gekarakteriseerd door ee~ goede metabole instelling 
met een relatief geringe insuline dosis. De beta cellen lijken 
gedurende korte tijd ten dele te herstellen. Echter, na enige we-
ken of maanden neemt de insuline behoefte (de hoeveelheid die no-
dig is om een zo normaal mogelijk metabolisme te handhaven) weer 
toe. Diverse studies suggereren dat de aanwezigheid van enige 
resterende beta eel activiteit geassocieerd is met een minder 
snel metabool ontregelen en mogelijk oak met minder chronische 
diabetes complicacies. Dit heeft geresulteerd in intensief onder-
zoek naar mogelijkheden om de remissie periode te beinvloeden (en 
te verlengen). Retrospectief onderzoek geeft aanwijzingen voor 
een positieve invloed van een goede metabole regulatie, verkregen 
zo snel mogelijk na de start van de insuline therapie. Bij kinde-
ren is het bereiken van een goede metabole regulatie een moei-
lijke opgave, mede door bet feit dat vaak meerdere injecties (>2) 
per dag nodig zullen zijn. De komst van CSII opent echter nieuwe 
perspectieven. 
Om na te gaan hoe CSII de metab-ole instelling en de remissie 
periode van nieu¥e kinderen met IDDM beinvloedt is gekozen veer 
een prospectief gerandomizeerd onderzoek (beschreven in dit 
proefschrift). Aangezien CSII nooit tevoren in een groep niet ge-
selecteerde nieuwe patienten is gehanteerd, dient eveneens geke-
ken te worden naar de uitvoerbaarheid van deze therapie, in de 
eerste plaats voor het kind en zijn familie en in de tweede 
plaats voor het behandelend team. 
In hoofdstuk 2 worden IDDM, de pathogenese en mogelijke 
oorzaken besproken~ Erfelijke aanleg, gecombineerd met een viraal 
of ander agens, leidt waarschijnlijk tot een verstoring van het 
immuun apparaat. Deze resulteert in de auto immuun destructie van 
de beta cellen. Voor de patient betekent het een levenslange af-
hankelijkheid van insuline injecties. Tien t.ot 15 jaar na het 
begin van de ziekte treden in een aantal gevallen ernstige com-
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plicaties op (nefropathie~ retinopathie, neuropathie en cardio-
vasculaire afwijkingen). Dat deze chronische ziekte een invloed 
kan hebben op de psyche van de patient ligt voor de hand. Vele 
factoren kunnen hierin een rol spelen. 
De remissie periode wordt in de 2e paragraaf uitvoeriger be-
sproken. Met de remissie periode wordt een periode bedoeld, die 
vaak optreedt kort na de start met insuline therapie. Gedurende 
deze periode heeft de patient een goede metabole regulatie met 
een relatief geringe insuline dosis. In dit proefschrift wordt 
deze periode gekarakteriseerd door 3 parameters: 
de metabole regulatie (in de normale range) 
- de endogene insuline productie (in de normale range) 
- de insuline dosis (< 0.5 E/kg/24 uur) 
Morfologische studies tonen in deze periode hyperactiviteit en 
regeneratie van de beta cellen. De metabole ontregeling aanwezig 
bij de ontdekking van IDDM is weer (bijna) genormaliseerd en voor 
handhaving van een goede metabole regulatie is slechts een 
geringe insuline dosis nodig. Dit lijkt te wijzen of op een her-
stel van beta eel activiteit of op een toegenomen gevoeligheid 
voor de toegediende insuline. Ret is niet duidelijk in hoeverre 
deze periode door de therapie wordt beinvloed. De ontdekking van 
het C-peptide (een eiwit, dat in even grate hoeveelheden als 
insuline wordt uitgescheiden door de pancreas) en de ontwikke-
ling van een bepalingsmethode hiervoor biedt de mogelijkheid om 
de endogene insuline productie te meten. Het belang van endogene 
insuline productie wordt gekenschetst door al eerder genoemde 
bevindingen. De aanwezigheid van enige endogene insuline 
productie lijkt geassocieerd te zijn met een minder snel meta-
bool ontregelen. Eveneens zouden mogelijk minder frequent chro-
nische complicacies optreden in aanwezigheid van een endogene in-
suline productie. 
Retrospectief onderzoek WLJSt op een posLtLeve associatie 
tussen snel normaliseren van bet metabolisme na de ontdekking van 
IDDM en een vaker optredende en langer durende remissie. Eveneens 
wordt een associatie beschreven tussen de leeftijd en bet 
voorkomen van een remissie periode (hoe jonger des te korter en 
minder frequent). In hoeverre andere factoren, zeals immunologi-
sche, een rol spelen in bet voorkomen van de remissie periode is 
nag onbekend. Het doel van de in dit proefschrift beschreven 
studie is na te gaan wat de invloed van CSII is op de metabole 
regulatie en op de remissie periode van kinderen met IDDM. 
In hoofdstuk 3 worden de doelstellingen van de therapie en de 
methode waarop deze nagestreefd worden in bet Sophia Kinderzie-
kenhuis, beschreven. In bet Sophia Kinderziekenhuis (deel van bet 
Academisch Ziekenbuis Rotterdam) draagt bet diabetes team, be-
staande uit 1 kinderarts-endocrinoloog, I kinderarts, I gespecia-
liseerde verpleegkundige, een dietiste en - voor de duur van bet 
onderzoek - een arts, zorg voor ongeveer ISO kinderen met IDDM. 
Het doel van de behandeling is om een goede metabole regulatie te 
krijgen, zonder hypo- of hyperglycaemie en met een normale ont-
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wikkeling. Patient- en oudereducatie en zelfcontrole met behulp 
van bloedsuikerbepalingen vormen de grondslag voor een goede be-
handeling. Getracht wordt ziekenhuisopnames zoveel mogelijk te 
beperken. Een 24 uurs bereikbaarheidsdienst van een van de team-
leden is hiervoor noodzakelijk, opdat ouders en/of patient bij 
onverwachte problemen contact op kunnen nemen voor overleg. 
Na de ontdekking van IDDM wordt de eerste praktische en theore-
tische instructie zo mogelijk thuis gegeven door de gespeciali-
seerde verpleegkundige. Dit is ondermeer afhankelijk van de mate 
van ontr.egeling van de patient, de thuissituatie (aanwezigheid 
van telefoon) en de beschikbaarheid van de gespecialiseerde ver-
pleegkundige. In de loop der tijd worden onder meer voor herha-
ling van praktische technieken, vakantie instructie en pedagogi-
sche en/of psychologische problemen huisbezoeken gebracht. Onge-
veer een half tot 1 jaar na de ontdekking van IDDM worden de ou-
ders uitgenodigd om deel te nemen aan een herhalingscursus in bet 
ziekenbuis (gedurende een vijftal avonden). 
Met pomp behandeling is in het begin van dit onderzoek nag 
weinig ervaring (I patie"nt). Verwacht wordt dat CSII een betere 
~m~tatie van de fysiologiscbe insuline productie zal geven (zij 
bet nag steeds op de verkeerde plaats toegediend). 
In boofdstuk 4 worden de vraagstelling en bet protocol van de 
studie verder uftgewerkt. In een prospectief gerandomizeerd 
onderzoek worden 30 nieuwe kinderen met IDDM (successievelijk 
naar het SKZ verwezen) met hetzij CSII, hetzij conventionele 
injectie tberapie behandeld. In beide groepen wordt 
semisynthetische humane insuline gebruikt. Mondelinge en schrif-
telijke toestemming tot deelname aan het onderzoek wordt aan ou-
ders (en kinderen > 12 jaar) gevraagd. Gedurende 2 jaar worden de 
kinderen maandelijks gevolgd. In de eerste 3 maanden is de fre-
quentie van ziekenhuisbezoeken frequenter. Na afloop van de 2 
jaar worden de kinderen psychologiscb getest. In dit proefschrift 
worden de resultaten gegeven na I jaar follow-up. De 
psychologische testen zullen dan nag niet door alle kinderen ge-
maakt zijn. Dit betekent dat bet slechts om preliminaire gegevens 
zal gaan, wat betreft de psychologische testen. 
Bij de diagnose IDDM wordt de mate van metabole ontregeling 
vastgelegd in de bloedsuiker, de bleed pH en de ketonurie. HLA 
typering en virusserologie Z~Jn uitgevoerd om na te gaan in 
hoeverre deze samenhang vertonen met bet al dan niet voorkomen 
van een remissie periode. 
De "uitvoerbaarheid" van CSII bij nieuwe niet geselecteerde 
kinderen met IDDM wordt getoetst door 4 parameters: 
de acceptatie van de therapie door kind (en ouders) 
de praktische problemen (en hun gevolgen op de metabole regu-
latie) 
- de frequentie waarmee telefoniscb overleg plaatsvindt 
de frequentie van huisbezoeken door de gespecialiseerde ver-
pleegkundige. 
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Als belangrijkste parameters voor de metabole controle worden 
maandelijks geglycosyleerd bemoglobine (sHbAI) en balfjaarlijks 
diverse intermediair metabolieten bepaald. De frequentie van 
bloedsuiker controles en bet voorkomen van bypoglycaemie worden 
eveneens betrokken bij de metabole controle evenals de insuline 
dosis. 
Maandelijks bepaalde C-peptide excretie in 24 uurs urine vormt 
de parameter voor de endogene insuline productie. De glucagon 
stimulatie test wordt eenmaal per half jaar uitgevoerd om 
eveneens informatie te verkrijgen betreffende de endogene insuli-
ne productie na stimulatie. De samenbang tussen deze twee para-
meters wordt bescbreven. Voor de C-peptide excretie in 24 uurs 
urine zijn referentie intervallen berekend voor gezonde kinderen 
van verschillende leeftijden. 
Om na te gaan in boeverre de immunologiscbe factoren een 
samenhang vertonen met de remissie periode (of een van de drie 
relevance factoren) zijn cytoplasmatische antistoffen tegen de 
eilandjes van Langerhans, complement en niet-complement binden-
de, en oppervlakte antistoffen tegen eilandjes van Langerhans 
bepaald. Insuline antilichamen zijn op 2 manieren bepaald voor de 
start van de therapie. Drie, 6 en 9 en 12 maanden na de ontdek-
king zijn ze met een methode bepaald. Tenslotte worden de sta-
tische analyses beschreven, die gehanteerd zijn om samenhang 
tussen de verscbillende parameters aan te tonen. 
Hoofdstuk 5 geeft de resultaten van bet onderzoek. Van de 34 
naar bet SKZ verwezen kinderen zijn er 4 drop outs. Twee kinderen 
waren te klein voor de op dat moment beschikbare pomp (de Autosy-
ringe AS6C, ongeveer I jaar later is de kleinere Eli Lilly/CPI 
betatron 9204 beschikbaar gekomen). Een meisje had een belaste 
familie anamnese voor IDDM en kreeg een pomp in plaats van de ge-
plande CT. Een patience is met CT behandeld in verband met haar 
sociale acbtergrond. 
De leeftijd van de 2 groepen verschilt significant. De pomp-
kinderen zijn ouder. Qua metabole ontregeling bij de ontdekking 
zijn de 2 groepen goed vergelijkbaar. 
Pomp therapie bij niet geselecteerde nieuwe pacienten blijkt 
zeker een haalbare kaart te zijn. De acceptatie van de therapie 
is goed. Slechts I meisje heeft na 28 maanden CSII therapie te 
kennen gegeven op CT te willen overgaan. Praktische problemen 
leidend tot (ernstige) metabole ontregelingen bebben zich niet 
voorgedaan. De CSII groep belt minder vaak. De frequentie huis-
bezoeken verschilt niet tussen de 2 groepen~ De resultaten van de 
psychologiscbe testen betreft slechts 15 kinderen. Wat betreft de 
meeste aspecten lijken de 2 groepen goed vergelijkbaar. Uit een 
test komt duidelijk naar voren dat kinderen met CSII minder li-
chamelijke klachten bebben. Deze data zijn ecbter wel 
preliminair. 
De metabole regulatie is, wat betreft het sHbAI, significant 
beter in de CSII groep. De intermediair metabolieten verschillen 
niet significant. Blo~dsuikers worden in beide groepen ongeveer 
even vaak gecontroleerd. Hypoglycemieen komen niet frequenter 
voor in een van beide groepen. De CSII groep en CT groep gebrui-
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ken vergelijkbare doses insuline. Kortom, wat de metabole regu-
latie betreft is alleen bet sHbAl significant verschillend. 
De C-peptide excretie in 24 uurs urine in de 2 groepen is niet 
verschillend, evenmin als de plasma C-peptide waarden na stimula-
tie met glucagon. De C-peptide excretie bij de ontdekking ver-
toont echter een significance correlatie met C-peptide excretie 
na I jaar. 
De remissie periode duurt in de CSII groep gemiddeld 4 maan-
den langer, een significant verschil. Geen directe associatie 
wordt gevonden tussen de leeftijd of de ernst van metabole ontre-
geling bij de ontdekking van de ziekte en de remissie periode. De 
immunologiscbe factoren lijken evenmin een relatie te vertonen 
met de duur of bet optreden van een remissie periode, ecbter.met 
een uitzondering. Naast de correlatie tussen C-peptide excretie, 
gemeten bij de ontdekking en na J jaar, blijkt de aanwezigbeid 
van insuline antilichamen voor de start van de tberapie een sig-
nificant negatieve correlatie te vertonen met C-peptide excretie 
na I jaar. Een eenduidige samenbang tussen de metabole instelling 
(sHbAl) en de endogene insuline productie (C-peptide excretie in 
24 uurs urine) is niet gevonden. Wel vale bet op, dat slecbts 
eenmaal een daling van de C-peptide excretie niet voorafgegaan 
wordt door een stijging van het sHbAJ. Een duidelij_ke samenhang 
wordt gevonden in beide groepen tussen de endogene insuline pro-
ductie en de toegediende insuline tussen de 2 groepen. Alhoewel 
de mate van samenhang niet significant verschilt, lijkt de CSII 
groep een iets betere associatie te tonen. 
In hoofdstuk 6 worden de verkregen resultaten vergeleken met 
andere studies. -Bij kinderen is deze therapie tot op heden 
slechts in geselecteerde pacienten populaties gehanteerd. Ver-
schillen tussen de resultaten van dit onderzoek en dat van ande-
ren Z~Jn de tijdskosten, de acceptatie en bet voorkomen van meta-
bole disregulaties. Ten dele kunnen deze toegeschreven worden 
aan bet moment waarop de therapie gestart wordt. De kinderen 
hebben nog geen "diabetes verleden". Het is mogelijk dat de nog 
aanwezige endogene insuline productie eveneens een rol speelt bij 
bet minder snel ontregelen. Bovendien moet men zich realiseren 
dat bet om kinderen gaat. Kinderen worden mogelijk beter in de 
gaten gehouden door hun ouders. Dit leidt tot sneller ingrijpen 
bij een dreigende ontregeling. 
Door een nauwkeurige follow-up van de patiencen kan in de toe-
komst misschien vastgesteld worden welke van deze 3 factoren de 
belangrijkste bijdrage levert. Ret is niet goed mogelijk om de 
psychologische data te evalueren, doordat deze nag zeer 
incompleet zijn. Wel lijkt CSII zeker geen negatieve invloed uit 
te oefenen op de kinderen. Ret belang van een intensieve educatie 
in bet voorkomen van metabole ontregelingen is alom bekend en 
geaccepteerd. 
Wat betreft bet sHbAl is de metabole regulatie van de CSII 
groep significant beter. Bij een leeftijdscategorie valt die bet 
meeste op, te weten bij de kleintjes van 5 jaar of jonger. Door 
hun leeftijdsafhankelijke problemen is bet zeer moeilijk om bij 
hen een acceptabele metabole centrale door middel van CT te 
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verkrijgen. Voor deze leeftijdscategorie vormt de komst van de 
kleine pompjes een uitkomst. Een contrast met andere studies is 
de relatief geringe frequentie van bloedsuiker controles. Dit 
gaat niet gepaard met een verhoogd optreden van hypo- of hyper-
glycaemie. Mogelijk speelt ook hier het moment waarop de therapie 
gestart is een rol. 
Opvallend is de gelijke insuline dosis van de 2 groepen 
ondanks het verschil in sHbAI. Hierbij meet men zich echter rea-
liseren dat insuline dosis niet hetzelfde betekent als insuline 
behoefte. Met name bij CT kan men niet ongestraft de insuline 
dosis ophogen om de metabole regulatie te verbeteren. Dit gaat 
gepaard met een verhoogde kans op hypoglycemieen. Een andere 
mogelijke verklaring voor de gelijke dosis kan gezocht 
worden in een verschil in insuline sens~t~v~teit. Hiervoor is 
echter verder (in vivo en in vitro) onderzoek noodzakelijk. Het 
volgen van de kinderen, nadat de 2 jaar van de studie voorbij 
zijn, is zeer interessant. Op die wijze kunnen mogelijk verdere 
gegevens verkregen worden over de samenhang tussen de metabole 
regulatie, de remissie periode en het ontstaan van chronische 
complicaties. Wel dient men zich te realiseren dat het om een 
kleine groep patienten gaat. Suggesties voor de follow-up van de-
ze patienten staan beschreven in hoofdstuk 6. 
De endogene insuline productie is niet verschillend tussen de 
2 groepen. De significante associatie tussen de endogene insu-
line productie bij de ontdekking en de pToductie na 1 jaar is 
eveneens in een andere studie beschreven. Het benadrukt het 
belang van een vroege diagnose en een vroege start met therapie. 
Eveneens significant geassocieerd met de endogene insuline 
productie na l jaar is de aanwezigheid van insuline antistoffen 
voor de start met insuline therapie. Hun aanwezigheid leidt tot 
of is geassocieerd met een significant lagere C-peptide excretie 
na 1 jaar. Wat de rol van deze antistoffen is, is niet bekend. In 
hoeverre zij slechts een "marker" zijn voor beta eel destructie 
of actief betrokken zijn bij deze destructie dient verder onder-
zocht te worden. 
De remissie periode duurt significant !anger (4 maanden) in de 
CSII groep. In tegenstelling tot de retrospectieve studies is 
geen correlatie gevonden tussen de remissie periode en de 
leeftijd of de ernst van de metabole ontregeling. Deze verschil-
len berusten mogelijk op de verschillende definities en criteria, 
die gehanteerd worden bij de remissie periode. Echter, het is ook 
mogelijk dat een bepaalde leeftijdsgrens van belang is. Hetzelfde 
kan gelden voor de mate van ontregeling: De 3 kinderen, die in-
traveneus insuline toegediend kregen na de ontdekking vertonen 
geen remissie. 
De overige parameters vertonen evenmin een associatie met de 
remissie periode. 
De samenhang tussen sHbAl en C-peptide excretie is niet 
eenduidig. Dat de metabole regulatie wel degelijk van belang kan 
zijn blijkt uit het feit, dat slechts in I geval een daling van 
de C-peptide excretie voorafgaat aan een stijging van het sHbAI. 
Verder onderzoek zal nodig zijn om deze samenhang te evalueren. 
De significante correlatie in beide groepen tussen insuline dosis 
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en endogene insuline productie verschilt in geringe mate. Het is 
verleidelijk om te suggereren dat dit verschil wijst op een ver-
schil tussen de 2 groepen in sensitiviteit veer insuline. Men zou 
kunnen speculeren dat de insuline toegediend via CSII effectie-
ver is (gezien de betere sHbAI bij een gelijke insuline dosis). 
Diverse andere studies suggereren een betere insuline sensitivi-
teit bij CSII gebruik. 
In hoofdstuk 6 worden tot slot 2 indicaties veer CSII bij 
nieuwe kinderen met IDDM gegeven. De al eerder genoemde catego-
rie jonge kinderen (~ 5 jaar) vormt de eerste groep. De 2e in-
dicatie voor CSII is nu neg niet van toepassing, maar hopelijk in 
de nabije toekomst wel. Indien methodes ontwikkeld zijn voor 
verdergaande interventie in bet destructieve proces "IDDM" kan 
CSII als interim therapie gehanteerd worden om gedurende korte 
tijd de remissie periode te handhaven. 
Terugkomend bij de vragen, die aan het begin van deze samen-
vatting geformuleerd zijn, kunnen de volgende antwoorden gegeven 
worden: 
CSII is toepasbaar bij niet geselecteerde nieuwe diabetes pa-
tienten. Preliminaire resultaten van de psychologische testen 
suggereren geen negatieve invloed van CSII op de kinderen en 
hun sociale act~v~teiten. 
Met betrekking tot sHbAI is de metabole regulatie in de pomp-
groep significant beter. De overige parameters, waaronder de 
insuline dosis,vertonen geen verschillen tussen de 2 groepen. 
- De remissie periode duurt ongeveer 4 maanden langer in de CSII 
groep. Geen directe associatie is gevonden tussen het optreden 
van een remissie en een van de vele parameters. 
De C-peptide excretie bij de ontdekking en de aanwezigheid van 
anti-insuline antistoffen voor de start met insuline therapie 
vertonen een significance correlatie met de C·-peptide excretie na 
1 jaar. 
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dankbaar voor zijn kritische kanttekeningen en waardevolle advie-
zen. Professor dr R. van Strik is van bet begin a£ aan bij de 
"pompstudie" betrokken geweest. De wijze waarop hij mij met de 
data en de statistische analyse ervan geconfronteerd heeft~ heeft 
mij bijzonder geboeid. Ik heb er veel van geleerd. Zender hun 
continue interesse en feedback zou dit proefschrift niet tot 
stand gekomen zijn. 
Zr J.J. de Visser heeft mij de eerste beginselen van de behan-
deling en benadering van diabetes patienten bijgebracht. Voor al-
gemeen pediatrische problemen bij de projectkinderen heb ik m1J 
te allen tijde kunnen wenden tot R.S.R. Aarsen, kinderarts. 
Corine Houtzagers, arts, ben ik zeer erkentelijk voor de morele 
steun, die zij gedurende het onderzoek heeft gegeven en voor het 
overnemen van de laatste loodjes. Bij de behandeling van diabetes 
mellitus neemt bet dieet nog altijd een belangrijke plaats in. De 
dames A. Hart en K. van den Heuvel, dietistes, ben ik zeer erken-
telijk voor hun betrokkenbeid bij bet pompproject. De klinisch 
chemici, de heren N.C. den Boer en W.G.F. Grose~ bebben zorgge-
dragen voor de meest relevante bepalingen van bet onderzoek. 
Bovendien heb ik mij te allen tijde met vragen en voor overleg 
tot hen kunnen wenden, iets waarvoor ik hun zeer dankbaar ben. 
De beer T. Weterings en mevrouw J. van Tt Hof ben ik zeer erken-
telijk voor de daadwerkelijke uitvoering van de bepalingen. 
Vele bepalingen zijn uitgevoerd door of dankzij de volgende 
personen: : dr Binder, de dames Cboufour en Hooghe, de heren Huy-
mans, de Jongh en Molenaar. Ret zal duidelijk zijn dat zonder hun 
inspanningen dit onderzoek niet plaats had kunnen vinden. De niet 
in dit proefschrift beschreven experimenten met eilandjes van 
Langerhans (en vetbolletjes) zijn dankzij mevrouw P. Heyse zeer 
leerzaam en boeiend geweest. 
Mevrouw dr F. Slijper ben ik zeer veel dank verschuldigd voor 
haar waardevolle adviezen betreffende de psychologische testen en 
voor bet testen van de kinderen, uitgevoerd door haar zelf en 
mevrouw D. Kicken. 
Op de afdeling Kleuters zijn de pomppatienten keer op keer prima 
opgevangen. De zusters van functiekamers hebben zorg gedragen 
voor de uitvoering van de glucagontesten. Ik ben hun bier zeer 
erkentelijk voor. 
Onopboudelijk heeft de beer C. den Ouden van de instrumenten-
dienst zijn kennis, tijd en belangstelling beschikbaar gesteld. 
Zender zijn hulp bij bet keuren van de verschillende pompen (en 
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bet repareren van de pompen!) was bet pompproject-vast niet met 
zo weinig praktische problemen verlopen! De verzekeraars van de 
pomppatienten ben ik erkentelijk voor bet gestelde vertrouwen in 
onze kliniek en hun welwillendheid in het overnemen van de finan-
ciele zorg van de pompbehandeling. 
In bet wetenschappelijk laboratorium heb ik gedurende de 3 jaar 
van bet onderzoek zeer plezierig en rustig mogen werken. Suzanne, 
Christel en Dicky hebben mij frequent gebolpen met bet verwerken 
van de vele bleed samples. 
Mevrouw E. Nelemans ben ik dank verschuldigd voor de steun, 
verleend bij bet opzoeken van de literatuur. De dames Wielsma, 
Moerman en Berkhouwer dank ik voor de vele malen, dat zij nog net 
even tussendoor voor mij bebben willen typen. De AVD heeft zorg 
gedragen voor de fraaie uitvoering van de figuren in dit proef-
schrift. Berenice Noordam heeft zowel de omslag van dit proef-
schrift geillustreerd als de inhoud van pomp instructieboeken. 
In september 1984 heeft dr S.G.Th. Hulst mij de eerste zet in 
de goede richting gegeven. Zender de morele steun en praktiscbe 
hulp van mijn zusje dr I.D. de Beaufort in de zomer 1985 was dit 
proefschrift zeker niet voltooid. Mijn moeder mevrouw drs 
C.J.L.M. de Beaufort-Sickingbe ben ik dankbaar voor haar morele 
en concrete steun gedurende deze onderzoeksperiode. Zij heeft 
niet alleen altijd ruimte weten te creeren maar mij eveneens aan-
gemoedigd om die dingen te doen die mij boeiden. Mevrouw M.N. 
Schiro van der Loeff-Chenault ben ik dank verschuldigd voor bet 
corrigeren van Engels (of is bet nu Amerikaans?) 
Mevrouw A.E.M. van Geen heeft bet gehele manuscript getypt en 
niet eenmaal! Voor baar geduld en goede humeur ben ik haar zeer 
dankbaar. Mijn familieleden aan Beauforten en Schimmen zijde ben 
ik heel erkentelijk voor hun belangstelling en bet geduld dat zij 
gedurende de afgelopen periode met mij gehad hebben! 
Bram's kalmte en zijn relativeringsvermogen hebben mij continu 
gesteund in deze drukke periode. Ik verbeug me op Luxemburg!! 
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CURRICULUM VITAE 
De auteur van dit proefschrift werd in 1956 te Markelo geboren. 
Na bet behalen van bet diploma gymnasium b~ta aan bet Johan van 
Oldebarnevelt gymnasium te Amersfoort studeerde zij geneeskunde 
aan de Erasmus Universiteit te Rotterdam. Gedurende haar studie 
werkte zij 3 maanden als student assistent bij de afdeling Taxi-
cologie in bet H6pital Fernand Widal (hoofd: Prof. Chantal Bis-
muth) te Parijs. Na bet voltooien van de studie in 1982 began zij 
als research fellow (mogelijk gemaakt door Sophia Stichting 
Wetenschappelijk Onderzoek) in het Sophia Kinderziekenhuis aan 
bet onderzoek dat tot dit proefschrift heeft geleid. Zij was 
werkzaam binnen bet Diabetes Team (hoofd: dr G.J. Bruining) van 
mei 1982 tot oktober 1985. In oktober 1985 begon zij met haar 
opleiding kindergeneeskunde in bet Sophia Kinderziekenhuis 
(opleider: Prof. dr H.K.A. Visser) te Rotterdam om deze voort te 
zetten in april I986 in bet H6pital d'Enfants (opleider: Prof. 
M. Pierson) te Nancy. De auteur van dit proefschrift is getrouwd 
met drs A.N. Schim van der Loeff. 
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LIST OF ABBREVIATIONS 
CSII Continuous subcutaneous insulin infusion 
CT Conventionally treated, Conventional Injection Therapy 
HLA Human leucocyte antigen 
ICA Islet cell antibodies 
ICCA 
ICCA-CF 
ICSA 
IDDM 
IgG 
IgGia 
IgGib 
NEFA 
RIA 
sHbAl 
SKZ 
UCP 
Islet cell cytoplasmic antibodies 
Complement fixing islet cell cytoplasmic antibodies 
Islet cell surface antibodies 
Insulin dependent diabetes mellitus 
llrumunoglobulin class G 
Anti insulin antibodies, determined according to the 
method of Christiansen 
Anti insulin antibodies, determined according to the 
modified more sensitive PEG method, described by Laurit-
zen 
Non-esterified fatty acids 
Radio Immune Assay 
Stable glycosylated hemoglobin Al 
Sophia Kinderziekenhuis (Sophia Childrens' Hospital) 
Urinary C-peptide percentage 
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